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Lay Abstract  
For doctors to be able to tailor appropriate treatment for individual patients 
(personalised medicine), it is necessary to analyse and profile specific biological 
processes involved in the patients’ illness.  This can be achieved by using a 
diagnostic kit for a specific disease.  For example in leukaemia, the use of patients’ 
biological material to detect and profile the type of cancer they have, would direct 
the most useful treatment.  In this study, a collection of chemical compounds was 
synthesised with the aim of investigating cancer biomarkers (enzymes) from 
leukaemia patients.  
The compound library, containing “bar code” peptides associated with 
leukaemia, was designed and synthesised.  This barcode can be read using a tool 
called a microarray.  In this thesis, methods of linking the peptide and the barcode 
were investigated, and the best strategy was employed for the synthesis of the library.  
A library based on this set-up was tested with cells and analysed.  This strategy could 
be used for analysing other cancers and diseases. 
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Abstract       
Dysfunctional or over and under expressed enzymes play a crucial role in a variety of 
diseases.  A tool that can identify dis-regulated enzymes in individual patients would 
be beneficial and would allow personalised treatment.  For this purpose, a 10,000 
membered ‘spit-and-mix’ PNA-encoded peptide library with a cell penetrating 
peptide was synthesised and interrogated with K562 cell lysate and intact K562 cells.   
This allowed the specific enzyme activity pattern for ABL tyrosine kinase 
from both inside a cell and a lysate to be obtained.  Hybridisation of this library with 
a DNA-microarray resulted in bio-fouling by the cell lysate, thereby preventing 
analysis of the phosphorylation pattern.  To allow extraction and purification of the 
peptide library from the cell lysates, a His-tag was incorporated into the library, and 
enabled successful library analysis.   
In addition to this 10,000 member library, a focused 100 PNA-encoded 
peptide library was synthesised.  The library included peptide sequences known to be 
phosphorylated by specific tyrosine kinases deregulated in acute lymphoblastic 
leukaemia (ALL) with a PNA-tag complementary to a DNA microarray.  Different 
ligation methods to conjugate the peptides to PNA-tags were screened – this included 
amide coupling, copper catalysed azide–alkyne cycloaddition, strain promoted 
azide–alkyne cycloaddition and Diels–Alder cycloaddition.  The inverse electron 
demand Diels–Alder cycloaddition between a tetrazine and norbornene was chosen 
as the preferred ligation method, and the reaction conditions optimised.   To purify 
the library from cell lysate, a His-tag was again coupled to each member using the 
strain promoted azide–alkyne cycloaddition. 
To test the tetrazine ligation, fluorescence in situ hybridisation (FISH) was 
used in cells, whereby a fluorophore was ligated onto a tetrazine–conjugated PNA 
probe.  This was hybridised onto an mRNA in fixed cells.  Results indicated that the 
ligation needed further optimisation.   
  
 
P a g e  | IV 
Acknowledgment 
First of all I like to thank Professor Mark Bradley for the opportunity of and 
guidance throughout this postgraduate research and CTMM for the funding.  I also 
would like to thank my mother for helping me through some of the rough patches 
that turned up, during this and previous studies and her help.   
Others to thank are everyone in the Bradley group (past and present) for their 
help, support and helping me to grow, and for making it a mostly enjoyable 
experience.  Especially, Effie, Nicos, Juan Jo, Mazen, Jeff, and Nanna for help with 
the chemistry.  I am also thankful for finding good friends, with whom I had a great 
time going on weekend breaks and pubs for some drinks, in no particular order: 
Cairnan, Frank, Anne, Martha, Neil, Aurélie, Thingsoon, Bacon, Matt, Geraldine, 
Andrew, Liz, Chris and the rest.  I also thank Anne that she introduced me to the 
Swing dancing community in Edinburgh, where I found more new friends, with 
which I had a good time, not only dancing but also getting together for a drink.  And 
maybe I should say sorry to everyone in the Bradley group for talking so much to 
you, but well most of the time I think you also liked it, so nah I’m not really sorry. 
I also had a lot of fun taking part in the 48 h film project with Cairnan, Frank, 
Anne, Thingsoon and Will making a nice little movie (Thin Icing).   
Finally I would like to thank my family, all my siblings (Alex, Wolfi, Andy, 
Sibylle, Harry, Ly und Julia) and their families for support, and the fun times we had 
when I visit good old Germany.  If I forgot anyone, sorry I’ll be thanking you to, but 
as my mind was getting more and more like a Swiss cheese (probably due to some of 
the good times, all the chemicals and solvent vapours in the lab), I don’t remember 
everything anymore.   
 
Content        
DECLARATION ................................................................................................................................... I 
LAY ABSTRACT................................................................................................................................ II 
ABSTRACT ........................................................................................................................................ III 
ACKNOWLEDGMENT .................................................................................................................... IV 
CONTENT ............................................................................................................................................ V 
LIST OF ABBREVIATIONS ...........................................................................................................VII 
1. INTRODUCTION ...................................................................................................................... 2 
1.1. TYROSINE KINASES .............................................................................................................. 2 
1.1.1. Tyrosine kinases and Disease ......................................................................................... 3 
1.1.2. Personalised Medicine ................................................................................................... 4 
1.2. PEPTIDE NUCLEIC ACID ....................................................................................................... 5 
1.2.1. Applications of PNA ....................................................................................................... 6 
1.2.2. Synthesis of PNA ............................................................................................................ 9 
1.3. INTRODUCTION TO DNA MICROARRAYS .............................................................................11 
1.3.1. Microarrays and Encoded PNA–libraries .....................................................................13 
1.3.2. Microarrays for clinical use ..........................................................................................14 
1.4. LIGATION METHODS IN CHEMICAL BIOLOGY .......................................................................15 
1.4.1. Native Chemical Ligation ..............................................................................................15 
1.4.2. Click chemistry ..............................................................................................................17 
1.4.3. Inverse Electron Demand Diels–Alder Reactions using Tetrazines ..............................19 
1.4.4. Other ligations ...............................................................................................................21 
1.5. AIMS ...................................................................................................................................23 
2. CELL LYSATE ANALYSIS WITH A PNA ENCODED 10,000 MEMBERED SPLIT-
AND-MIX LIBRARY .........................................................................................................................26 
3. EVALUATION OF LIGATION METHODS .........................................................................41 
3.1. PEPTIDE COUPLING .............................................................................................................41 
3.2. COPPER(I)-CATALYSED AZIDE–ALKYNE CYCLOADDITION (CUAAC) ...............................42 
3.3. NON-COPPER CLICK LIGATION ...........................................................................................45 
3.4. TETRAZINE..........................................................................................................................47 
3.4.1. 3,6-Bis(3,5-dimethyl-1H-pyrazol-1-yl)-s-tetrazine ........................................................47 
3.4.2. Synthesis and test ligation of trans-cyclooctane ............................................................50 
3.4.3. Mono-Acid tetrazine ......................................................................................................51 
Content 
P a g e  | VI 
3.4.4. Stability of norbornene during TFA cleavage ...............................................................58 
3.5. CONCLUSION ......................................................................................................................61 
4. EVALUATION OF A PNA IN SITU HYBRIDISATION AND FLUOROPHORE 
LIGATION STRATEGY ...................................................................................................................63 
4.1. INTRODUCTION ...................................................................................................................63 
4.2. RESULTS AND DISCUSSION .................................................................................................69 
4.2.1. PNA synthesis ................................................................................................................70 
4.2.2. In-cell hybridisation and ligation ..................................................................................72 
4.3. CONCLUSION ......................................................................................................................75 
5. PNA–PEPTIDE LIBRARY ......................................................................................................77 
5.1. SYNTHESIS OF PNA-TAGS ...................................................................................................77 
5.2. SYNTHESIS OF PEPTIDE FRAGMENTS....................................................................................81 
5.3. LIGATION OF PEPTIDES TO PNA-TAGS ...............................................................................90 
6. CONCLUSION ..........................................................................................................................97 
7. EXPERIMENTAL ...................................................................................................................101 
7.1. GENERAL SECTION ............................................................................................................101 
7.2. GENERAL EXPERIMENTAL PROCEDURES............................................................................103 
7.3. CHAPTER 3 ........................................................................................................................106 
7.4. CHAPTER 4 ........................................................................................................................124 




List of Abbreviations 
µW Microwave 
28S rRNA 28S Ribosomal ribonucleic acid 
Abl Abelson 
ACN Acetonitrile 
ALL Acute lymphoblastic leukaemia 
Alloc Allyloxycarbonyl 
AML Acute myeloid leukaemia 
anhyd. Anhydrous 
Ar Arene 
BCR Breakpoint cluster region 
BCR–ABL  Breakpoint cluster region–Abelson 
Bhoc Benzhydryloxycarbonyl 
Bts Benzothiazole-2-sulfonyl 
CAPS Cryopyrin-associated periodic syndromes 
cDNA Complimentary deoxyribonucleic acid 
CF Carboxy fluorescein 
CM ChemMatrix 
CML Chronic myeloid leukaemia 
CPP Cell penetrating peptide 




List of Abbreviations 
P a g e  | VIII 
EDC(•HCl) 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(hydrochloride) 
EDTA Ethylenediaminetetraacetic acid 
EEDQ 2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline 
ELSD Evaporative light scattering detector 
FAM Fluorescein 
FGFR Fibroblast growth factor receptors 
FISH Fluorescent in situ hybridisation 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-





Her-2/neu Human epidermal growth factor receptor 2/neuro 
HFIP Hexafluoroisopropanol 
HMPA Hexamethylphosphoramide 
JAK Janus kinase 
LAH Lithium aluminium hydride 
LDA Lithium diisopropylamide 
mCPBA meta-Chloroperoxybenzoic acid 
MLST Multilocus sequence typing 
Mmt Monomethoxytrityl 
M-PER Mammalian protein extraction reagent 
mRNA Messenger ribonucleic acid 
MRSA Methicillin-resistant staphylococcus aureus 
List of Abbreviations 
P a g e  | IX 
Nor-Flu Norbornene fluorescein 
NTA Nitrilotriacetic acid 
Pbf 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl 
PCR Polymerase chain reaction 
PEG Poly(ethylene glycol) 
PEGA Poly[acryloyl-bis(aminopropyl)polyethylene glycol] 
PMA Phosphomolybdic acid 
Rho Rhodamine 
smFISH Small molecule fluorescent in-situ hybridisation 
spAAC Strain promoted azide–alkyne cycloaddition 
TAMRA 5(6)-Carboxytetramethylrhodamine 
TBAF Tetrabutylammonium fluoride 
TBTA Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 





Tyr2 Tyrosine kinase 2 
TZ Tetrazine 
TZ-OH 4-(6(Pyrimidine-2-yl)-1,2,4,5-tetrazin-3-yl) benzoic acid 
TZ-OSu 4-(6(Pyrimidine-2-yl)-1,2,4,5-tetrazin-3-yl) benzoic 
succinamide 






















Introduction  Chapter 1 
P a g e  | 2 
1. Introduction 
1.1. Tyrosine kinases 
Kinases are a family of enzymes that phosphorylate specific substrates.  There are 
three main families the tyrosine, the serine/threonine, and dual kinases (targeting 
both tyrosine and serine/threonine), but other amino acids such as histidine and 
arginine are also targeted by kinases.  Tyrosine kinases are important mediators of 
various signalling processes, leading to cell proliferation, differentiation, migration, 
metabolism and programmed cell death.1  In healthy cells tyrosine kinases are tightly 
regulated, with dysfunction due to mutation or overexpression, often leading to 
malignancy.   
There are more than 500 kinases encoded in the human genome, of which 90 
are tyrosine kinases.2,3  These enzymes transfer a ɣ-phosphate group from adenosine 
triphosphate (ATP) to the target tyrosine, thereby phosphorylating the protein 
(Scheme 1.1).  Of the 90 tyrosine kinases, 58 are proteins with a predicted 
transmembrane domain, which can be grouped into 20 subfamilies based on their 
kinase domain sequences (kinase domain is the catalytic side of a protein).4  The 
remaining 32 kinases are non-receptor or non-membrane spanning tyrosine kinases 
and fall into 10 subfamilies based on their kinase domain sequences.3   
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1.1.1. Tyrosine kinases and Disease 
Protein tyrosine kinases have been shown to play a key role in many disease states, 
such as different cancers,5–7 type 1 diabetes,8 and rheumatoid arthritis.9  The 
dysfunction of kinases results in over or under expression of activity.  Three tyrosine 
kinase families are described below, which illustrate the diversity of malfunctioning 
enzymes.   
The fibroblast growth factor receptors (FGFRs).  There are four members in 
this family, FGFR 1–4, which are master regulators of a broad spectrum of cellular 
and developmental processes, migration, proliferation, and apoptosis.  Mutations in 
these enzymes can lead to severe illnesses like cancer5 or Pfeiffer syndrome.10 
The vascular endothelial growth factor receptors (VEGFRs).  VEGFR 1–3 
belong to this family, which regulates blood and lymphatic vessel development and 
homeostasis.  Their dysfunction has shown to play a role in many diseases including 
diabetic retinopathy, psoriasis, and arthritis.  VEGFRs also play a role in cancer 
where the growth of tumour blood vessels is promoted.11 
The Janus kinase (JAK) family.  JAKs are one of the ten recognised families of 
non-receptor tyrosine kinases.  Its members, JAK 1–3 and tyrosine kinase 2 (Tyk2), 
are normally localised in the endosome and the plasma membrane due to their 
association with cytokine receptors.12  The JAK family plays a critical role in blood 
formation and the immune response.  Mutation of members in this family are related 
to myeloproliferative disorders, acute lymphoblastic leukaemia (ALL), acute 
myeloid leukaemia (AML), and other leukaemias.  These disorders are all related to 
an overexpression of those enzymes, in contrast, loss of function of some members 
leads to immunodeficiency.6   
As kinases play a role in disease, especially in some cancers, treatments 
targeting kinase activity have been developed to control or even prevent the specific 
disease from developing further.7,13–15  A small molecule that targets specific tyrosine 
kinases in cancer is Gleevec 1.1, which targets the breakpoint cluster region–Abelson 
protein (BCR–ABL) that is present in 95% of chronic myeloid leukaemias (CML) 
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and up to 30% of acute lymphoblastic leukaemia patients (ALL).7  When added to 
cells, Gleevec resulted in a 92–98% decrease in the formation of cells that express 




Another drug in development, is Ponatinib (1.2) that targets FGFR protein 
tyrosine kinases.13  This inhibitor is currently being explored in clinical trials, which 
1.2 also showed some inhibition of BCR–ABL kinase in CML patients.  In mice this 
drug showed a reduction in tumour growth, and importantly showed similar potency 
as previously observed in the BCR–ABL models.13  There are many other kinase 
inhibitors that can be targeted therapeutically and these have been extensively 
reviewed in the literature.16,17  
 
1.1.2. Personalised Medicine 
Schleidgen has defined personalised medicine as: 
“Personalised medicine seeks to improve stratification and timing of 
healthcare by utilising biological information and biomarkers on the 
level of molecular disease pathways, genetics, proteomics as well as 
metabolomics.”19 
Introduction  Chapter 1 
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In general, personalised medicine is the improved treatment, for individual 
patients based on their genetic and family history.  The aim is to focus treatment, so 
that it is known that the intended treatment will work for specific enzymatic 
mutations.20  Personalised medicine is becoming an important strategy in patient 
care, and is employed in the treatment of CML.  In 95% of CML,7 a fusion between 
chromosome 9 and 22 results in the Philadelphia chromosome, which expresses the 
fusion oncoprotein BCR–ABL.  This enzyme is a tyrosine kinase and can be treated 
with a tyrosine kinase inhibitor (like Gleevec).21  This concept has been applied for 
many different diseases and is continuously growing.  Some examples where 
personalised medicine is used in clinics to date are in cystic fibrosis,22 various 
cancers,21,23 and inflammatory bowel disease,21 amongst others.   
 
1.2. Peptide Nucleic Acid 
Peptide nucleic acids (PNA) are synthetic mimics of deoxyribonucleic acid (DNA) 
(or ribonucleic acid (RNA)), first described in 1991 by Nielsen.24  Instead of the 
phosphate deoxyribose backbone of DNA, PNA is based on a peptide backbone 
where the nucleobases (guanine, cytosine, thymine and adenine) are attached via a 
methylene carbonyl spacer.  Because of its neutral character, PNA hybridises quickly 
and efficiently with DNA.  PNA forms very stable duplexes with complementary 
single-stranded DNA, RNA and PNA, through Watson–Crick base pairings (Figure 
1.1).25  Those complexes can be formed in a parallel (C-terminal of PNA facing the 
3’-end of DNA) or an anti-parallel (N-terminal of PNA facing the 3’-end of DNA) 
orientation.  The anti-parallel orientation is more favourable, showing a higher 
melting temperature (Tm) compared to the parallel complex.
26,27   
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Figure 1.1: Watson-Crick base paring of DNA (left, green) base with the complimentary PNA 
(right, red) base through intermolecular hydrogen bonding (blue dashed lines).28,29   
 
1.2.1. Applications of PNA 
PNAs have been used to inhibit the expression of specific proteins by hybridising 
either to the DNA-target sequence (antigene inhibition) or to a messenger RNA 
(mRNA) (antisense) (Figure 1.2).  PNA antigene inhibitors hybridise to a specific 
DNA sequence in the nucleus forming a PNA–DNA triplex, preventing the 
transcription of the gene,27,30  and subsequent protein synthesis.  Antisense PNA 
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inhibitors target mRNA in the cytoplasm forming an unnatural PNA–RNA duplex 
that cannot be read by ribosomes, hindering the production of a specific 
protein.27,31,32 
   
 
Figure 1.2: Antisense and antigene inhibition by a PNA inhibitor. 
 
Another application of PNA is as biosensors that can detect specific DNA 
sequences,30,33 and identify single point mutations.34,35  The detection of the target 
DNA can be achieved electrochemically, visually, or by mass spectrometry.36  Luo et 
al.33 investigated the detection of DNA using a PNA probe that was not immobilised 
on the surface of the electrochemical detector.  For this assay, a complimentary PNA 
sequence was synthesised and functionalised with a ferrocene (Fc) moiety and 
another PNA probe was prepared with methylene blue (MB).  Those indicators 
showed different peak currents and could be used in tandem.  When no DNA was 
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present, a signal was observed, but in the presence of a complimentary DNA 
sequence, the PNA–DNA duplex no longer bound to the detector surface due to 
charge interactions (Figure 1.3). 
 
 
Figure 1.3: Ilustration on how a PNA probe was used by Luo to detect electrochemiclly the 
presence of a DNA sequence.33 
 
A mass spectrometric method was developed by Bowler et al.34,35 to analyse 
DNA point mutations.  In this method, a PNA probe with a blank position opposite 
the nucleobases of interest was synthesised.  This probe was then hybridised with the 
DNA target, to form a duplex with a blank position in the PNA sequence.  To 
identify what nucleobases were present in the DNA, the four nucleobases were added 
as aldehydes, and only the complimentary nucleobase was incorporated into the 
missing position via imine formation.  After reducing the imine to the amine, the 
PNA was analysed by matrix-assisted laser desorption/ionisation time of flight mass 
spectrometry (MALDI–TOF MS) to identify which nucleobase was incorporated 
Introduction  Chapter 1 
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(Figure 1.4).  A further development of this method, is the use of fluorescent-
labelled nucleobase aldehyde monomers to detect single point mutations.37   
 
Figure 1.4: Dynamic chemistry applied to the analysis of single point mutations.   
 
Other examples of PNA are as molecular beacons,27 and fluorescent in situ 
hybridisation (FISH) probes (introduced in depth in Chapter 3). 
 
1.2.2. Synthesis of PNA 
Standard solid phase peptide synthesis (SPPS), using an Fmoc approach, can be 
employed to synthesise PNA oligomers.26,38  In the SPPS approach, the PNA 
monomers are synthesised with appropriate protecting groups (Scheme 1.2) 
including fluorenylmethyloxycarbonyl (Fmoc), tert-butyloxycarbonyl (Boc), 
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monomethoxytrityl (Mmt), 2-(4-biphenyl)isopropoxycarbonyl (Bpoc) and N-(1-(4,4-
dimethyl-2,6-dioxocyclohexylidene)ethyl) (Dde) (Dde has been used by the Bradley 
group extensively in parallel with Fmoc-peptide to synthesise PNA-encoded peptide 
libraries).29,39–41  Fmoc/benzhydryloxycarbonyl (Bhoc) protected PNA monomers are 
commercially available. 
 
Scheme 1.2: Generic synthesis of PNA monomers. 
 
 
SPPS is typically employed for the synthesis of PNA.  The amino acid 
monomer is first activated to form an active ester, which is then coupled to a free 
amine on a solid support.  To reduce the potential of side reactions and to improve 
reactivity, Lee38 reported a cyclic PNA monomer (1.3) that is self-activated and 
efficient in PNA synthesis.  In this case, the protecting group on the backbone of the 
PNA monomer is benzothiazole-2-sulfonyl (Bts).  The Bts group being deprotected 
under mild conditions using 4-methoxythiophenol and N,N-diisopropylethylamine 
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(DIPEA).  An advantage of using this type of monomer is that no additional 
compounds are needed for the coupling reaction (Scheme 1.3). 
 
Scheme 1.3: Cyclic PNA monomer (1.3) synthesis and SPPS described by Lee.38  
 
1.3. Introduction to DNA microarrays 
Microarrays are small analytical devices that can be used to analyse a large number 
of analytes in a rapid manner.  The word microarray comes from the Greek word 
‘mikro’, meaning small, and the French word ‘arayer’, meaning ordered.  This 
technology was first reported by Fodor and co-workers42 in the early 1990s, 
(although Southern43 also has a claim) when a 1024 membered peptide array was 
synthesised for the first time.  The peptides were synthesised on the surface of a slide 
using light sensitive protecting groups, and screened using a fluorescently labelled 
antibody.42  The surfaces used now extend to glass, silicon or nylon, containing 
hundreds to millions of different compounds (DNA,44 peptide,45 polymers,46 small 
molecules,47 tissue,48 alongside others49) in an ordered arrangement on the surface.  
Microarrays have many different applications.  In this section examples are described 
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to show their scope and breadth, but this is by no mean an extensive review of 
microarrays.   
A peptide microarray was used by Li50 to detect the protein kinase A (PKA) 
activity in cell lysates.  For this, 10 peptide sequences specific for PKA were first 
immobilised on the surface of a microarray, followed by the incubation of the array 
with cell lysate.  The detection of the phosphorylation was achieved by using an anti-
phosphoserine-biotin antibody, which in turn was detected by a streptavidin gold 
nanoparticle.  Final imaging was by resonance light scattering analysis.  The result of 
this showed that the peptides had different phosphorylation efficiencies, and the best 
peptide was then used in a different experiment to quantify PKA concentration in 
different cell lines.  The quantification of enzyme in the different cell lines was 
comparable with the results from the commercial enzyme-linked immunosorbent 
assay (ELISA) kit. 
Hansen51 synthesised a polymer microarray with 291 different polymers and 
a positive control collagen to interrogate platelet rich plasma.  The aim was to find 
polymers that would activate the platelets.  12 ‘hit’ polymers were found that 
activated platelets (confirmed by fluorescent and scanning electron microscopy).  
One polymer had, after a 30 min exposure, a grater coverage of platelets bound to the 
spot surface compared to collagen and formed lager aggregates.51   
The Neri group52 synthesised a 30,000 membered small molecule DNA 
encoded library and screened it against human interleukin-2.  To synthesise this 
library, 100 different small molecules were first encoded with a unique DNA 
sequence.  This was followed by mixing and splitting (into 300 pools) before 300 
small molecules were reacted to each of the 100 molecules and a second unique 
DNA code added.  The library was then treated with the protein of interest 
immobilised onto a magnetic bead.  After washing away non-bound molecules and 
eluting the most potential binders, the DNA code was amplified by polymerase chain 
reaction (PCR) before the ‘hits’ were analysed using a microarray.  The results were 
validated by resynthesising the most abundant small molecules.52   
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1.3.1. Microarrays and Encoded PNA–libraries 
There are benefits to carrying out biological screening of libraries in solution 
compared to surfaces.  This is because enzymes/proteins may interact with the 
surface, while accessibility may be reduced.  Due to this, some groups have 
synthesised libraries (peptides and small molecules), which are encoded with a PNA-
tag, with the entire library decoded by hybridising the library onto a microarray.  
For example, Svensen53 synthesised a PNA-encoded peptide library using a 
split-and-mix method, with six different amino acids (proline (Pro), lysine (Lys), 
glutamic acid (Glu), leucine (Leu), tyrosine (Tyr) and lysine like peptoid (Llp)).  
These were chosen to cover all the different classes of natural amino acids, in 
addition, the Llp was included.  This study was set out to investigate the cell 
permeability potential of the library.  The library was incubated with different cell 
lines and after trypsin treatment (to remove any peptides and members of the library 
still on the surface of the cell) the cell lines were lysed.  The PNA-encoded library 
members from inside the cell were collected and purified, and a microarray was used 
to identify which tetramer peptide showed the ability to enter cells.  Surprisingly, the 
best peptide for all the cells was the negatively charged peptide Glu-Llp-Glu-Glu.  
This was verified and showed to possess the same or better uptake abilities compared 
to the positive control.  In addition, it was possible to obtain homing peptides that 
were readily taken up by one specific cell line, but not others.53  This study shows the 
power of how all members of a library can be interrogated to obtain huge amount of 
information in a single experiment. 
Daguer54 used a PNA-encoded small molecule library to find a new binding 
molecule for streptavidin.  In this study, the 62,500 membered library was hybridised 
onto a DNA-microarray, followed by incubation with labelled streptavidin.  After 
scanning of the microarray, one feature was highly fluorescent.  This turned out to be 
a derivative of dehydrocholic acid (1.4), that was highly selective for streptavidin 
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(KD = 87 nM).
54  This example shows how a small molecule library encoded with 
PNA can be used to identify ligands that bind strongly to a specific protein.   
 
Pouchain40 synthesised a 10,000 membered PNA-encoded peptide library to 
interrogate the Abelson tyrosine kinases (Abl).  The library was treated with ATP 
and the kinase and after hybridisation onto a microarray, an anti-phosphotyrosine 
antibody was added followed by a secondary antibody labelled with a Cyanine 3 dye 
(Cy3). Scanning the microarray allowed the profiling of the tyrosine kinase 
activety.40  With this method it was possible to quantify the phosphorylation for each 
substrate.  155 peptides out of the 10,000 were strongly phosphorylated (in 
agreement with known Abl specificity) while new target proteins were identified by 
comparing the peptide sequences of the ‘hits’ with a database that contains all the 
amino acid sequences of human proteins.   
 
1.3.2. Microarrays for clinical use 
Microarrays have been used in clinical environments,55 and some examples are given 
below. 
Balow56 used a DNA microarray for the profiling of the gene expression of 
patients with cryopyrin-associated periodic syndrome (CAPS), and compared the 
expression profile before and after treatment with interleukin-1 inhibitor (anakinra).  
This study was carried out with 22 CAPS patient and 14 healthy controls to obtain a 
profile of gene expression for CAPS.  90 genes were identified that can be used to 
classify CAPS.  Using this set of genes, 17 samples from an independent dataset 
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were correctly identified.  Interestingly 15 out of 16 CAPS samples were also 
correctly identified from patients who had been treated with anakinra despite these 
patients being in clinical remission.56  
Monecke57 used a microarray to analyse and identify different methicillin-
resistant staphylococcus aurous (MRSA) strains encoding the β-pore forming 
Panton-valentine leukocidin.57   
 
1.4. Ligation methods in chemical biology 
Chemical ligation is a technique that allows the synthesis of long peptides by joining 
together smaller fragments.  In this project, chemical ligation will be used for 
attaching individual PNA-tags to peptides.  There are several different strategies,58–61 
of which the most popular are discussed below. 
 
1.4.1. Native Chemical Ligation 
Native chemical ligation is the reaction between a C-terminal thioester, and an N-
terminal cysteine residue, to form an amide bond between two peptides (Scheme 
1.4).  Cysteine is a relatively uncommon amino acid (~2%) in nature,62 therefore 
introduces a limitation in the synthesis of long peptides, where several smaller 
peptides63–65 chains are combined together, although it can be removed by treatment 
with Raney Nickel. 
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Scheme 1.4: Native chemical ligation reaction between a thioester and cysteine to form an 
amide bond. 
 
Seitz59 used this method to couple small PNA chains together, for this a 
cysteine PNA-monomer analogue was synthesised (1.5).  A templated native 
chemical ligation was used, where a DNA sequence acted as the template binding 
both PNA sequences and bringing the two ends into close proximity.66–68  On closer 
investigation, it was determined that using DNA as a template, native chemical PNA 
ligation was as fast and selective as an enzymatic ligation.66,68 
 
 
Yang63 synthesised a lysine derivative in which a thiol group was introduced 
in the γ-carbon of lysine (1.6).  Using this monomer it was possible to perform a dual 
native chemical ligation, with different protecting groups on the two amine 
functionalities.  Using 1.6, Yang showed that native chemical ligation could be 
carried out with lysine instead of cysteine, which is more abundant in proteins. 
For native chemical ligation, it is necessary to have a thioester peptide, which 
is challenging when Fmoc-chemistry is used for the peptide synthesis.  Because of 
this, Blanco-Canosa65 prepared an aromatic N-acylurea moiety linker at the C-
terminus (1.7), which could easily be transformed into a thioester by thiolysis.  When 
cleaved, the acylurea moiety on the peptide is stable under acidic conditions, but in 
neutral aqueous buffers it undergoes rapid thiolysis yielding the thioester on the C-
terminus of the peptide needed for the ligation.  This thioester can also be produced 
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in situ during the ligation step, allowing the native chemical ligation to proceed 
relatively efficiently.65  To test this new linker, a 29 amino acid long rabies-derived 
peptide was synthesised in two fragments, followed by their ligation.  The linker 1.7 
shows a smart alternative, which is more efficient than methods used to make 
thioesters of peptides, as it can be included in the Fmoc-solid phase synthesis. 
 
1.4.2. Click chemistry 
Copper(I)-catalysed azide–alkyne cycloaddition (CuAAC), first described by Meldal 
in 2002,60 is the reaction of an azide with an alkyne in the presence of a copper(I) 
catalyst to form a 1,2,3-triazole.  This reaction has since been used in bioorthogonal 
conjugation to label DNA,69 material science to synthesise polymers,70 medical 
chemistry for the synthesis of biological active compounds,71 and many more 
examples.  In PNA–peptide chemistry, this reaction can be used to connect PNA and 
peptide analogues that have previously been functionalised with alkyne and azide 
moieties (Scheme 1.5). 
 
 
Scheme 1.5: Click chemistry reaction 
 
Two methods have been widely used, amongst others, by Bouillon72 and 
Landi73 who used copper sulphate with sodium ascorbate in a water/alcohol solution 
for their reactions, while Jolck74 and Tornoe60 used CuI and a base in different 
solvents.  Both of these methods have been used on solid support, where the alkyne 
or azide–peptide is covalently bound to the resin,60 or in solution phase.75 
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It has been reported that the reaction can be problematic when a copper 
catalyst is used in the presence of DNA and PNA.  Peng and co-workers76 have 
shown that in the absence of an additive, DNA is degraded by the conditions used in 
the copper-click reaction.  Fokin et al.77 have shown that the tris[(1-benzyl-1H-1,2,3-
triazol-4-yl)methyl]amine (TBTA) ligand stabilises the Cu(I) oxidation state in 
water, and used this for the bioconjugation to a virus where a azide/alkyne was 
introduced into the membrane, which was then stained by adding a alkyne/azide dye.  




In the past decade, several attempts have been made to use copper or 
ruthenium free click chemistry.  Bertozzi and co-workers reported that strained 
cyclic alkynes (1.9) undergo a [3+2] cycloaddition with an azide without the use of a 
catalyst.79  To test the reactivity, the alkyne was reacted with different azides (2-
azido-ethanol, benzyl azide, and others), which all showed the only product observed 
were the two regioisomeric triazoles in approximately equal amounts.  Biomolecules 
have been functionalised with an azide group, followed by the ligation using a 
biotinylated cyclic alkyne with Western blots used to analyse the reaction to confirm 
that the reaction was suitable for biological labelling.79   
Further investigation into strained cyclo-octynes showed that the electron 
deficient alkyne bond increased the rate of the click reaction.  This was achieved by 
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introduction of two fluorine substituents onto the α-carbon of the alkyne (1.9, R = 2 
F),80 and was used by Baskin80 to label cells.  In this work, the Staudinger ligation, a 
non-fluorinated cyclic alkyne and the fluorinated alkyne were all tested.  This 
showed that the fluorinated compound labelled live cells 20 times faster than the 
others.  This indicates that electron deficient cyclic alkynes react faster compared to 
just cyclic alkynes.   
 
1.4.3. Inverse Electron Demand Diels–Alder Reactions 
using Tetrazines 
The inverse-electron demand Diels–Alder reaction between a tetrazine and an alkene 
gives a [4+2] cycloaddition, followed by an irreversible [4-2] ring opening reaction 
with the release of diatomic nitrogen as the only side product (Scheme 1.6).58,81,82  
As it is an inverse-electron demanding Diels–Alder reaction, the diene, in this case 
the tetrazine, reacts more efficiently when electron withdrawing groups are attached 
to the tetrazine, and the dienophile is more electron rich, or more strained (e.g. cis- vs 
trans-cyclooctene).83   
 
Scheme 1.6: Inverse-electron demand Diels–Alder reaction between a tetrazine and an 
alkene. 
The reaction between a tetrazine and norbornene was used by Schoch61 to 
covalently label DNA after oligomer synthesis with fluorescent labels (Scheme 1.6).  
For this DNA oligomers were synthesised that included a norbornene group.  This 
was used to test the effectiveness of the ligation depending on the position on the 
oligomer.  It was shown that the tetrazine ligation was very selective, with yields of 
65–80% after only 1 h reaction, and 94–96% conversion after 17 h.  There seemed to 
be no preference of where on the oligo the ligation was carried out, and in contrast to 
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N-hydroxysuccinimide ester coupling and the copper click reaction, this Diels–Alder 
conjugation showed higher efficiency of labelling with lower reaction 
concentrations. 
 
Scheme 1.7: Inverse-electron demand Diels–Alder reaction using tetrazine. 
 
Antibodies functionalised with norbornene, and subsequently treated with a 
near infrared (NIR)-fluorescent dye functionalised with a tetrazine, showed 
significant ligation of the tetrazine to the antibody after a 30 min incubation period.  
For the labelling of the A549 (adenocarcinomic human alveolar basal epithelial) 
cells,84,85 a trans-cyclooctene functionalised antibody was used to detect the 
epidermal growth factor receptor (EGFR) receptor, which is overexpressed in those 
cells.  After the incubation of the antibody, the tetrazine with a NIR-dye attached, 
was added to the live cells, and imaged after 10 min.  This showed good labelling of 
the cells.  These examples show the potential of tetrazine ligation and labelling of 
live cells.  It was also shown that tetrazines are stable in the buffers used for the 
ligation and reaction on the cell surface.   
In a study of different dienophiles with tetrazine undertaken by 
Thalhammer,83 it has been determined that the fastest Diels–Alder reaction occurred 
when a trans-cyclooctene (1.10) was used.  This reacted up to six orders of 
magnitude faster than the corresponding cis-isomer, still three orders of magnitude 
faster than the cyclooctyne.83  This shows how to tune the reaction with different 
dienophiles.   
 
Xie and co-workers86 investigated a similar type of reaction based on the 
inverse-electron demand Diels–Alder reaction.  Instead of an alkene, a ketone was 
used to couple with the tetrazine (Scheme 1.8).  This reaction needed a proline 
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catalyst to work, as the proline undergoes a Schiff-base reaction with the ketone, 
forming a double bond, which is the actual reactive dienophile.  Using this method, 
several small molecules were synthesised, which showed the first examples of a 
Diels–Alder tetrazine reaction in the presence of a catalyst. 
 
Scheme 1.8: Proline-catalysed direct inverse electron demanding Diels–Alder reactions of 
ketones with 1,2,4,5-tetrazines.   
 
 
This was just a small example of the uses of tetrazines, but tetrazines are 
being increasingly investigated for different ligations from biological labeling85 to 
prodrugs87 and as high energy materials,88 showing a wide interest in the scientific 
community.   
 
1.4.4. Other ligations 
Some other ligation methods used are shown below.  One of those ligations is the 
ketoacid–hydroxylamine ligation, which uses very mild reaction conditions and is 
very chemoselective.  The only by-products are H2O and CO2.  Bode and co-
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workers89,90 used this to couple two polypeptides together, using no additional 
reagents.  It was carried out in aqueous dimethylformamide (DMF) at temperatures 
between 37 and 60 °C (Scheme 1.9).91  One of the advantages of this method, over 
the most commonly used native chemical ligation, lies with the N-terminal amino 
acid used.  Any amino acid can be used to couple to the ketoacid of the other peptide, 
whereas for native chemical ligation it is important to have a sulphur containing 
amino acid, like cysteine or a modified lysine.  The bond formed in this reaction is a 
normal amide bond, which is useful for the synthesis of medium to large peptides 
with any sequence desired, and it does not rely on a specific amino acid in the 
sequence for the ligation to occur.91   
 
 
Scheme 1.9: Ketoacid–hydroxylamine ligation 
 
A hydrazone ligation (Scheme 1.10) as used by Blanco-Canosa92 is the 
reaction between an aldehyde and a hydrazine, which chemoselectively reacts.  
Aniline can be used as a catalyst.  In addition to mild conditions (the reaction carried 
out at pH 7.0), the peptide side chains do not need to be protected during the ligation.  
Using this ligation method it was possible to control the ratio of peptides coupled to 
the surface of a quantum dots as the ligation is selective and high yielding.92   
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Enzymatic ligations are another example that can be used for the synthesis of 
long peptides and proteins.  Pritz91 used the enzyme Sortase A to conjugate a cell 
penetrating peptide to a PNA sequence.  Sortase A is a transpeptidase that cleaves a 
pentapeptide sequence (Scheme 1.11) between the threonine (Thr) and glycine (Gly) 
residue and transfers it onto the amine of a polyglycine terminated peptide.91,93   
 
 
Scheme 1.11: Reaction mediated by Sortase A (SrtA). 
 
1.5. Aims 
The aim of the work in this thesis was to synthesise PNA-encoded peptides.  This 
included a generic split and mix 10,000 membered kinase library, and a 100 
membered library to encompass the specific substrates of tyrosine kinases.  The 
libraries were modified by the attachment of a cell-penetrating peptide motif to allow 
cellular delivery, with the aim of analysing intracellular kinase activity, and a poly-
histidine tag.  The histidine (His)-tag was designed to allow the isolation of the 
library from crude cell lysates following interrogation of enzyme activity in cancer 
samples from patients.  The PNA-encoded libraries were designed to be analysed 
using a customised DNA-microarray to thus determine which enzymes were 
functional/over-active dysfunctional.  The thesis thus reports: 
I. Screening and synthesis of a new 10,000 membered PNA-encoded 
peptide library with enhanced scope for tyrosine kinase substrates 
compared with a previously used library;40  
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II. Optimisation of library screening methods with cell lysates, and 
purification of the library using a His-tag; 
III. Intercellular kinase activity screening, by addition of a cell 
penetrating peptide to the 10,000 membered library for internalisation;  
IV. Synthesis of 100 PNA tags and 100 peptides using SPPS; 
V. Optimisation of the ligation of the PNAs and peptide library, 
VI. PNA-based FISH analysis;   
VII. Screening of different hybridisation conditions for the DNA-
microarray analysis of the library; incubation of the library with 
purified enzymes to validate the tool using cell lysate from leukaemia 
cells to interrogate enzymatic activity with and without inhibitors 



















The work presented in this chapter was carried out in collaboration with Dr Eftychia Koini 
(University of Edinburgh), Dr Mazen Sleiman (University of Edinburgh), Dr Ruben van Boxtel 
(University Medical Center Utrecht) and Dr Koen Braat (University Medical Center Utrecht) 
individual contributions are indicated throughout the chapter. 
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2. Cell lysate analysis with a PNA encoded 10,000 
membered split-and-mix library  
This section of the project was based on previously published work by Bradley,40 
where a 10,000 membered tyrosine kinase library was synthesised using different 
amino acids (acidic, basic, hydrophilic and hydrophobic).  This library was screened 
with several tyrosine kinases to identify their preference for amino acids surrounding 
a central tyrosine residue (Figure 2.1).   
 
 
Figure 2.1: Peptide library as published by Bradley.40 
 
The library was synthesised using the ‘split-and-mix’ approach first reported 
by Furka in 1988.94,95  This technique allows for the synthesis of large libraries using 
relatively few coupling steps.  As the name suggests synthesising a split-and-mix 
library means that the “synthesis resin” is split into portions before the different 
amino acids are coupled (and in our case their PNA-codes).  Once coupling of the 
amino acids and PNAs are complete, the split resin samples are combined and 
thoroughly mixed before being split again into equal portions prior to the next amino 
acid coupling (Figure 2.2).   
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Figure 2.2: Representation of a split-and-mix synthesis method used for a PNA-encoded 
peptide library.  First the resin was split into four equal amounts, followed by the coupling of 
the first amino acid, and its corresponding triple PNA code.  The split resins were mixed 
together, and split again into four equal batches.  The next amino acid was then coupled with 
its corresponding PNA-codes.  The mixing, splitting and coupling steps where repeated until 
the desired number of couplings was achieved. 
With this method a new library containing 10,000 members was synthesised 
using only 4 split-and-mix cycles, with a total of 40 couplings for the varying amino 
acids and 120 couplings for their corresponding PNA codes.  Data base searching 
showed that the old library covered about 5% of all the known tyrosine kinase 
recognition sequences.  Thus a new library was designed to cover about 20% of all 
known tyrosine kinase sequences (Table 2.1) and synthesisedA on polyethylene 
glycol polyacrylamide copolymer (PEGA) resin (0.2 mmol/g). 
                                                 
A Library synthesis on Fmoc-Rink-PEGA resin by the author and Dr Eftychia Koini. 
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Table 2.1: PhosphoSitePlus® database analysis of amino acids around the phosphorylation 
site of all known tyrosine kinases.  Numbers are shown as a percentage, with the yellow 












Alanine 6.97 6.00 0 6.47 6.65 
Arginine 5.61 4.75 0 4.94 5.40 
Asparagine 4.75 4.63 0 3.76 5.00 
Aspartic Acid 7.80 8.70 0 6.40 6.76 
Cysteine 1.20 1.31 0 1.50 1.84 
Glutamic Acid 7.51 7.48 0 8.94 7.53 
Glutamine 4.15 3.94 0 5.28 4.14 
Glycine 7.80 6.70 0 6.61 6.58 
Histidine 2.21 2.54 0 2.58 2.07 
Isoleucine 3.48 6.20 0 4.46 4.24 
Leucine 7.16 7.73 0 7.75 7.35 
Lysine 6.56 5.62 0 5.08 6.12 
Methionine 1.86 1.58 0 2.08 2.52 
Phenylalanine 2.35 2.62 0 2.99 2.80 
Proline 7.75 5.85 0 3.48 5.65 
Serine 8.97 7.47 0 10.46 8.95 
Threonine 5.10 5.61 0 5.46 5.98 
Tryptophan 0.49 0.62 0 0.62 0.64 
Tyrosine 3.29 3.77 100 4.38 3.58 
Valine 4.94 6.89 0 6.49 5.54 
        = Amino acids used for the improved library. 
For this library, an analysis of all known tyrosine kinase substrates was 
undertaken and the 10 amino acids with the highest abundance for the two positions 
on either side of the phosphorylation site were chosen.B  A cell penetrating peptide 
(CPP 2.1, Lys9) was also added to the library to allow the library to enter cells in 
order to enable analysis of the enzyme activity inside a cell.   
To ensure this to be achieved a CPP was synthesised on a 2-chlorotrityl 
functionalised polystyrene resin and cleaved as shown in Scheme 2.1. 
                                                 
B Analysis done by Dr Ruben van Boxtel. 
His-tag split-and-mix library  Chapter II 
P a g e  | 29 
 
 
Scheme 2.1: Top: Synthesis of protected CPP 2.1.  Pre-activated 2-chlorotrityl polystyrene 
resin was functionalised with Fmoc-Ahx-OH (Fmoc-aminohexanoic acid) in the presence of 
DIPEA.  Followed by Fmoc-deprotection using piperidine and coupling of Fmoc-Lys(Boc)-OH 
using Oxyma/DIC.  After repeating the coupling nine times, the CPP was capped with acetic 
anhydride and cleaved from the linker with AcOH:TFE:DCM.  Bottom: MALDI-TOF MS 
spectra and HPLC (insert) of 2.1. 
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The protected peptide was then coupled to the PNA encoded library using 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrogen chloride (EDC•HCl) and N-
hydroxysuccinimide as the last step before cleavage from the Rink-linker (Scheme 
2.2).   
 
Scheme 2.2: New PNA-encoded library synthesised (split-and-mix method) on PEGA resin 
using Fmoc-chemistry and Oxyma/DIC covering 20% of known tyrosine kinase substrates 
and coupling of the CPP (4.1).  Amino acids used: A, D, E, G, K, L, N, P, R, S. 
The library 2.2 was added to both cell lysate and K562 (human 
erythromyeloblastoid leukaemia) cells (Figure 2.3A) to obtain a specific fingerprint 
of kinase activity in cells.  However, when the library was hybridised onto the 
microarrays and scanned, the entire surface of the microarray ‘lit-up’ in the Cy5 
signal (used for phosphorylation information) thus interfering with the analysis of 
this experiment (Figure 2.3C).  In contrast Figure 2.3B shows the hybridisation 
control, where the library 2.2 was incubated with a rec. Abl kinase, followed by 
hybridisation onto a microarray.  No contamination was visible on the surface of this 
array, and from the expansion it can be seen that some of the spots are yellow, 
meaning information of phosphorylation could be extracted.  This observation was 
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unexpected and was thought to be due to proteins from the cell adhering to the 
microarray surface.   
 
Figure 2.3: A: Showing K562 cells after incubation of library 2.2 (2 µM) in media for 2 h.  
Merged image of bright field and fluorescent: λex = 527-563 nm; λem = 570-650 nm. Bar = 200 
µm;  B: Image of microarray with library 2.2 treated with rec. Abl kinase hybridised, showing 
no contamination of the surface between the spots, the yellow spots show phosphorylation 
information (Cy5 signal);  C: Image of a microarray following hybridisation of library 2.2 from 
cell lysate from K652, showing proteins stuck onto the microarray with the expansion 
showing the surface between individual spots showing fluorescence.  B and C: A custom 
DNA arrays (4 × 44k) from Agilent was used, and hybridisation preformed in GenHyb buffer 
(genetix).  Hybridisation at temperature decreasing from 60 °C to 50 °C in 5 °C steps every 
30 min, followed by 2 °C steps every 30 min to 40 °C and finally at 37 °C for 18 h. Green 
signal of TAMRA, red signal Cy5. C   
To overcome this problem, the library (with an average weight of 10,000 Da) 
was partitioned between 30,000 and 3,000 Da filters to remove as much of the cell 
protein debris as possible.  Unfortunately, some of the library was not recovered 
from the 30,000 Da filter.  After extensive washing of the filter, some of the library 
                                                 
C Work by Dr Ruben van Boxtel. 
B C A 
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was still left on the filter (filter was coloured red).  Therefore, results obtained from 
this library would not give an accurate measure of enzyme activity, as there was no 
possibility of knowing what was left on the filter. D    
To reduce the high background signal, various detergents were investigated to 
try and wash away the protein debris.  Figure 2.4 shows a comparison of the 
hybridisation signal of the library 2.2 when treated with three different detergents.  
Figure 2.4a) shows the control experiment where the library was hybridised directly, 
and b) – d) show the hybridisation using Tween 20, NP40 and Triton-X as detergents 
respectively.   
 
Figure 2.4: Test of the different detergents and their effects on hybridisation.  To K562 cells 
were added Tween 20, NP40 and Triton-X for 10 min, followed by the addition of library 2.2 
and incubation for 2 h at 37 °C in the presence of protease/phosphatase inhibitors.  After 
centrifugation, the supernatant was used for the hybridisation.  a) Library 2.2 hybridised 
without lysate and detergent; b) Tween 20; c) NP40; and d) Triton-X.  The signal produced 
by TAMRA (which all members of the library possess) was used to determine the efficiency 
of the hybridisation.E  
 
                                                 
D Work by Dr Ruben van Boxtel. 
E Microarray experiment carried out by the author and Dr Ruben van Boxtel.  Data analysed by Dr van 
Boxtel. 
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Compared with the positive control, where the majority of the population was 
at a Cy3 intensity between 2000–4000 units, all the detergents were signals less than 
2000.  Since the same amount of library was used for all the experiments, it clearly 
showed that these detergents affected the hybridisation of the PNA-encoded library. 
Thus, a different method for collecting or purifying the library from the cell 
debris was required.  For this purpose, a His-tag was chosen and introduced into the 
library.  The His-tag was first investigated by Hochuli96 in the late 80’s and has been 
hugely used since its discovery for protein purification.97–99  The imidazole group of 
histidine binds to Ni(II), which is immobilised on a solid support.  Consequently any 
material without a His-tag can be washed away, before the library is released from 
the support.   
Different cleavage cocktails were tested for the qualitative cleavage of a fully 
protected Fmoc-His-tag peptide from 2-chlorotrityl linker (see Table 2.2).  In this 
study, different concentrations of hexafluoroisopropanol (HFIP) and trifluoroacetic 
acid (TFA), and a mixture of trifluoroethanol (TFE) and acetic acid, were compared.  
The evaporative light scattering detector (ELSD) signal from high pressure liquid 
chromatograph (HPLC) was chosen to evaluate which conditions were best for the 
cleavage of His-tag so that all the trityl protection groups stayed intact.  A fully 
protected His-tag is important because unprotected side chain amines would 
introduce side-products and interfere with the reaction when the activated ester His-
tag is coupled to the resin bound peptide.  Sinapinic acid matrix used for MALDI-
TOF MS, is acidic enough, and has been shown, to deprotect the acid sensitive 
protection groups when spotted onto the MALDI-plate, and because of this the 
MALDI-TOF MS spectra could show partially unprotected peptides even if none 
were present originally.100     
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81% 87% 97% 
Percentage of fully protected His-tag product peak area under the ELSD-HPLC chromatogram;  HFIP 
cleavage reaction and TFE each for 2 × 30 min;  TFA 3 × 10 min.   
* = combined cleavage solutions evaporated with toluene;   
** = combined cleavage solutions evaporated with hexane. 
 
From Figure 2.5, it can be seen that 20% HFIP (HPLC trace Right) reduced 
the amount of fully protected His-tag (79%) compared to 97% of desired peptide 
when just 10% of HFIP (HPLC trace Left) was used.   
 
 
Figure 2.5: ELSD-HPLC trace of test cleavage for protected Fmoc-His-tag showing the fully 
protected peptide (Left) with 10% HFIP and an additional peak for the His-tag with one Trt 
group being deprotected (Right) when 20% HIFP was used. 
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Using TFA resulted in the cleavage of some of the protecting groups, but 
never exceeded in more than 80% of successful cleavage/deprotection.  The milder 
conditions of TFE:AcOH showed the same result as 10% HFIP.  In addition to the 
different conditions, alternative work-ups were investigated.  For HFIP, the cleavage 
solutions were either evaporated after addition of CHCl3 or toluene, but both of those 
did not show any difference in ELSD signal.  As for TFA, the solvents used for the 
work-up were hexane or toluene.  A 6% decrease of the mono unprotected side 
product was detected in the ELSD when hexane was exchanged for toluene.  This 
could be due to the higher boiling point of toluene compared to hexane.  As the side 
chain protection groups of the protected peptide were acid sensitive, a higher 
concentration of acid should be avoided.  In the case when hexane was used as the 
work-up solvent, hexane evaporated at a faster rate than acetic acid and therefore 
increased the possibilty of losing some of the protection groups of the peptide.  
Toluene has a similar boiling point as acetic acid and therefore would evaporate at a 
similar rate (azeotropes), thereby avoiding the build-up of acetic acid during work-up 
and deprotection of the peptide.  From these test reactions, 10% HFIP in CHCl3 
cleavage condition for the protected His-tag with the C-terminal acid functionality 
intact was chosen.  
The His-tag with Rhodamine (Rho) attached 2.3, was synthesised on a 2-
chlorotrityl linker attached to a polystyrene resin (Scheme 2.3).  Compound 2.3 was 
cleaved from the linker using 10% HFIP in CHCl3.  During the synthesis of the new 
10,000 library of 2.2 half of the resin was set a side with the Fmoc/Dde/ 
allyloxycarbonyl (Alloc) protection still intact.  To this resin, the CPP 2.1 was added 
via the lysine side chain after de-protecting the Alloc group with Pd(PPh3)4, while 
the His-tag was coupled onto the Fmoc deprotected amine using EDC•HCl and N-
hydroxysuccinamide (Scheme 2.4).F 
 
                                                 
F Library synthesised by myself, Dr Mazen Sleiman and Dr Eftychia Koini. 
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Scheme 2.3: Top: Synthesis of protected Rho-His-tag 2.3.  Pre-activated 2-chlorotrityl 
polystyrene resin was functionalised with Fmoc-Ahx-OH in the presence of DIPEA.  Followed 
by Fmoc-deprotection using piperidine and coupling of Fmoc-His(Trt)-OH using Oxyma/DIC.  
After repeating the coupling six times, Fmoc-Ahx-OH was coupled, followed by 5(6)-carboxyl 
aminoethyl rhodamine coupling.  Final cleavage of the protected Rho-His-tag 2.3 from the 
linker using AcOH:TFE:DCM.  Bottom: MALDI-TOF MS spectra and HPLC (Insert) of 2.3. 
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Scheme 2.4: Coupling of His-tag (2.3) and CPP (2.1) to a 10,000 membered split-and-mix 
PNA encoded peptide library.  The resin was deprotected using H2N-OH to allow selective 
cleavage of the Dde-group in the presence of the Fmoc-group, and capped the PNA 
sequence using Ac2O.  The Alloc group was deprotected using Pd(II) followed by coupling of 
2.1.  To couple 2.3, piperidine was used for the deprotection of Fmoc, followed by addition of 
His-tag 2.3.  TFA:TIS:DCM:PhOH was used for the cleavage of 2.4 from the Rink-linker and 
protection group removal. 
 
 
To test the His-tag purification (Scheme 2.5), a small amount of library 2.4 
was dissolved in 200 µL of Buffer 1 (20 nM 2-amino-2-hydroxymethyl-propane-1,3-
diol (TRIS), 150 nM NaCl, 5% Glycerol, pH 8).  The library was incubated for 1 h 
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with 10 µL of Ni-beads.  The beads turned from colourless to red, and were filtered 
off.  The library was eluted by adding 200 µL Buffer 2 (20 nM TRIS, 150 nM NaCl, 
0.1 M ethylenediaminetetraacetic acid (EDTA), pH 8) to the Ni-beads, and agitating 
for 4 × 15 min.  The combined filtrates gave 82% recovery of the library. 
 
 
Scheme 2.5: Library 2.4 test purification using Ni(II) column.  2.4 was dissolved in Buffer 1, 
Ni(II)-beads were added mixed for 60 min.  The red beads were filtered, and after washing, 
suspended in Buffer 2.  After 15 min of shaking the beads were filtered and washed with 
Buffer 2 (× 3), and the filtrates were combined. 
 
Dr Koen Braat mixed the library 2.4 with lysate of human embryonic kidneys 
cells transformed with large T antigen (HEK 293T, 50 µg), 2× kinase buffer, 
protease/phosphatase inhibitor and mammalian protein extraction reagent (M-PER), 
and incubated for 4 h.  After incubation the library was purified using Ni(II)-( 
nitrilotriacetic acid) NTA agarose beads.  After overnight incubation of the mixture 
with the beads at 4 °C, the beads were washed, and the library eluted for 90 min at 4 
°C.  The library was then mixed with the hybridisation buffer (GenHyb), and 
denatured at 90 °C for 10 min.  After this the solutions were added to the microarray 
and hybridised (Figure 2.6).   
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Figure 2.6: Experimental setup showing the incubation, purification and hybridisation onto a 
custom DNA microarray from Agilent (4 × 44k) of library 2.4 with 293T cell lysate.  Image of 
microarray showing: TAMRA in red and Cy5 in green; with the yellow spot showing members 
of the library being phosphorylated.G 
 
 
From the microarray image in Figure 2.6 the cell protein contamination did 
not appear again, and phosphorylation information could be obtained, showing that 
the His-purification was successful.   
In summary, it has been shown that a His-tag purification of the PNA-peptide 
library prior to hybridisation on the microarray is suitable for library isolation from a 
complex cell lysate.  It was also possible to deliver the library into cells by the 
addition of the CPP. 
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3. Evaluation of Ligation Methods 
To evaluate the best method for ligating a PNA library to a library of peptides several 
different ligation strategies were investigated.  These ligation reactions were:  
i. Standard amide coupling. 
ii. Copper catalysed azide–alkyne cycloaddition (copper-click, CuAAC). 
iii. Copper-free click reactions with an azide and a strained cyclic alkyne 
(spAAC).  
iv. Diels–Alder reaction between a tetrazine (TZ) and an alkene.   
After the evaluation of the different reactions, the most promising was selected and 
optimised for the synthesis of the PNA–peptide library. 
 
3.1. Peptide Coupling 
A fully protected peptide (Pep035, Appendix 2) was synthesised using a 2-
chlorotrityl linker attached to polystyrene resin.  The linker is acid labile and when 
treated with a mixture of TFE:AcOH:DCM (1:1:8), peptides are cleaved from this 
linker with all the side chain protecting groups intact.  In addition, the peptides will 
be obtained with an acid functionality at the C-terminus, allowing coupling to an 
amine via a standard amino acid coupling methods.   
For the test reaction, (Scheme 3.1) Oxyma and DIC were used to pre-activate 
the acid group of the protected peptide 3.1 by forming an active ester.  After 10 
minutes pre-activation, the peptide (3 eq) was reacted with the free amine group of a 
PNA (PNA100, Appendix 1) (attached to a resin via a Rink linker).  After the 
coupling reaction a Kaiser test was inconclusive, it was not clearly positive or 
negative.  Cleavage and analysis of the PNA–peptide 3.2 by MALDI-TOF MS and 
HPLC (ELSD detection) indicated that conjugation had not occurred, with only the 
unmodified PNA recovered.  This may have been due to steric hindrance, as the fully 
protected peptide 3.1 and PNA fragments are very large and bulky (3484 g mol-1 and 
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6183 g mol-1, respectively), while the polystyrene resin also had a reasonably high 
loading of 0.5 mmol/g.   
 
Scheme 3.1: Peptide ligation test using a fully protected peptide acid and a PNA attached to 
a Rink linker on a polystyrene-resin. 
 
3.2. Copper(I)-Catalysed Azide–Alkyne Cycloaddition 
(CuAAC)   
6-Azidohexanoic acid 3.3 was readily synthesised from commercially available 6-
bromohexanoic acid 3.4 and sodium azide in 91% yield, and then coupled directly 
onto a Rink linker-PS resin.  To this resin 5-hexynoic acid was coupled using CuSO4 
and sodium ascorbate, and the product cleaved with TFA (Scheme 3.2).  Material 
analysed showed the formation of the desired product 3.5 in a 91% crude yield with 
9% of the cleaved azide still present (Figure 3.1).   
 
Scheme 3.2: Synthesis of 6-azidohexanoic acid and test click reaction on solid support. 
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Figure 3.1: LCMS and HPLC with ELS detection spectra of crude product 3.5 from CuAAC 
ligation test (Scheme 3.2). 
 
Following this positive result, an alkyne functionalised peptide 3.6 was 
prepared and coupled to the azide functionalised beads, again using CuSO4 and 
sodium ascorbate.  Initially, peptide 3.6 was reacted with an azide containing PNA 
bound to the resin (PNA-resin 3.7) under several different conditions as shown in 
Scheme 3.3.71,101  Unfortunately, cleavage from the linker showed only the azide 
functionalised PNA (3.7). 
 
 
Scheme 3.3: Copper(I)-catalysed azide–alkyne cycloaddition ligation using different 
standard conditions. 
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Burrows and Muller102 reported that copper ions can interact with DNA, and 
therefore lower or inhibit the copper from catalysing the reaction.  To overcome 
these problems and stabilise the Cu(I) ions, Chan synthesised a ligand that binds 
strongly to copper(I).78  This ligand, tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] 
amine (TBTA, 1.8), was easily synthesised in one step from tripropargyl amine 3.8 
and benzyl azide 3.9, using CuSO4 as a catalyst in 63% yield (Scheme 3.4).   
 
 
Scheme 3.4: Synthesis of TBTA 1.8. 
 
Alkyne peptide 3.6 and azide–PNA-resin 2.7 were reacted in the presence of 
TBTA 1.8 (6 eq), CuI (3 eq) and sodium ascorbate (3 eq).  After 24 h, the resin was 
sequentially washed with DMSO, a solution of TBTA in piperidine:DCM (1:4), 
DMF, and DCM to remove as much of the copper as possible.  Subsequent cleavage 
from the resin and purification by HPLC resulted in the desired adduct 3.10 in an 
overall yield of 40% (Scheme 3.5).  Since copper can interfere with biological 
reactions,103 it was crucial to determine the overall copper concentration after the 
washing and purification steps.  The copper concentration in the PNA–peptide 3.10 
was determined by inductive coupled plasma-mass spectrometry to be 1.57–1.82 ppb 
(0.025–0.029 µM).  Kennedy103 has studied the toxicity of different copper 
complexes in different cells, and showed that the copper toxicity is dependent on the 
ligand present.  The compound which was the most toxic was shown to be so at a 
concentration of 0.74 µM, which is higher than what was determined from this 
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ligation experiment, but as there is some copper present, the CuAAC was not used 
for ligation as a precaution.  
 
 
Scheme 3.5: CuAAC ligation using the tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine 
(TBTA, 1.8) ligand. 
 
3.3. Non-Copper Click Ligation 
Following on from the copper catalysed click reaction, Agard et al.79 developed an 
azide–alkyne cycloaddition reaction without the need of a catalyst.  This required the 
synthesis of the strained cyclic alkyne 3.14 (4-cyclooctyn-1-ol) (Scheme 3.6).  1,5-
Cyclooctene 3.11 was converted to the mono epoxide 3.12 with meta-
chloroperoxybenzoic acid (mCPBA).  The epoxide was then opened with LiAlH4 to 
give the cis-cyclooctenol 3.13,104 followed by di-bromination using Br2 in DCM.
105  
A dual elimination step would generate the triple bond 3.14.  Although several 
different reactions for the final step were tried (see Scheme 3.6), no product was 
identified, possibly due to product volatility.   
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Scheme 3.6: Synthesis of 4-cyclooctyn-1-ol 3.14 from 1,5-cyclooctene 3.11. 
 
The commercially available bicyclo[6.1.0]non-4-yn-9-ylmethyl succinimidyl 
carbonate was thus used, which was coupled to the free amine of the test peptide 
3.15.  After cleavage, peptide 3.15 was coupled to the resin bound azide–PNA 3.7.  
The resin was washed to remove the excess peptide, and the peptide–PNA conjugate 
cleaved to give the desired ligation product 3.16 (Scheme 3.7).  Analysis of the crude 
product mixture by MALDI-TOF MS and HPLC, found the product was formed in 




Scheme 3.7: Ligation test of copper-free click reaction using the strained cyclooctyne and 
azide.  
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3.4. Tetrazine 
The last ligation strategy tested was based on the inverse electron demand Diels–
Alder reaction between a tetrazine (TZ) and alkene.  The test TZ used was 3,6-
dichloro-s-tetrazine 3.17,§§ which was prepared in the Bradley group using the 
synthesis described by Gong (Scheme 3.10).106  This tetrazine was coupled via a 
nucleophilic aromatic substitution of one chlorine to the free amino terminal of the 
PNA-resin (Scheme 3.8), by dissolving the TZ 3.17 in DCM with 2 eq of DIPEA.   
 
Scheme 3.8: Dichloro-TZ 3.17 addition to the amino terminal of the resin bound PNA. 
 
3.4.1. 3,6-Bis(3,5-dimethyl-1H-pyrazol-1-yl)-s-tetrazine 
Peptide 3.1 was functionalised with a 5-norbornene-2-carboxylic acid using standard 
SPPS coupling conditions on a trityl linker.  After cleavage, peptide 3.18 was added 
to the Cl-TZ-PNA 3.19 resin at 75 ˚C (Scheme 3.9).  Analysis of the cleaved 
material showed that the reaction had not gone to completion, with starting material 
(TZ-PNA) present by HPLC analysis, suggesting that the functional groups were not 
reactive enough. 
 
Scheme 3.9: Ligation test of norbornene-peptide 3.19 and Cl-TZ-PNA 3.20 on resin. 
 
                                                 
§§ Synthesised by Elizabeth Jameson 
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Two different ways to improve this reaction were explored: using a more 
electron poor TZ and introducing an alkene that was more reactive.  As the reaction 
temperature was already at 75 ˚C, greater heating was not further investigated. 
3,6-Bis(3,5-dimethyl-1H-pyrazol-1-yl)-s-tetrazine 3.20 is a precursor to the 
3,6-dichloro-1,2,4,5-tetrazine 3.17, and can be coupled to the N-terminus of the PNA 
through nucleophilic aromatic substitution.  The synthesis of this tetrazine was easily 
achieved in high yields by employing commercially available starting materials 
(Scheme 3.10).  Guanidine hydrochloride 3.21 reacted with hydrazine in two hours 
to give triaminoguanidine monohydrochloride 3.22 quantitatively.  The adduct 
formed was used without purification to produce 3,6-bis(3,5-dimethylpyrazol-1-yl)-
1,4-dihydro-1,2,4,5-tetrazine 3.23 in good yields (69%) by reacting it with 2,4-
pentanedione 3.24.  The oxidation of the dihydro-s-tetrazine 3.23 to s-tetrazine 3.20 
was carried out by using either NaNO2
106 or isoamyl nitrite107 giving 56% and 
quantitative yields respectively.   
 
 
Scheme 3.10: Synthesis of dichloro-tetrazine 3.17 from guanidine hydrochloride 3.21.  
Reaction in the box done by Elizabeth Jameson. 
 
The dimethylpyrazol-TZ 3.20 was first coupled to the N-terminus of the PNA 
(using the same conditions as for the dichloro tetrazine 3.17), and then reacted under 
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the same conditions as in Scheme 3.9 with the peptide 3.18.  Unfortunately, this did 
not result in the formation of any desired product.  For a better understanding of the 
Diels–Alder reaction and to optimise the conditions for the desired product, two 
small molecules were synthesised to mimic this reaction (Table 3.1).  
 
Table 3.1: Reverse electron demanding Diels–Alder cycloaddition test reactions between 
3.25 and 3.26. 
 
 
1 eq of alkene 3.25 3 eq of alkene 3.25 
Temp ˚C DMSO NMP DMF DMSO NMP DMF 
RT 0% 0% 0% 0% 0% 0% 
45 6% 3% 6% 4% 3% 3% 
110 42% 30% 38% 27% 38% 33% 
Area of product peak under the ELSD-HPLC chromatogram given in %  
 
Table 3.1 shows the different reaction conditions used for this ligation test 
reaction, including alterations in the equivalence of alkene 3.25 to tetrazine 3.26, 
reaction temperatures and solvents.  From this it could be concluded that a higher 
reaction temperature than 110 ˚C or longer reaction time than 24 h would be needed 
to give a fully complete reaction.  Therefore a different TZ/alkene pair was 
investigated. 
 
Evaluation of Ligation Methods  Chapter III 
P a g e  | 50 
3.4.2. Synthesis and test ligation of trans-cyclooctane 
Parallel to the synthesis of the tetrazine moiety, the alkene moiety was also 
investigated.  It has been shown that trans-cyclooctane rapidly undergoes the 
cycloaddition with a TZ.83  The cis-cyclooctanol 3.13 can be prepared from 1,5-
cyclooctadiene 3.11 in two steps as described in Scheme 3.6.  Here the cis-isomer 
was used to make the trans-isomer 3.27. 
 
Scheme 3.11: Synthesis of trans-cyclooctene succinimide carbonate 3.28 starting from 
previously prepared cis-cyclooctenol 3.13.  
 
The reaction involved cis–trans isomerisation using UV light at 254 nm in 
the presence of methyl benzoate.  This was left for 12 h and at every 2 h interval the 
reaction solution was passed through a column containing AgNO3 on silica.  AgNO3 
binds strongly to trans-cyclooctane 3.27 but not to the cis-isomer 3.13, therefore 
removing the product from the reaction.  The yield of this reaction was low, and the 
two isomers of the product were collected in 16% and 12% yields.  Attempts to 
scale-up this reaction by constantly pumping the solution through AgNO3 on silica 
and manual filtering out the product failed.   
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The trans-cyclooctanol was coupled to the peptide by first converting the 
alcohol to the succinimide carbonate 3.28 (Scheme 3.11), and then reacting for 18 h 
with the free N-terminus of the model peptide.  After cleavage from the resin, peptide 
3.29 was reacted with the prepared chlorotetrazine–PNA 3.19 (on solid support) for 
18 h (Scheme 3.12).  After work up, the analysis showed the formation of the PNA–
peptide 3.30, but yet again showed the presence of unreacted starting PNA.  This 
may have been due to the re-isomerisation of some of the trans- to the cis-
cyclooctane, which is less/non-reactive,83 or it could also be steric hindrance as both 
of the fragments are large molecules. 
 
 
Scheme 3.12: Ligation test using trans-cyclooctene–peptide 3.29 and Cl-TZ-PNA 3.19. 
 
3.4.3. Mono-Acid tetrazine 
Following on from the difficulties with the Diels–Alder ligations, a different strategy 
was employed.  5-Norbornene-2-carboxylic acid was used, as this has been used in 
the literature in conjunction with 4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic 
acid 3.31 (TZ-OH).107  It is reported that the Diels–Alder reaction between those two 
moieties takes place within 10 min.85  Synthesis of the tetrazine 3.31, following a 
procedure from a patent,108 proved to be difficult.  The maximum yield obtained was 
5% using the published purification methods, but some symmetrical acid by-product 
was still present.  The same group published a paper with an altered method, which 
improved the yield, but still resulted in the symmetrical acid contamination after 
Evaluation of Ligation Methods  Chapter III 
P a g e  | 52 
purification.107  To overcome this, the product was purified by flash column 
chromatography, resulting in the desired pure product in 13% yield (Scheme 3.13).  
This low yield could have been because of the product is very polar and even using 
20% methanol and 5% AcOH in DCM, it migrated very slowly down the silica 
column.   
 
Scheme 3.13: Synthesis of 4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic acid 3.31. 
 
To a solution of the TZ-OH 3.31 in methanol, one equivalent of the 
norbornene was added.  The completion of the reaction could be followed/estimated 
visually, as the tetrazine solution was purple/red, which turned colourless/yellow 
once the reaction was completed within 30 min.   
Next, different reaction conditions for the coupling of the TZ on solid phase 
were screened with product formation analysed by HPLC and MALDI-TOF MS.  
Table 3.2 displays the results of coupling tests with the first column showing the 
different activation reagents used.  For all the experiments the TZ was dissolved in a 
mixture of dimethyl sulfoxide (DMSO):DCM.  It was noted that under the cleavage 
conditions (TFA:TIS:DCM, 90:5:5) that the TZ functionality was decomposing.  To 
analyse which coupling method worked best, norbornene acid was added to the TZ 
before the cleavage of the test PNA.  From this screening test, DIC/Oxyma and N-
hydroxysuccinimide (HOSu)/py coupling protocols were selected to further test and 
optimise the reaction conditions. 
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Table 3.2: TZ peptide coupling screening. 
 
 
1 h, 60 ˚C 3 h 24 h 
DIC 
MS: 
A:     
B:     
MS: 
A:     
B:     
MS: 
A:     
B:     
ELSD: 
A: 55% 
B:   0% 
ELSD: 
A: 70% 
B:   0% 
ELSD: 
A: 62% 




A:     
B:     
MS: 
A:     
B:     
MS: 
A:     
B:     
ELSD: 
A: 77% 
B:   5% 
ELSD: 
A: 90% 







A:     
B:     
MS: 
A:     
B:     
MS: 
A:     
B:     
ELSD: 
A: 83% 
B:   0% 
ELSD: 
A: 91% 
B:   0% 
ELSD: 
A: 40% 




A:     
B:     
MS: 
A:     
B:     
MS: 
A:     
B:     
ELSD: 
A: 55% 
B:   0% 
ELSD: 
A: 44% 
B:   0% 
ELSD: 
A: 20% 




A:     
B:     
MS: 
A:     
B:     
MS: 
A:     
B:     
ELSD: 
A: 65% 
B:   0% 
ELSD: 
A: 81% 
B:   0% 
ELSD: 
A: 79% 
B:   0% 
EEDQ 
MS: 
A:     
B:     
MS: 
A:     
B:     
MS: 
A:     
B:     
ELSD: 
A: 56% 
B:   0% 
ELSD: 
A: 71% 
B:   0% 
ELSD: 
A: 82% 





A:     
B:     
MS: 
A:     
B:     
MS: 
A:     










MS:  indicates that the mass of the product B or starting material A is not seen and the  indicates 
the presence of the correct mass; ELSD: gives the relative % according to the area of the peak in the 
HPLC chromatogram. 
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The different optimisation reaction conditions can be seen in Table 3.3.  The 
tetrazine acid (TZ-OH, 3.31) was coupled using Oxyma and DIC with different 
reaction times, from 1 h to 24 h in DMF.  From these results, it can be seen that the 
tetrazine decomposed when left overnight and no difference was observed between a 
2 × 1 h and the 2 × 3 h coupling.  It was noted that a solution Oxyma, DIC and 
tetrazine in DMF was colourless after 18 h, indicating decomposition in DMF.  
However, this was not seen when DMSO was used.  As for the succinamide 
tetrazine, different solvent mixtures were used for the coupling (Table 3.3).  The best 
result was obtained when a mixture of DMF/pyridine (py) (19:1) was used, and in 
this mixture the tetrazine did not decompose.   
 
Table 3.3: TZ peptide coupling optimisation.  
 
TZ-OH, Oxyma/DIC TZ-OH, HOSu/py, 18 h 











77% 77% 37% 78% 80% 88% 24% 
% based on area in HPLC chromatogram with an ELS detector 
 
Finally, the coupling conditions of the two best results were repeated, to 
evaluate which would be the best for the synthesis of the library (Table 3.4).  Using 
Oxyma/DIC in DMSO/DCM (2:1) for 2 × 1 h showed the best results. 
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Table 3.4: Re-evaluation of optimised TZ peptide coupling reactions. 
TZ-OH, 
Oxyma/DIC, 







% based on area in HPLC chromatogram with an ELS detector 
 
To test the ligation with this tetrazine, the norbornene functionalised peptide 
3.18 was added to the TZ-PNA resin (Scheme 3.14).  Following the conditions used 
before for other ligation methods, the conjugate 3.32 was cleaved and analysed.  
Again, there was still some of the unreacted TZ-PNA present (30%), so it was 
decided to attempt the ligation in solution. 
 
 
Scheme 3.14: Ligation test using norbornene-peptide 3.18 and TZ-PNA. 
 
Evaluation of Ligation Methods  Chapter III 
P a g e  | 56 
For the ligation in solution the TZ would need to remain intact after cleavage.  
From some of the earlier cleavages when the standard cleavage mixture was used 
(TFA:TIS:DCM, 90:5:5) the red colour of the tetrazine disappeared after about two 
hours, probably due to the tetrazine being reduced.  Different cleavage mixtures were 
screened and the reactions were analysed by ELSD-HPLC and MALDI-TOF MS 
(Table 3.5, Figure 3.2a).   
 



























87% 96% 42% 20% 
% based on area in HPLC chromatogram with an ELS detector 
 
From the Table 3.5 it can be clearly seen that the best conditions for cleaving 
the TZ-PNA 3.33 was achieved when TFA:H2O (95:5) was used.  As for the others, 
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PhOH as a scavenger also gave a relatively good result.  The lowest yield was 
obtained in the case were indole was used in the reaction.  It is known that indole can 
also act as a dienophile in the presence of TZ, and hence the yield for the desired 
product may have been reduced.109  
As a final test to determine if the TZ was still active towards the ligation after the 
cleavage, 5-norbornene-2-carboxylic acid was added to the crude 3.33 fragment and 
analysed (Table 3.6, Figure 3.2b).  As a control, norbornene acid was ligated to a 
TZ-PNA resin 3.34 before cleaving the Diels–Alder product from the Rink-liner 
using the standard methods (TFA:TIS:DCM, 90:5:5).  This resulted in a crude purity 
of 3.35 of 88%.  The best result for the Diels–Alder reaction in solution was obtained 
when the TZ as cleavage with TFA and water in a 95:5 ratio.  This showed that the 
TZ was still active in the Diels-Alder reaction, following the TFA treatment.   
 
Table 3.6: Crude TZ-PNA 3.34 from Table 3.5 treated with Norbornene. 
 
A B C D E F G H 
45% 46% 40% 51% 45% 58% 16% 0% 
% based on area in HPLC chromatogram with an ELS detector 
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Figure 3.2: A) HPLC-ELSD and MALDI-TOF MS after cleavage using TFA:H2O (95:5) TZ-
PNA 3.33; and B) HPLC-ELSD and MALDI-TOF MS of reaction between norbornene and 
TZ-PNA 3.33 to form the conjugate 3.35. 
 
3.4.4. Stability of norbornene during TFA cleavage 
In a paper published by Brown,110 it was suggested that TFA can add to the double 
bond of norbornene even at low temperatures.  As the cleavage conditions for 
peptides linked to a resin functionalised with the Rink-linker involve high 
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concentrations of TFA, and most of the peptides that have been used in the study 
were synthesised with an acid sensitive chloro trityl linker, a study was undertaken of 
the stability of norbornene.  For this purpose, a small peptide with different 
functionalities (arginine (Arg), Lys, phenylalanine (Phe) and Tyr) and protecting 
groups (2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf), Boc and tBu) was 
synthesised on an amino-methyl polystyrene resin with a Rink linker.  After the 
coupling of 5-norbornene-2-carboxylic acid using Oxyma and DIC as activators, the 
peptide was cleaved under different conditions and analysed (Table 3.7, Figure 
3.3a).  None of the cleaved products showed the addition of TFA across the 
norbornene double bond.  Some of the Pbf protecting group was not removed under 
the conditions used, and a longer cleavage time was needed for complete 
deprotection.  This though was not a problem as the norbornene was stable under 
vigorous TFA cleavage conditions.   
 












100%b 100% 100% 79% 100%c 
% based on area in HPLC chromatogram with an ELSD; a conc. HCl; b TZ-OH 3.31 was added before 
cleavage as a positive control; c Pbf protection group still attached. 
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Figure 3.3: Peptide 3.36 reaction with TZ-OH 3.31 after peptide cleaved from resin using 
TFA: A) MALDI-TOF MS and HPLC of starting peptide 3.36; B) MALDI-TOF MS and HPLC 
of conjugate 3.37. 
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A solution of TZ-OH 3.31 in DMSO and DCM (1:1) was added to the 
cleaved peptide.  After 60 min reactions were analysed by HPLC and MALDI-TOF 
MS (Figure 3.3 b), and they all showed the conversion of the starting material 3.36 
to the desired product 3.37.  For peptides where the Pbf group was not deprotected, 
the mass of the adduct 3.37 plus the Pbf-groups was seen in the MALDI-TOF MS.  
As a control, peptide 3.36 was also made without the norbornene functionality.  This 
peptide was then treated with the same TZ-OH solution.  Upon analysis by LC-MS 
and HPLC-ELSD, the TZ-OH signal had disappeared.  This was an unexpected 
result.  TZ-OH 3.31 is unstable under basic environments, but in the stock solution 
(3.31 in DMSO:DCM (1:1) with 0.1% DIPEA) the TZ-OH was stable for several 
days.  This would perhaps indicate that the arginines in the peptides are basic enough 
to decompose the tetrazine.   
 
3.5. Conclusion 
In conclusion, the best ligation method was the reaction between 4-(6-(pyrimidin-2-
yl)-1,2,4,5-tetrazin-3-yl)benzoic acid 3.31 and 5-norbornene-2-carboxylic acid.  The 
coupling reaction of the tetrazine to a resin bound amine was found to be ideal when 
using Oxyma/DIC in DMSO/DCM (2:1) for 2 × 1 h, while the cleavage conditions 
were best using TFA:H2O (95:5).  It was also shown that norbornene was stable 
under the standard TFA cleavage conditions, which is in contrast to work published 
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4. Evaluation of a PNA in situ hybridisation and 
fluorophore ligation strategy 
4.1. Introduction 
Fluorescent in situ hybridisation (FISH) is a cytogenetic technique that visualises the 
presence of specific DNA/RNA sequences and their location, be it in the nuclei or 
the cytoplasm.  FISH probes are synthesised with a complimentary sequence to the 
target sequence and with a fluorophore attached.  This probe hybridises to the target 
DNA/RNA sequence (Figure 4.1A) and can be analysed by fluorescence 
microscopy.  Figure 4.1B and C shows FISH being used to show the presence of a 
specific DNA sequence on a chromosome (red dots), and mRNA inside the 
cytoplasm (white dots).   
 
 
Figure 4.1: A: Cell with a FISH-probe hybridising to a DNA or RNA target; B: Image of FISH 
used to highlight in red DNA sequences on a chromosomes; C: Image of FISH being used to 
show mRNA sequences inside the cytoplasm (dots).111  (Image B as published by Genet112 
in the open access journal Molecular Cytogenetics, and C as published by Shaffer111 in the 
open access journal PLoS ONE). 
 
“FISH in operation” 
Detection of mRNA 
in Cytoplasm 
“FISH in operation” 
Detection of DNA 
sequence on a Gene 
Nucleus 
Gene 
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FISH developed from in situ hybridisation methods which were first reported 
in the late 60’s by John113 and Pardue114 using radiolabelled RNA/DNA probes.  To 
improve signal detection, reduce the time for imaging and increase the safety aspect, 
various methods were developed that used fluorescence instead of radiolabels.115,116  
This included the use of biotinylated DNA probes that could be detected by either 
labelled streptavidin,117 or with a rabbit anti-biotin antibody, followed by a 
fluorescein-labelled anti-rabbit antibody.118  FISH is used in clinical situations for the 
detection of mutations related to illnesses, personalised medicine, and for the 
detection and classification of hematopoietic malignancy (leukaemia, multiple 
myeloma, amongst others) and non-hematopoietic malignancy (lung cancer, breast 
cancer, amongst others).119  Following the development of PNA,24 in situ 
hybridisation with PNA was utilised for FISH experiments, with advantages over 
DNA probes due to stronger affinities towards target DNAs in comparison to DNA-
DNA interactions.120   
Taneja120 compared a DNA (30mer) probe labelled with fluorescein and a 
PNA (15mer) probe labelled with Cy3, to analyse the presence of triple repeats 
(CTG) in DNA in fixed human myotonic dystrophy cells.  In this experiment, a 
DNA-probe was firstly hybridised, followed by addition of a PNA-probe, which 
targets the same DNA-target as the DNA-probe.  The PNA-probe was found to 
completely replace the DNA-probe.  In addition, it was observed that the PNA-probe 
identified more targets in the sample compared to the DNA-probe, and the PNA-
probe florescence signal was more intense with respect to the DNA counterpart 
probe.  Both of these indicate that the PNA-probe was more selective and has a 
higher affinity for the DNA-target compared to the larger DNA-probe.  Santangelo121 
used molecular beacons (Cy3/black hole quencher 2 (BHQ-2) / Cy5/BHQ-3) to 
visualise real-time dynamic measurement of RNA localisation in living cells with 
response to drug molecules or external stimulants.  FISH was used (which usually 
uses fixed cells) to confirm the RNA localisation pattern in live cells, which showed 
good correlation with respect to the live cells. 
Another development using the principle of FISH was termed “small 
molecule FISH” (smFISH) by Femino.122  Femino used five oligonucleotide probes 
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that hybridise to adjacent sequences on mRNA to determine the target mRNA 
molecule location inside a cell.  Several different mRNA targets have been tested.  In 
all, it was demonstrated that using this approach of multiple dye molecules on a 
single probe improved the sensitivity and increased the signal to noise ratio when 
compared with a single probe labelled with one dye.  The oligomers were between 50 
and 65 nucleobases, and each molecular probe had five fluorophore molecules 
attached (Figure 4.2 A).  Many examples exist in which smFISH was 
applied.111,123,124  Tyagi125,126 attached only one dye to a 3ꞌ position of the probe, but 
used multiple probes (50) that bind sequentially to the target RNA.  One of their 
examples was the visualisation of the mRNA of the fusion protein BCL–ABL.  Two 
sets of probes were synthesised that detected the exon 1 sequence located at the 5ꞌ 
end of BCR mRNA and the exon 11 of ABL mRNA that is located near the 3ꞌ end 




Figure 4.2: A: Five smFISH probes with five fluorophore per probe used by Femino;122 B: 
smFISH method used by Tyagi to detect the mRNA fusion BCL-ABL.126 
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The probes were labelled with TAMRA (for ABL) and Alexa Fluor 594 (for 
BCR).  In the smFISH experiment, K562 cells were used as they express the target 
fusion protein, and HeLa (cervical cancer) cells were used as a negative control.  The 
individual signals for both ABL and BCR where visible in both cell lines, but only in 
K562 cells both of the signals (ABL and BCR) were located in the same spot (Figure 
4.3), indicating the percent of BCL–ABL fusion mRNA.126   
 
Figure 4.3: Top: Cell images of K562 images showing the presence of ABL (red dots), BCR 
(green dots) and BCR-ABL (yellow dots) mRNA, and HeLa cells (negative control) only 
showing the presence of ABL and BCR  (as published by Markey126 in open access journal 
PLoS ONE). 
Another method for intracellular detection of DNA strands is based on the 
azide–alkyne Huisgen cycloaddition (Figure 4.4).127  A modified nucleobase was 
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introduced to a cell and during cellular replication and incorporated into the DNA 
strand.  An advantage of using these small nucleobase modifications (alkyne or azide 
functionalised) compared to others, where the functional group is a fluorophore, is 
that the smaller monomers do not interfere significantly with the folding and 
hydrogen bonding of the DNA duplex.128  Many examples exist in the literature 
where such monomers are introduced into DNA followed by the ligation of a 
fluorophore using the copper(I)-catalysed azide–alkyne cycloaddition (CuAAC).129–
132   
 
Figure 4.4: Some examples of modified bases incorporated into DNA and subsequently 
modified using a CuAAC coupling reactions. 
 
In order to address the toxicity issue of copper(I) and its ability to partially 
degrade DNA and proteins,103,133 Luedtke132 investigated the use of a copper free 
Huisgen cycloaddition, known as “strain-promoted AAC” (spAAC).  In the 
experiment the group was comparing the ligation effectiveness of both the CuAAC 
and spAAC, which showed that spAAC was not as effective in the ligation when the 
DNA was not denatured before the ligation.  When the DNA was denatured the 
fluorescence intensity was the same for both reactions.  Interestingly, this experiment 
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showed evidence that the copper free cycloaddition ligated to single stranded DNA, 
whereas CuAAC ligates throughout the DNA sequence.  This differentiation is useful 
in identifying single stranded DNA in the nucleus.   
Another interesting development using the CuAAC reaction was carried out 
by Carell,69  who used three different alkyne nuclear base monomers, and introduced 
them into DNA.  Two of the monomers had a protecting group that can be 
orthogonally removed, freeing the alkyne that can then undergo CuAAC with 
different azides.  Here three different labels where coupled on to the DNA (Scheme 
4.1), including biotin and several different fluorophores were introduced.   
 
Scheme 4.1: Top: Modified nucleobases used for the synthesis in the DNA synthesis; and 
Bottom: Labeling of the DNA strand with three different probes using CuAAC reaction.  After 
the first click reaction, the TMS protection group was removed, followed by the second click 
reaction.  TIPS was then removed subsequently before the third click reaction. 
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4.2. Results and Discussion 
The approach here was to utilise tetrazine chemistry to label PNA-probes.  Thus TZ-
PNA was hybridised in situ to a mRNA target, followed by in situ ligation of a 
fluorophore (Figure 4.5).   
 
Figure 4.5: FISH experimental procedure: After fixing the cells the TZ-PNA probe was 
hybridised onto the RNA target, followed by ligation of Nor-Flu 4.3 to the tetrazine, followed 
by washing and imaging of the cells by microscopy.  
 
PNA probes targeting the mRNA of glyceraldehyde 3-phospate 
dehydrogenase (GAPDH) and Ribosomal RNA 28S were used to verify the approach 
in fixed HeLa cells (Figure 4.6). 
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Figure 4.6: PNA probes used for the FISH experiment. 
FISH experiments were carried out with linear PNAs, which were 
functionalised with TZ-OH 3.31.  Detection of TZ probes was carried out by 
intracellular hybridisation to the target RNA followed by incubation with norbornene 
functionalised 5-aminofluorescein 4.3 (see Figure 4.5, and Scheme 4.3).  This 
system has the advantages of a short PNA sequences being used unlike the approach 
of Santangelo,121 which simplifies the synthetic procedure and purification.  A 
carboxyl fluorescein-PNA (CF-PNA) construct was used as a positive control to 
validate the hybridisation of the probe to the target mRNA inside cells.   
 
4.2.1. PNA synthesis 
Synthesis of the PNA probes was carried out using a semi-automated peptide 
synthesiser with microwave heating on ChemMatrix resin with an attached Rink-
amide linker.  Following PNA preparation (Figure 4.6), TZ-OH 3.31 or 5,6-
carboxyfluorescein were coupled to the PNAs (Scheme 4.2).   
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Scheme 4.2: Synthesis of PNA probes 4.1A, 4.1B, 4.2A, and 4.2B using a Biotage® 
Initiator+ SP Wave peptide synthesiser with ChemMatrix (CM) resin. 
 
Employing cleavage conditions optimised for tetrazine functionalised 
peptides (TFA:H2O, 95:5; 3 h) resulted in the expected product with the attachment 
of a group resulting from the cleavage of the Bhoc-protecting groups.  Polystyrene 
resin has a hydrophobic backbone enabling free water molecules to scavenge the 
released diphenylmethyl carbo-cations.  In contrast, the backbone of ChemMatrix-
resin is composed of PEG-chains, which may hinder water molecules from 
scavenging.  This effect was avoided by substituting water with phenol, which 
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resulted in the generation of the expected PNAs.  To attach a fluorophore onto the 
TZ-moiety of the PNA probe by tetrazine ligation, a fluorescent-norbornene 
conjugate was prepared.  This was achieved by coupling 5-aminofluorescein 4.4 to 
exo-5-norbornenecarboxylic acid using HBTU/DIPEA.  After purification the desired 
product 4.3 was obtained in 13% yield.   
 
Scheme 4.3: Synthesis of norbornene-fluorescein 4.3 by coupling norbornene acid to 5-
aminofluorescein 4.4.  
 
4.2.2. In-cell hybridisation and ligation 
Fixed cells were incubated with PNA-probes (4 µM) at 37 ˚C for 20 h as described in 
the literature.121  The hybridisation solution was removed and the cells were washed, 
followed by addition of 4.3 (4 µM) to TZ-PNA incubated cells.  The ligation was 
carried out for 2 h and the cells were washed, and stained with a cell nucleus stain 
4',6-diamidino-2-phenylindole (DAPI) prior to imaging.  As shown in Figure 4.7 it 
can clearly be seen that 4.1A is able to detect GAPDH mRNA by hybridisation (as 
indicated by strong fluorescence (Figure 4.7A)).  The use of probe 4.1B followed by 
ligation of 4.3 did not result in a significant fluorescence signal (Figure 4.7B, shows 
a very weak signal).  This could have been because the ligation had not been 
completed in the time allocated for the reaction, as intracellular TZ–Nor ligation in 
fixed cells maybe slower than in solution phase or live cells.  A similar result was 
seen for the 28S rRNA-probe 4.2A compared with the TZ probe 4.2B (Figures 4.7C 
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and 4.7D, respectively).  However, the control probe 4.2A had a remarkably lower 
fluorescence in comparison to control probe 4.1A.  As the control probe 4.2A did not 
show much fluorescence, which indicates that much less 28S mRNA was present in 
the cell.  As a negative control, fixed cells were incubated with the ligation probe 
Nor-Flu 4.3 in the absence of any PNA and TZ.  This was done to show that when 
cells are treated with 4.3 only, no fluorescence would be observed, and indeed none 
was observed.   
 
Figure 4.7: FISH experiment using 4 µM of probe A: 4.1A; B: 4.1B after incubation with 
Nor-Flu 4.3 (4 µM); C: 4.2A; D: 4.2B after incubation with Nor-Flu 4.3 (4 µM); and E: cells 
treated with DAPI and Nor-Flu 4.3 (4 µM).  DAPI: λex = 340–395 nm; λem = 430–505 nm; 
FAM: λex = 447–495 nm; λem = 500–554 nm.  Bar = 50 µm 
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To investigate the intracellular stability of the TZ-norbornene construct, 
ligation was carried out prior to incubation in the cells and the construct added to 
cells.  It can be seen that the fluorescence intensity increased when the pre-ligated 
probe was used, (after the ligation, the solution of 4.1B and 4.3 was treated with TZ-
CM resin (prepared in-house) for 2 h to scavenge any unreacted 4.3 before the 
ligated probe was used in the FISH experiment).  As seen in Figure 4.8B, the 
fluorescence increased when the ligation was carried out before the ligation 
compared to the intracellular ligation, although the intensity was still much lower 
than the positive control probe 4.1A (Figure 4.7A).  This could be an indication that 
either ligation in fixed cells needs longer reaction times, or that the long-term 
exposure of the tetrazine to the cellular environment interferes with the TZ 
chemistry.  It is also possible that higher concentrations of the labelled tetrazine are 
needed to “push” the in vivo chemistry to completion.  The formaldehyde cellular 
fixing generates a complex 3D network and this might interfere with the labelling 
reaction kinetics.   
 
 
Figure 4.8: A: probe 4.1B with Nor-Flu 4.3 ligation in cells;  B: probe 4.1B with Nor-Flu 4.3 
ligation before incubation with cells;  C: cells treated with DAPI and Nor-Flu 4.3.  DAPI: λex = 
340-395 nm; λem = 430-505 nm; FAM: λex = 447-495 nm; λem = 500-554 nm.  Bar = 50 µm 
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4.3. Conclusion  
PNAs complementary to two specific mRNA located inside cells were synthesised.  
The PNAs terminated with either fluorescein or a TZ-moiety was used to ligate a 
norbornene-fluorescein.  However, following hybridisation, the ligation could not be 
achieved with any great efficiency.  Tests of a pre-ligated PNA-fluorescein construct 
demonstrated the ability to detect the target mRNA, showing that the final product is 
stable in a cellular environment and hybridised.  Future work could be to use alkyne 
tagged-DNA or alkyne-tagged PNA probes and label them with tetrazine probes, 
such as those recently reported by Weissleder134,135 that “switch-on” fluorescence 
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5. PNA–Peptide Library  
Peptide libraries were synthesised with a PNA-tag attached, to allow hybridisation 
onto a DNA microarray.  The peptide sequences chosen were designed to allow the 
interrogation of tyrosine kinase activity found within human leukemic tissue, with 
phosphorylation by aberrant overexpressed tyrosine kinases.  This was achieved by 
the parallel synthesis of the desired PNA and peptide sequences, with the library 
assembled by ligation of each of the fragments. 
 
5.1. Synthesis of PNA-tags 
For the synthesis of the PNA-tags coupling on a diverse set of resins along with a 
variety of coupling methods were evaluated.  The resins (characterised in Table 5.1) 
were used in combination with Oxyma/DIC or HBTU/DIPEA, with the synthesis of 
the PNA started by coupling of the Rink-linker.  This was followed by coupling of 
the PNA monomers to form the tag sequence.   




Swelling in DMF 
mL/g 
ChemMatrix CM 1.0 8 
Low Loading 
Polystyrene 
LL-PS 0.5 6 
TentaGel TG 0.21 5 
Polyethylene Glycol 
Polyacrylamide 
PEGA 0.4 11 
All of the couplings were carried out in a 96-well filter plate, as this was to be 
used to synthesise the full 100 PNA-tags.  The coupling was left at 60 ˚C for 45 min, 
then cleaved using standard TFA conditions, and analysed by MALDI-TOF MS and 
HPLC.  For the PNA synthesis Oxyma/DIC gave better results than the HBTU, and 
was therefore used for the full synthesis.  As for the resin, LL-PS and CM showed 
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similar results, but due to the relative higher cost of CM, LL-PS was used for the 
synthesis of the library.   
Satisfied with the optimisation of the coupling conditions for the well plate 
synthesis of the PNA, a liquid handling robot was programmed to disperse the 
desired activated monomer solution into the correct wells.  All of the PNA sequences 
were designed to have melting temperatures between 34–36 ˚C (Appendix 1), and 
because of this, and for ease of synthesis, guanine was not used.   
Once the programming was verified, PNAs synthesis was attempted.  Ten 
random members of the library were selected (Figure 5.1), and after synthesis a 
small amount was of resin was cleaved and the PNA analysed, showing good crude 
purity by HPLC (65–78%, detection 254 nm).  The remaining PNAs were 
synthesised in batches of 20 per plate.  This also included the resynthesis of 5 PNA’s 
which had a lower purity compared to the rest of the sequences. 
 
Figure 5.1: Parallel synthesis of PNA-tags using a 96-filter well plate with 20–30 mg of resin 
in each well. 
After all 100 PNAs (Appendix 1) were synthesised, the members were stored 
in individual solid phase extraction (SPE)-tubes at −18 °C as Fmoc-protected 
sequences.  A small sample of each PNA was taken and analysed by MALDI-TOF 
MS to validate if all the sequences had been synthesised.  During this, it was noted 
that samples displayed masses of 2–6 Da more than the calculated mass.  This was 
believed to be a calibration error and led to the inclusion of an internal standard 
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(containing Insulin and oxidized bovine Insulin B chain).  One of the examples 
(PNA049) can be seen in Figure 5.2, showing both before (top) and after (bottom) 
calibration, giving the expected mass.  Therefore all PNA’s gave the expected mass 
following MS calibration.   
 
 
Figure 5.2: Analysis of PNA049 (3733.49 Da) with an Internal standard (MALDI-TOF MS 
calibration: INS_BOVIN 3494.65 Da and 5730.61 Da); Top: MALDI-TOF-MS spectra of 
PNA049 showing a mass of 3739.49 Da without calibration;  Bottom: MALDI-TOF-MS 
spectra of PNA049 showing a mass of 3734.05 Da with calibration. 
 
After all PNAs were synthesised, Fmoc-Ahx-OH and 4-(6-(pyrimidin-2-yl)-
1,2,4,5-tetrazin-3-yl)benzoic acid (TZ-OH, 3.31) were sequentially coupled, and the 
modified PNA’s cleaved and purified by prep-HPLC.  The yields after purification of 
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HPLC and MALDI-TOF MS traces of pure PNA028 and PNA050 are shown in 
Figure 5.3).  Lower yields can be attributed to loss of material during HPLC 




Figure 5.3: Structure of TZ-PNAs 5.1; Top: chemical structure and generic representation of 
PNA’s.  HPLC with ELS detection (insert) and MALDI-TOF MS (without internal standard):  
Middle: PNA028 (theoretical mass of 4144.69 Da); and Bottom: PNA050 (theoretical mass 
of 4117.65 Da).  (Note no internal calibration required subtraction of 11 Da to the observed 
masses). 
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5.2. Synthesis of peptide fragments  
The corresponding peptide sequences synthesised (Appendix 2) were all known in 
literature to be phosphorylated solely by tyrosine kinases that are overexpressed in 
acute lymphoblastic leukaemia (ALL).  Most sequences had seven amino acids on 
either side of the tyrosine, and did not contain cysteine or methionine.  The absence 
of those two amino acids was intended to facilitate handling and synthesis of the 
library, eliminating the risk of oxidation.   
The peptides were synthesised on aminomethyl PS resin functionalised with a 
Rink-linker (0.75 mmol/g).  The synthesis was carried out on a fully automated 
peptide synthesiser, which could synthesise two complete peptides during a 24 h 
period.  After each peptide was completed, a small amount was cleaved and 
analysed, which resulted in the manual resynthesis of 21 peptides.   
 
  
Scheme 5.1: Peptides were synthesised on Fmoc-Rink functionalised polystyrene resin (45 
µmol), and the resin placed in a 12-channel CEM peptide synthesiser with microwave 
heating.  After automated coupling of the amino acid sequence, Fmoc-Ahx-OH and Fmoc-
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For the automated synthesis HBTU/DIPEA was used in the couplings, 
because Oxyma decomposed in DMF during the long synthesis (12 h per run).  For 
the manual synthesis, Oxyma/DIC was used.  To all the peptides, aminohexanoic 
acid and Fmoc-Lys(Dde)-OH (5.3) were manually coupled using Oxyma/DIC. 
The problems with the hybridisation of the 10,000 membered library 
demonstrated the importance of a His-tag (Chapter 2) mediated purification.  Thus 
TAMRA-Lys(Nor)-(His(Trt))6-Ahx-OH (5.4, Scheme 5.3) was included in the 
library.  His-tag 5.4 was synthesised on 2-chlorotrityl polystyrene resin, which was 
first activated by SOCl2 in dry DCM, followed by the coupling of Fmoc-Ahx-OH in 
dry DCM/DIPEA.  Six Fmoc-His(Trt)-OH residues were coupled followed by Fmoc-
Ahx-OH and  Fmoc-Lys(Dde)-OH (5.3, synthesised by coupling between the 
hydrochloric salt of Fmoc-Lys-OH and Dde-OH (Scheme 5.2)).136,137 
 
 
Scheme 5.2: Synthesis of Fmoc-Lys(Dde)-OH 5.3.  Dde-OH was prepared by reacting 
acetic acid with 5,5-dimethylcyclohexane-1,3-dione in the presence of DMAP and EDC•HCl.  
Dde-OH was then coupled with Fmoc-Lys-OH•HCl in the presence of DIPEA.136,137  
 
The Dde protecting group was cleaved using hydroxylamine hydrochloride 
and imidazole as described by Bradley et al.29,41  exo-5-Norbornenecarboxylic acid 
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was coupled onto the free amino lysine side chain, followed by the coupling of 5-
carboxytetramethylrhodamine (TAMRA, 5.5) after Fmoc deprotection.   
 
 
Scheme 5.3: TAMRA-Nor-His-tag 5.4 was synthesised on 2-chloro trityl functionalised 
polystyrene resin, by adding Fmoc-Ahx-OH, followed by Fmoc deprotection using piperidine.  
The coupling of Fmoc-His(Trt)-OH (repeated 6 times), was followed by the coupling of Fmoc-
Ahx-OH and Fmoc-Lys(Dde)-OH (5.3).  Finally, Dde was removed using NH2-OH and the 
free amine coupled to exo-5-norbornenecarboxylic acid.  The Fmoc-group was deprotected 
and TAMRA-OH (5.5) was coupled. 
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It is important to note that for this His-tag 5.4, TAMRA 5.5 was used as a 
single isomer.  This was because it would produce additional isomers during the 
ligation if more than one isomer of TAMRA was used.  To synthesise the single 
TAMRA isomer, 3-dimethylaminophenol was first reacted with trimellitic anhydride 
in refluxing toluene.  The product 4-dimethylamino-2-hydroxy-2′,4′-dicarboxy-
benzophenone 5.6 was isolated by crystallisation form methanol as a red solid in a 
19% yield.  5.6 was reacted with 3-dimethylaminophenol and trimethylsilyl-
polyphosphate in dry DMF under reflux, to form the desired single isomer of 
TAMRA in 90% yield after purification (Scheme 5.4).138     
 
 
Scheme 5.4: Synthesis of single isomer 5-carboxytetramethylrhodamine 5.5.  3-
dimethylaminophenol and trimellitic anhydride were refluxed in toluene.  The 4-
dimethylamino-2-hydroxy-2′,4′-dicarboxy-benzophenone 5.6 was crystallised from methanol, 
and refluxed with 3-dimethylaminophenol and trimethylsilylpolyphosphate in DMF for 3 h to 
give 4-TAMRA-OH (5.5) as a single isomer. 
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After the successful coupling of TAMRA, the protected His-tag 5.4 was 
cleaved using the optimised method (10% HFIP in CHCl3).  It proved very difficult 
to couple the His-Tag 5.4 to the 100 peptides.  To test the coupling of His-tag 5.4 to 
the resin bound peptides 5.2, five of the peptides were taken, and the protected His-
tag was coupled using Oxyma and DIC.  After 18 h, washing, and repeat of the 
coupling step, a Kaiser test139 was carried out to verify the successful coupling.  
Thereafter the peptides were cleaved and analysed.  The crude MALDI-TOF MS 
spectra indicated the presence of the desired product.  Purification proved rather 
difficult, as for the first peptide purified none of the fractions collected showed the 
right mass in the MALDI-TOF MS spectra.  Other peptides purified showed a mass 
corresponding to the unprotected His-tag and the mass of the product in the same 
fraction.  Because the crude mass spectra of the first 5 peptides showed the desired 
peak, and while purifying these peptides, further 20 peptides were used to couple the 
His-tag.  However, this proved to be more difficult as the Kaiser test remained 
positive after 3 couplings, and all of the His-tag was used up at this point.  For these 
20 peptides, most of them did not show the product peak in the crude MALDI-TOF 
MS, and purification of 14 of those peptides by HPLC did not show the right mass in 
any of the fractions, or the fractions showed both the His-tag and the product in the 
same fraction.  In summary, of the 25 peptides 5.7 that were used by coupling the 
His-tag 5.4 to the peptide, only eight products showed the right mass, of which five 
showed the presence of unprotected His-tag in the mass spectra.  It was thought that 
because of the resin used for the peptide synthesis (aminomethyl polystyrene with a 
loading of 1.23 mmol/g), the His-tag 5.4 (2987 Da) may have been to sterically 
hindered to couple onto the amine on the resin. 
It was decided, therefore, to use 20 of the peptides and couple Rhodamine 
and norbornene directly without a His-tag (Figure 5.4).  This peptide–PNA library 
would then be used for the hybridisation optimisation and enzyme tests.  The peptide 
library 5.8 was synthesised by conjugating 5(6)-carboxyrhodamine (mixture of 
isomers was used as none of the single isomer of TAMRA was left and due to time 
constrains, no more could be synthesised) and exo-5-norbornenecarboxylic acid (as 
the single isomer) to 20 of the pre-synthesised resin bound peptides (5.2) using 
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Oxyma and DIC, followed by standard cleavage from the Rink-linker.  All peptides 
were purified by HPLC and after freeze-drying the desired products obtained in 1–
18% yield.  The HPLC peptide purification method used for 5.8 separated the two 
isomers (due to the dye). 
 
Figure 5.4: Top: First attempt of His-tag peptide library (5.7) synthesis, with His-tag coupled 
via peptide coupling, fluorophore: 5-TAMRA (5.5); and Lower: Peptide library 5.8 without 
His-tag, for enzyme test reactions, fluorophore: 5(6)-carboxy rhodamine. 
 
 
Thus, it was decided to try another method for solution phase ligation of the 
His-tag to the peptides.  5-(11,12-Didehydrodibenzo[b,f]azocin-5(6H)-yl)-5-
oxopentanoic acid 5.9 was synthesised (Scheme 5.5) in 7 steps from commercially 
available dibenzosuberenone with stepwise yields ranging from 54–89%.  The 
Beckmann rearrangement was used to expand the seven membered ring to the eight 
membered to give 5.10, by first reacting the aldehyde 5.11 with hydroxylamine 
hydrochloride to form the oxime 5.12 via a Schiff-base reaction.  The oxime was 
heated in acid to initiate the rearrangement.  The amide 5.10 was reduced to the 
amine 5.13 with LiAlH4, followed by coupling of glutaric acid monomethyl ester 
chloride to form amide 5.14.  To introduce the alkyne functionality, the alkene was 
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first dibrominated using Br2, followed by a di-dehydrobromination with 
tBuOK to 
form the alkyne ester 5.15.  Finally the acid 5.9 was obtained by ester hydrolysis of 
5.15 with LiOH.   
 
Scheme 5.5: Synthesis of 5-(11,12-didehydrodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanoic 
acid 5.9 in 7 steps from dibenzosuberenone 5.11.105  
 
With the cyclic alkyne 5.9 in hand, the His-tag was resynthesised on Rink 
functionalised aminomethyl polystyrene resin (0.7 mmol/g, Scheme 5.6).   
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Scheme 5.6: Synthesis of a His-tag peptide with a norbornene group for tetrazine ligation to 
the PNA and a strained alkyne 5.9 for copper-free click ligation to the peptide.  
 
Aminohexanoic acid was coupled as a spacer, followed by Fmoc-Lys(Dde)-
OH 5.3.  After Dde-deprotection, norbornene was coupled to the resin and alkyne 5.9 
was coupled after Fmoc-deprotection.  The peptide was then cleaved from the Rink-
linker using the TFA:TIS:DCM (90:5:5), and purified by HPLC to give the Alkyne-
Nor-His-Tag 5.16.   
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The second peptide library 5.17, which will be used to couple the His-tag 
5.16 via the copper-free click reaction to the peptide, followed by the ligation of the 
TZ-PNA to this conjugant.  For this synthesis 37 of the resin bound peptides (5.2) 
were used to couple the readily available 5(6)-carboxyrhodamine, and the in-house 
prepared 6-azidohezanoic acid 3.3 (Scheme 5.7).   
 
Scheme 5.7: Synthesis of peptide library 5.17 from resin bound peptides 5.2.  37 peptides of 
5.2 was coupled 6-azidohexanoic acid 3.3 after Fmoc-deprotection, followed by removal of 
Dde-OH using NH2-OH and imidazole.  5(6)-Carboxy-Rho-OH was coupled and final 
deprotection and cleavage from the Rink-linker using TFA:TIS:DCM.  
 
After the successful coupling with Oxyma and DIC of both the azide and 
Rhodamine, the peptides were cleaved using standard conditions and purified by 
HPLC, 34 members of the peptide library 5.17 were obtained in a yield of 1–19%.   
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5.3. Ligation of Peptides to PNA-Tags 
To test the ligation of the peptide to the PNA, one peptide (Pep001 (Appendix 2)) 
was ligated to PNA001 (Appendix 1) using 1.5 eq of peptide (Scheme 5.8) to try 
and push the ligation to completion before decomposition of the TZ.  The ligation 
was carried out in H2O:ACN (1:1) containing 0.1% TFA.   
 
 
Scheme 5.8: Ligation of 20 TZ-PNAs 5.1 and 20 members of the peptide library 5.8. 
 
After 8 h reaction, the ligation mixture was analysed by HPLC with ELSD 
detection, which showed the presence of both starting materials and an additional 
product peak.  As the reaction was not completed, it was left for another 10 h, 
however, this did not make a major difference in the HPLC trace (HPLC after 18 h 
Figure 5.5).  Once this test reaction and purification was carried out and the product 
collected, the remaining 19 ligations were carried out.  The conjugates were 
recovered after HPLC purification and lyophilisation in a 16–76% yield with respect 
to the PNA used.  Lig010 showed no ligation. 
PNA-Peptide Library  Chapter V  
P a g e  | 91 
 
Figure 5.5: Top: HPLC spectrum at 254 nm of starting material PNA100;  Middle: HPLC 
spectrum at 254 nm of Pep002;  Bottom: HPLC spectrum at 254 nm of crude Lig002, 
showing product peak after 18 h reaction.  The broad peaks of PNA were due to formic acid 
used for the analysis and not TFA. 
 
As tetrazines react faster with cyclic alkynes than with norborene,83  the order 
of addition for the ligation was important.  First, the His-tag 5.16 was ligated using 
the cyclic alkyne to react with the azide of the peptide (strain-promoted alkyne–azide 
cycloaddition, or copper-free click), followed by the scavenging of any unreacted 
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alkyne using azide functionalised scavenger resin, and finally the ligation of the TZ-
PNA 5.1 (Scheme 5.9).  For LigLib 2, the first ligation between the 34 members of 
peptide library 5.17 and the His-tag 5.16 was left to react for 18 h in a 1:1 mixture of 
H2O and acetonitrile (ACN) at 50 °C, followed by scavenging of any unreacted 5.16 
by azide-resin scavenger pre-swollen in DCM.   
 
 
Scheme 5.9: Ligation of His-tag 5.16 to the 34 members of peptide library 5.17, followed by 
scavenger resin to remove unreacted 5.16, and final ligation of 34 TZ-PNAs 5.1 to give 19 
members of LigLib 2 after purification. 
 
This scavenger resin was prepared in house by coupling 6-azidohexanoic acid 
directly onto amino-methyl polystyrene resin.  The scavenger resin, which reacted 
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with the excess of His-tag 5.16, was filtered off and the filtrate was added to TZ-
PNAs 5.1.  The tetrazine norbornene ligation was left to react for 18 h at 50 °C 
(Scheme 5.9).  After HPLC purification, 19 out of the 34 members of this double 
ligated PNA-peptide library (LigLib 2) were obtained in 4–20% yields.  The loss of 
members may be due to the fact that 5.16 hydrolysed over time, preventing the 
copper-free click reaction from proceeding.  When the last crude conjugates were 
purified (detection/collection at 300 nm on the HPLC), it was noted that multiple 
additional peaks had appeared compared with the conjugates at the beginning.  Those 
additional peaks, however, where not seen in at 530 nm detection wavelength.  This 
would indicate that those extra peaks did not have Rhodamine coupled, and therefore 
the copper-free click reaction between the His-tag 5.16 and the peptide library 5.17 
did not occur.  When the His-tag 5.17 was re-analysed by MALDI-TOF MS, the 
mass of the peptide increased by 18 Da, indication that potential of the alkyne being 
hydrated over time.  With the alkyne hydrated, it cannot undergo the ligation with the 
peptide, and it also cannot be scavenged by the resin, leaving the His-tag in the 
reaction mixture when it was added to the TZ-PNA 5.1.  This would allow the 
ligation between the tetrazine and norbornene of both, the hydrolysed His-tag and the 
peptide-His-tag fragment, to occur.  This would account for the presence of the extra 
peaks, and the loss and lower yields of some of the members of LigLib 2. 
In addition, it proved a great challenge to detect the desired mass (~8,000 Da) 
of each of the members in this LigLib 2.  The detection difficulties may be due to the 
structure of the product, or the possibility of eight different isomers per member 
(Figure 5.6).  The eight possible isomers arise from the orientation of the two 
ligation moieties (tetrazine and norbornene for the Diels-Alder reaction and the 
cyclic alkyne and azide for the copper-free click ligation) when they come together 
for the reaction to accrue.  This gives rise to four different orientations in the product.  
The other isomers come from the Rhodamine used, as this was not a single isomer.  
HPLC purification of the peptide library 5.17 did not separate the isomers of all the 
peptides.  Therefore some members of LigLib 2 will have all eight isomers.  Two 
isomers from the copper-free click reaction, another two from the Diels-Alder 
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ligation, giving four isomers for isomer of the peptide used (Figure 5.6).  Therefore 
eight isomers if there were two isomers of rhodamine present in the peptide.   
 
 
Figure 5.6: Possible isomers produced during the ligation of LigLib 2, and combinations of 
those account for the eight possible isomers in the members of LigLib 2;  Top: Two isomers 
from the copper-free click reaction;  Centre: Two isomers of the Diels-Alder reaction; and 
Bottom: Two isomers of Rhodamine used during the peptide synthesis.  
 
 
In summary, after screening of resin and reaction conditions for the PNA 
synthesis, 100 PNA-tags were synthesised on solid phase in a 96 well-plate using 
Oxyma/DIC as coupling reagents.  After the successful synthesis of the PNA 
sequences, TZ 3.31 was coupled to the N-terminus and the PNA-tags were cleaved 
off the resin and purified by HPLC.  Following the PNA-tag synthesis, the 
corresponding 100 peptides were synthesised on an automated peptide synthesiser.  
Next, a side-chain protected His6-tag sequence was synthesised on a chlorotrityl-PS 
resin, however, the subsequent coupling of the protected His-tag to the resin bound 
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peptides was unsuccessful.  Therefore, ADIBO was synthesised and coupled to a 
His-tag to allow incorporation to the peptides in solution phase.  Finally, this 
solution-based approach was applied to construct a PNA-encoded peptide library 
LigLib 2 (19 members successfully obtained).  In addition, a library (LigLib 1, 19 
members) for the optimisation of the microarray hybridisation protocol was 
synthesised by functionalising the peptides with norbornene and TAMRA, followed 
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6. Conclusion 
A new 10,000 membered cell penetrating PNA-encoded peptide library for the 
interrogation of tyrosine kinases was designed and successfully obtained using the 
split-and-mix method.  Microarray analysis of cell lysate from K562 cells, after 
interrogation with the library, showed signal interfering presence of cell debris on the 
surface of the array.  To overcome this, different detergents were screened, but they 
all hindered the hybridisation of the library onto the array.  Therefore, a His-tag was 
added to the library members and then used with a Ni(II)-column to successfully 
purify the library prior to hybridisation.    
For the synthesis of a focused PNA-encoded library for known tyrosine 
kinases in leukaemia cells, different ligation methods were screen and optimised for 
the conjugation of a peptide to a PNA-tag.  The copper catalysed cycloaddition 
reaction was problematic in the presence of PNA.  This was overcome by utilising a 
TBTU (1.8) ligand in the reaction.  However, this approach was not further 
developed as copper has been shown to interact with biological processes and traces 
of copper were still observed after purification.  Another method ligation method, the 
inverse-electron demand Diels–Alder reaction between a tetrazine and an alkene, was 
investigated.  For this, different tetrazines were synthesised and coupled to a resin 
bound PNA fragment.  The trans-cyclooctane (3.28) and commercially available 
norbornene were coupled onto a peptide fragment, which was subsequently cleaved 
off the resin.  The ligation of the peptide (functionalised with 3.28 or norbornene) to 
the chloro-tetrazine (3.17) PNA-tag on resin showed that this reaction did not go to 
completion.  As access to TZ 3.17 was very difficult, TZ 3.20 was used instead.  
Unfortunately under these reaction conditions, the Diels–Alder reaction did not occur 
when norbornene was used.  Screening of optimised reaction conditions for the 
ligation, using TZ 3.26 with norbornene 3.25, showed that the norbornene and the 
tetrazine pair were not suitable the PNA-peptide ligation.  Therefore, a more reactive 
tetrazine was synthesised instead.   
The tetrazine ultimately used for ligation of the library was TZ 3.31.  
Different reaction conditions were screened for the coupling of the carboxy-
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functionalised tetrazine onto a PNA on a polymer resin, with Oxyma/DIC in 
DMSO/DCM (2 × 1 h) being the optimal conditions.  However, the ligation of the 
peptides to the tetrazine functionalised PNA on solid phase was not sufficient and a 
solution phase ligation was attempted.  For this, different conditions to cleave the 
TZ-PNA off the Rink-linker from polystyrene based resin were screened, with 
TFA:water (95:5) showing the best results.  However with PEG-based ChemMatrix 
resin, TFA:phenol (95:5) was used. 
Before construction of the full PNA-encoded peptide library, a FISH 
experiment was carried out to test the ligation in a biological system using tetrazine 
functionalised PNA-probes.  These probes were targeting two different mRNA 
sequences in fixed HeLa cells.  After incubation with the probes, a norbornene 
functionalised fluorescein was added to the cells.  Analysis of the cells by fluorescent 
microscopy showed that the PNA-probes had hybridised to the desired mRNAs 
(fluorescein-functionalised PNA controls), but the fluorescent signal for the TZ-
probes was much lower than expected.  This could have been due to the ligation 
requiring a longer reaction time on the cells or the TZ degrading.  To test this, 
norbornene functionalised dye was ligated with the TZ-PNA before incubation with 
the cells, showing that the Diels–Alder reaction did occur as indicated by a higher 
fluorescence compared with the intracellular ligation.   
Finally the library targeting kinases in leukaemia was assembled but due to 
problems encountered with the split-and-mix library a His-tag was included.  The 
His-Tag was first synthesised on a chlorotrityl-PS resin to allow peptide cleavage 
with side chain protecting groups intact, with a carboxy functionality at the C-
terminus.  The His-tag was coupled onto the N-terminus of the peptide sequences 
using an activated ester; however, after initial success the coupling was unsuccessful.  
As this was thought to be due to steric hindrance of the resin bound peptide, a 
different route (spAAC) was taken to incorporate the His-tag.  A new His-Tag was 
synthesised on a Rink-linker, incorporating both ADIBO (5.9) and norbornene 
moieties.  The peptides for the library were functionalised with TAMRA and an 
azide, whereas the PNA-tags were functionalised with the TZ.  After purification of 
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all fragments, the library was synthesised by first reacting the azide-peptide with 
ADIBO-His-tag (through the spAAC reaction), followed by the scavenging of any 
unreacted ADIBO-His-tag using azide-PS resin.  Finally, the TZ-PNA-tag was 
ligated with the norbornene of His-Tag–peptide fragment.  Due to hydration of the 
alkyne, and loss of members through the purification method, only 19 members of 
this library were obtained.   
As the His-tag addition to the library was problematic, a second library was 
synthesised, which could be used for optimisation or reaction conditions for the 
microarray analysis and enzyme screening test.  For this the peptides were 
functionalised with TAMRA and norbornene and the PNA-tags with the tetrazine.  
After the purification of each member and tag the ligation between the peptide and 
PNA accrued at 50 °C for 18 h.  However, HPLC analysis showed, that purification 
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7. Experimental 
7.1. General section 
Reactions involving moisture sensitive reagents were performed under a positive 
pressure of nitrogen.  Evaporation of solvents was performed at reduced pressure, 
using a Büchi rotary evaporator.  All chemicals were purchased from Aldrich, Acros, 
LinkTec or Fluka and used as received.  Microwave assisted heating was carried out 
by irradiating the reaction mixture in a Biotage® Initiator at 2.45 GHz.   
1H and 13C NMR spectra were recorded on a Bruker AVA400 (400 and 100 
MHz respectively) or AVA500 spectrometer (500 and 126 MHz respectively) at 298 
K in deuterated solvents.  Residual protic solvent CHCl3 (δH = 7.26 ppm), methanol 
(δH = 3.30 ppm) and DMSO (δH = 2.50 ppm) or deuterated solvent CDCl3 (δC = 77.0 
ppm), D4-methanol (δC = 49.0 ppm) and D6-DMSO (δC = 39.5 ppm) were used as an 
internal reference.  Peak positions are reported as downfield shifts in parts per 
million (δ) from TMS.  Coupling constants were measured in hertz (Hz).  
Resonances are characterised as singlet (s), doublet (d), doublet of doublet (dd), 
triplet (t), multiplet (m), or broad singlet (bs). 
Aluminium-backed silica plates (Merck silica gel 60 F254) were used for thin 
layer chromatography (TLC) to monitor solution-phase reactions.  TLC 
visualisation was carried out using ultraviolet (UV) light at 254 nm or by staining 
with of phosphomolybdic acid (PMA) solution.  Flash column chromatography was 
performed on silica gel using Kieselgel 60, 230-400 mesh (Merck). 
MALDI-TOF MS analysis was performed on an Applied Biosystems 
Voyager DESTR MALDI-TOF mass spectrometer and a Bruker ultrafleXtreme 
MALDI-TOF MS.  Sinapinic acid was used as a matrix and positive or negative ion 
mass spectra reported.  Chemical or electrospray ionisation mass spectrometry 
(CI/ESI-MS) analyses were performed on an Agilent Technologies LC/MSD Series 
1100/1200 quadrupole mass spectrometer.  Product peaks are reported with 
percentage intensities of the base peak. 
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HPLC was carried out on an Agilent Technologies 1100/1200 Chemstations 
coupled to a Polymer Lab 100 ES evaporative light scattering detector (ELSD).  
Solvents used were (A) H2O/0.1% formic acid, (B) CH3CN/0.1% formic acid, (C) 
MeOH/0.1% formic acid, (D) H2O/0.1% TFA and (E) CH3CN/0.1% TFA, at a flow 
rate of 1 mL/min.  The columns used were a Discovery C18 from Supelco (50 mm × 
4.6 mm, 5 µm) or Poroshell 120 SB-C18 from Agilent (50 × 4.6 mm, 2.7 µm) for 
methods 1+2, and an Acclaim® 120 C18 from Dionex (150 × 4.6 mm, 5 µm) for 
method 3+4.  The following methods were used: 
- Method 1 [eluents (A) and (B)]: 95% to 5% (A) over 10 min, 5% (A) for 4 min. 
- Method 2 [eluents (A) and (C)]: 95% to 5% (A) over 10 min, 5% (A) for 4 min. 
- Method 3 [eluents (D) and (E)]: 95% (E) for 2 min, 95% to 50% (E) over 8 min, 
50% to 5% (E) over 4 min, 5% (E) for 2 min. 
- Method 4 [eluents (D) and (E)]: 95% (E) for 2 min, 95% to 50% (E) over 13 min, 
50% to 5% (E) over 5 min, 5% (E) for 4 min. 
Preparative HPLC: ZORBAX 300SB-C18 preparative column (250 × 9.4 
mm, 5 μm, 300 nm pore size), at a flow rate of 2 mL/min with eluent D and E were 
used for purification.  The following gradients were used for PNA purification: 90% 
(D) for 3 min, 90% (D) to 50% (D) over 22 min, 50% to 5% (D) over 5 min, 5% (D) 
for 5 min, collection by UV at 300 or 580 nm, and peptide: 95% (A or D) to 40% (A 
or D) over 40 min, 40% to 5% (A or D) over 5 min, 5% (A or D) for 5 min, detection 
by UV at 254 or 600 nm.  
The liquid handler used was a 4-Tip MultiPROBE II EX systems from 
Packard, with customised programming of the WinPREP software.  The peptide 
synthesiser was a CEM Liberty 12-Channel Automated Microwave Peptide 
Synthesiser with the PepDrive software, using N,N,N′,N′-tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) as the coupling agent.  For 
single peptide and PNA synthesis a semi-automated peptide synthesiser, Biotage 
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Initiator+ SP Wave, was used with pre-activated monomers using Oxyma and N,N'-
diisopropylcarbodiimide (DIC) in dimethylformamide (DMF). 
 
7.2. General experimental procedures 
7.2.1. Peptide coupling 
Suitably protected Fmoc-amino acids (3 eq) and Oxyma or hydroxybenzotriazole (3 
eq) were dissolved in DMF (0.1 M) and mixed for 10 min.  To the resulting solution, 
DIC (3 eq) was added and the mixture was stirred for an additional 5 min.  The 
activated acid was added to the amino functionalised resin (1 eq), pre-swollen in 
dichloromethane (DCM), and the reaction was mixed for 3 h at room temperature or 
30 min at 60 °C.  The resin was washed with DMF (× 3), DCM (× 3) and methanol 
(× 1).  The coupling reaction was confirmed by a Ninhydrin test.139 
 
7.2.2. Fmoc deprotection 
Fmoc deprotection was carried out by pre-swelling the resin with DCM, followed by 
stirring/mixing with 20% piperidine in DMF for 2 × 7 min.   
 
7.2.3. Dde deprotection in presence of the Fmoc group 
A solution of hydroxylamine hydrochloride (1.3 eq) and imidazole (1 eq) in N-
methyl-2-pyrrolidone (0.27 M) was diluted with DCM (for PS and TentaGel resin) or 
DMF (PEGA resin), respectively in a 4:1 ratio.  This solution was added to the resin, 
mixed for 2 × 1.5 h, washed with DMF (× 3), DCM (× 3) and methanol (× 3).41 
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7.2.4. Dde deprotection in absence of the Fmoc group 
A freshly prepared solution of 4% hydrazine in DMF was added to the resin and left 
shaking for 5 × 10 min, and washed with DMF (× 3), DCM (× 3) and methanol (× 
3).41  
 
7.2.5. Cleavage from the Rink-linker and deprotection 
A cleavage cocktail was freshly prepared using either trifluoroacetic acid (TFA)/ 
triisopropylsilane (TIS)/DCM (90:5:5) or TFA/water (95:5 for tetrazine containing 
PNA and peptides on PS resin) or TFA/phenol (95:5 for tetrazine containing PNA 
and peptides on CM resin) or reagent K (TFA/TIS/DCM/phenol, 88.5:2.5:5:5, for 
Arg containing peptides).  The cocktail solution (twice the volume of the swollen 
resin) was added to the pre-swollen resin and agitated for 3 h.  The solution was 
collected by filtration and the peptide precipitated from the cleavage solution by the 
addition of cold Et2O (1:15 v/v).  The peptide was collected by centrifugation for 10 
min (~7000 RPM), and the liquid was decanted.  The peptide was re-dispersed in 
cold ether and centrifuged (× 3). 
 
7.2.6. Cleavage from the 2-chloro trityl linker 
The resin was swollen in DCM for 10 min, followed by filtration and addition of a 
solution of 1% TFA in DCM.  After 2 min the solution was added to a solution of 
10% pyridine in methanol.  This step was repeated 6–10 times.  The combined 
solutions were concentrated under reduced pressure, and the protected peptides were 
precipitated from cold ether.   
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7.2.7. Microarray experiment 
The PNA-peptide library (2 nM) was incubated with the recombinant kinase 
(Abl1, P3049, Invitrogen, 60 units) or cell lysate (from 3 × 106 cells), 2× kinase 
buffer (50 µL, solution contains: 100 mM Tris (pH 7.5), 20 mM MgCl2, 4 mM 
MnCl2, 2 mM dithiothreitol, 10 mM ATP) and protease and phosphatase inhibitor 
cocktails (for cell lysate only, 1 µL, Sigma Aldrich) as a solution (100 µL) between 1 
h and shaken overnight at 37 °C.  To this solution was then added GenHyb buffer 
(Genetix, 100 µL), and denatured at 90 °C for 10 min.  The hybridisation solution 
(100 µL) was added using pre-heated (60 °C) pipet tips onto the pre-heated cover 
slide.  The pre-heated microarray (custom made by OGT) was then placed on top of 
the cover slide and placed in the pre-heated hybridisation chamber.  The 
hybridisation was done by lowering the temperature every 30 min in a hybridisation 
oven from 65 to 55 to 50 to 48 to 46 to 44 to 42 to 40 to 37 °C, followed by 
overnight at 37 °C.   
For the detection, the microarray was washed for 10 min at 30 °C with wash 
buffer (pH 7.5, 2 × 45 mL, solution: 100 mM NaCl, 10 mM citric acid, 0.7% (w/v) 
N-lauroyl-sarcosine sodium salt, 0.1 mM ethylene glycol tetraacetic acid), followed 
by distilled water (45 mL,) and blocked with TPBS (45 mL, solution: 0.05% Tween-
20 in PBS (phosphate buffered saline), pH 7.4) containing 1% BSA (bovine serum 
albumin) for 1 h at 30 °C.  Then the array was washed with distilled water (45 mL), 
and labelled with an anti-phospho-tyrosine antibody (PY-20, P4110 from Sigma 
Aldrich, 100 µL, in a 1/500 dilution with TPBS/1% BSA) in the hybridisation 
chamber for 1 h at 30 °C.  This was followed by washing with TPBS/1% BSA (2 × 
45 mL) for 1 h at 30 °C and labelling with a secondary antibody (Cy5-goat anti-
mouse IgG (H+L), 100 µL, in 1/200 dilution with TPBS/1% BSA) for 10 min at 30 
°C.  Finally, the array was washed with TPBS/1% BSA (2 × 45 mL) for 10 min at 30 
°C, rinsed with distilled water (45 mL) and dried, before detection using a microarray 
scanner. 
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7.3. Chapter 3 
7.3.1.  (Z)-4-Cyclooct-1-ene monoepoxide (3.12) 
 
To a solution of cis-1,5-cyclooctadiene (5.0 mL, 4.0 g, 40 mmol, 1 eq) in CHCl3 (100 
mL) at 0 ˚C was slowly added over 2 h a mixture of 3-chloroperoxybenzoic acid 
(9.58 g, 55.5 mmol, 1.36 eq) in CHCl3 (100 mL).  The reaction mixture was stirred at 
room temperature for 18 h, followed by removal of solid residues.  The filtrate was 
washed with sat. NaHSO4 (100 mL), sat. NaHCO3 (100 mL) and sat. NaCl (100 mL).  
The organic layer was dried (anhyd. MgSO4), filtered and evaporated under reduced 
pressure to give an oily crude product.  (Z)-4-Cyclooct-1-ene monoepoxide 3.13 was 
isolated by flash column chromatography (eluting with 10% EtOAc/hexane) as a 
colourless oil (3.5 g, 69%).104 
1H NMR (500 MHz, CDCl3): δH 5.64-5.58 (2H, m, C
dH=CH), 3.09-3.05 (2H, m, 
CaH-O), 2.50-2.14 (4H, m, CbH2-CO), 2.10-2.03 (4H, m, C
cH2-C=C) 
13C NMR (125 MHz, CDCl3): δC 128.9 (HC=), 56.7 (CHO), 28.1 (CH2), 23.7 
(CH2). 
HPLC (method 1): tR = 11.6 min (88% purity, ELSD) 
MS (CI) m/z: 124.1 [M+, 23%] 
Rf (10% EtOAc/hexane): 0.63 
 
Experimental   Chapter VII  
P a g e  | 107 
7.3.2. (Z)-4-Cycloocten-1-ol (3.13) 
 
A suspension of LiAlH4 (4.95 g, 130.4 mmol, 3 eq) was prepared in anhyd. THF 
(250 mL) and stirred at 0 °C in an ice-bath.  A solution of cyclooctene monoepoxide 
3.12 (5.54 g, 44.7 mmol, 1 eq) in dry THF (25 mL) was slowly added over 15 min.  
The reaction mixture was warmed to room temperature and refluxed for 4 h.  The 
solution was cooled to 0 °C, and water (5.5 mL) was added drop wise, followed by 
addition of 15% aq NaOH (5.5 mL) and finally, water (40 mL).  The resulting 
mixture was allowed to stir for 3 h, during which time the grey solid turned white.  
Celite and anhyd. MgSO4 were added and stirred for 30 min, followed by filtration 
and washing with DCM (2 × 50 mL).  The combined organic filtrates were dried 
(anhyd. MgSO4), filtered and the solvent evaporated to yield the desired alcohol as a 
colourless oil (5.52 g, 98%), which was used in the next step without further 
purification.104 
1H NMR (500 MHz, CDCl3): δH 5.72-5.67 (1H, m, C
eH=CH), 5.62-5.57 (1H, m, 
CfH=CH), 3.82 (1H, m, CaH-OH), 2.33-2.27 (1H, m), 2.14-2.08 (3H, m), 1.96-1.83 
(2H, m), 1.74-1.61 (2H, m), 1.58-1.48 (2H, m). 
13C NMR (125 MHz, CDCl3): δC 130.2 (CH), 129.6 (CH), 72.8 (CHO), 37.8 (CH2), 
36.3 (CH2), 25.7 (CH2), 24.9 (CH2), 22.8 (CH2). 
HPLC (method 1): tR = 10.0 min (67% purity, ELSD) 
MS (CI) m/z: 127.1 [(M+H)+, 45%] 
Rf (10% EtOAc/hexane): 0.2 
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7.3.3. (E)-4-Cycloocten-1-ol (3.27) 
 
(Z)-4-Cycloocten-1-ol 3.13 (1.99 g, 15.7 mmol) was dissolved in a mixture of 
Et2O/hexane (9:1, 50 mL), and methylbenzoate (2.5 mL, 17.4 mmol, 1.1 eq) was 
added.  The reaction mixture was transferred to a quartz tube, placed into a light 
reactor, and irradiated at 254 nm.  After 30 min of irradiation the tube was removed 
from the reactor and the reaction mixture was filtered through a column filled with 
10% silver nitrate on silica (30 g).  The starting material was eluted with Et2O (100 
mL) from the silver nitrate column, evaporated and re-dissolved in the reaction 
solvent.  The solution was placed into the quartz tube and continued to be irradiated.  
This cycle was repeated 12 times.  After this the column was washed with fresh 
solvent of Et2O/hexane (9:1, 300 mL).  The silica was placed in a beaker and 30% aq 
ammonia (150 mL) and DCM (150 mL) was added.  After 15 min the solution was 
filtered, and the organic layer was separated.  The aqueous layer was washed with 
DCM (2 × 50 mL) and the combined organic layers were washed with water (150 
mL), dried with anhyd. MgSO4, filtered and evaporated.  The product was purified 
by column chromatography (silica, eluent: petroleum ether:EtOAc 9:1), to yield the 
two isomers as a pale yellow oil (major: 310 mg, 16%, minor: 227 mg, 12%).  The 
isomers were identified by comparison to the literature and NMR analysis.104,140   
Major isomer: 
1H NMR (500 MHz, CDCl3): δH 5.60-5.54 (1H, m, C
dH=CH), 5.42-5.35 (1H, m, 
CeH=CH), 3.48-3.45 (1H, m, CaH-OH), 2.36-2.25 (3H, m), 1.98-1.90 (4H, m), 1.71-
1.58 (3H, m). 
13C NMR (125 MHz, CDCl3): δC 135.1 (CH), 132.8 (CH), 77.8 (CHO), 44.6 (CH2), 
41.1 (CH2), 34.3 (CH2), 32.7 (CH2), 31.2 (CH2). 
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HPLC (method 1): tR = 0.7 min (99% purity, ELSD) 
MS (CI) m/z: 125.1 [(M-H)-, 100%] 
Rf (petroleum ether/ EtOAc 5:1): 0.2 
Minor isomer: 
1H NMR (400 MHz, CDCl3): δH 5.58-5.57 (2H, m, C
dꞌH=CeꞌH), 4.06-4.02 (1H, m, 
CaꞌH-OH), 2.42-2.34 (1H, m), 2.27-2.20 (2H, m), 2.17-2.07 (2H, m), 1.90-1.75 (4H, 
m), 1.69-1.62 (1H, m). 
13C NMR (100 MHz, CDCl3): δC 134.3 (CH), 133.1 (CH), 67.4 (CHO), 43.0 (CH2), 
34.1 (CH2), 34.0 (CH2), 29.3 (CH2), 27.7 (CH2). 
HPLC (method 1): tR = 10.5 min (84% purity, ELSD) 
MS (CI) m/z: 125.1 [(M-H)-, 50%] 
Rf (petroleum ether/EtOAc 5:1): 0.55 
 
7.3.4.  (E)-Cycloocten-4-yl 2,5-dioxopyrrolidin-1-yl 
carbonate (3.28) 
 
(E)-4-Cycloocten-1-ol 3.27 (minor isomer, 200 mg, 1.8 mmol) and triethylamine (1 
mL, 7.2 mmol, 4 eq) were dissolved in anhydrous acetonitrile (12 mL).  To this 
solution N,N-disuccinimidyl carbonate (1.01 g, 3.9 mmol, 2.1 eq) was added slowly, 
and the reaction mixture was stirred for 72 h.  The volatiles were evaporated and the 
remaining residue was taken up in ether, washed with 0.1 M HCl (20 mL), water (2 × 
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20 mL) and dried with anhyd. MgSO4.  The ether was evaporated and the resulting 
oil was purified by column chromatography (1:1 ether:hexane) yielding a pale yellow 
viscous oil (150 mg, 31%) and recovered starting material (51 mg, 25%).104 
1H NMR (500 MHz, CDCl3): δH 5.76-5.69 (1H, m, C
dH=CH), 5.65-5.59 (1H, m, 
CeH=CH), 5.05-5.02 (1H, m, CaHO), 2.90 (4H, s, 2 × CkH2), 2.55-5.38 (3H, m), 
2.24-2.20 (1H, m), 1.97-1.90 (2H, m), 1.83-1.68 (2H, m), 1.49-1.31 (2H, m).  
13C NMR (125 MHz, CDCl3): δC 168.8 (2 × qC), 151.0 (qC), 135.7 (CH), 131.2 
(CH), 78.6 (CHO), 40.5 (CH2), 34.1 (CH2), 32.1 (CH2), 29.6 (CH2), 27.6 (CH2), 25.5 
(2 × CH2). 
HPLC (method 1): tR = 8.2 min (85% purity, ELSD) 
MS (ESI) m/z: 265.2 [(M-2)+, 62%] 
Rf (1:1 ether/hexane): 0.13 
 
7.3.5. 6-Azidohexanoic acid (3.3) 
 
To a stirred solution of 6-bromohexanoic acid (5.12 g, 26.2 mmol) in DMF (16 mL) 
was added NaN3 (3.40 g, 52.3 mmol, 2 eq) and the mixture was heated at    85 °C for 
3 h.  The crude reaction mixture was diluted in DCM (350 mL) and washed with 0.1 
N HCl (2 × 250 mL).  The organic layer was dried with MgSO4, filtered, and 
concentrated under reduced pressure to yield the product (3.75 g, 91%) as an oil, 
which was used in the next step without further purification.141 
1H NMR (500 MHz, CDCl3): δH  3.28 (2H, t, J = 6.9 Hz, C
bH2C(O)O), 2.39 (2H, t, J 
= 7.4 Hz, CfH2N3), 1.70-1.59 (4H, m, 2 × C
c,eH2CH2), 1.47-1.41 (2H, m, 
CH2C
dH2CH2). 
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13C NMR (125 MHz, CDCl3): δC 178.5 (qC(O)O), 51.2 (CH2CO2H), 33.7 (CH2), 
28.6 (CH2), 26.2 (CH2), 24.2 (CH2). 
HPLC (method 1): tR = 0.7 min (99% purity, ELSD) 
MS (ESI) m/z: 156.1 [(M-H)-, 100% 
 
7.3.6. Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine 
(TBTA, 1.8)  
 
Benzyl azide (333 mg, 2.5 mmol, 3.3 eq) and trispropargyl amine (100 mg, 0.76 
mmol, 1.0 eq) were dissolved in DCM (0.7 mL), and water (0.7 mL) was added.  
CuSO4•5 H2O (10 mg, 0.04 mmol, 0.05 eq) and sodium ascorbate (23 mg, 0.12 
mmol, 0.15 eq) were added and the reaction mixture was stirred vigorously 
overnight.  DCM (7 mL) and water (7 mL) were added and the phases were 
separated.  The aqueous phase was extracted with DCM (2 × 20 mL) and the 
combined organic phases dried (anhyd. MgSO4), evaporated and purified by flash 
column chromatography (silica, DCM/methanol 95:5).  The resulting residue was 
dissolved in a small volume of DCM, precipitated in hexane and filtered to give 
TBTA (251 mg, 63%) as a colourless, amorphous solid.142 
1H NMR (500 MHz, CDCl3): δH 7.65 (1H, s, C=C
fH-N), 7.36-7.34 (3H, m, Ca,bHar), 
7.26-7.24 (2H, m, CcHar), 5.50 (2H, s, C
eH2Bz), 3.69 (2H, s, C
hH2-N). 
Experimental   Chapter VII  
P a g e  | 112 
13C NMR (125 MHz, CDCl3): δC 144.0 (qC), 134.5 (qC), 128.8 (2 × CH) 128.4 
(CH), 127.7 (2 × CH), 123.5 (CH), 53.8 (CH2), 46.8 (CH2). 
HPLC (method 1): tR = 8.8 min (99% purity, ELSD) 
MS (CI) m/z: 553.0 [(M+Na)+, 100%], 531.1 [(M+H)
+
, 32%] 
Rf (DCM/methanol 95:5): 0.90 
 
7.3.7. Triaminoguanidine monohydrochloride (3.22) 
 
Hydrazine monohydrate (16 mL, 340 mmol, 3.2 eq) was added to a well-stirred 
slurry of guanidine hydrochloride (10.3 g, 108 mmol, 1 eq) in 1,4-dioxane (50 mL), 
the reaction mixture was refluxed for 2 h.  On cooling the reaction, a white solid 
formed, which was collected by filtration, washed with 1,4-dioxane, and dried under 
vacuum to yield the desired product (15.08 g, 107 mmol, 99%).106,143 
13C NMR (125 MHz, CDCl3): δC 159.5 (C
a(N)3). 
MS (ESI) m/z: 105.2 [(M-Cl)+, 100%] 
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To a solution of triaminoguanidine monohydrochloride 3.22 (7.08 g, 50.1 mmol, 1 
eq) in water (50 mL), 2,4-pentanedione (10.2 mL, 100.2 mmol, 2 eq) was added 
dropwise over 1 h, the mixture stirred for a further 30 min at RT, and the reaction 
heated to 70 ºC for 4 h.  The yellow solid, which precipitated from the cooled 
mixture was filtered, washed with water and dried to yield the product (9.40 g, 34.5 
mmol, 69%) as a yellow solid.106,143 
1H NMR (500 MHz, CDCl3): δH 8.07 (2H, bs, NH), 5.98 (2H, s, C
cH), 2.50 (6H, s, 
CaH3), and 2.23 (6H, s, C
eH3). 
13C NMR (125 MHz, CDCl3): δC 150.0 (qC), 145.8 (qC), 142.3 (qC), 109.9 (CH), 
13.8 (CH3), and 13.5 (CH3). 
HPLC (method 1): tR = 9.3 min (97% purity, ELSD) 
MS (ESI) m/z: 271.2 [(M-H)+, 18%], 
 
7.3.9. 3,6-Dihydrazino-1,2,4,5-tetrazine (3.20) 
 
A solution of NaNO2 (2.88 g, 41.7 mmol, 2.8 eq) in water/DCM (9:1, 72 mL) was 
added to 3,6-bis(3,5-dimethylpyrazol-1-yl)-1,2-dihydro-1,2,4,5-tetrazine 3.23 (4.0 g, 
14.7 mmol, 1 eq), and cooled to 0 °C.  Acetic acid (2.0 mL) was added drop-wise, 
and the reaction mixture was warmed to room temperature overnight.  The organic 
layer was separated and the aqueous layer was washed with DCM (3 × 50 mL).  The 
combined organic layers were neutralised with 5% aq. K2CO3, dried (anhyd. 
MgSO4), filtered, and evaporated to yield the product (2.25 g, 8.3 mmol, 56%) as a 
red solid.106 
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1H NMR (500 MHz, CDCl3): δH 6.21 (2H, s, C
cH), 2.73 (6H, s, CaH3), and 2.41 
(6H, s, CeH3). 
13C NMR (125 MHz, CDCl3): δC 159.6 (qC), 154.8 (qC), 144.1 (qC), 112.2 (CH), 
15.0 (CH3), and 14.1 (CH3). 
HPLC (method 2): tR = 8.3 min (95% purity, ELSD) 




7.3.10. 3,6-Hydrazinobenzylamine-1,2,4,5-tetrazine (3.26) 
 
To a solution of 3,6-dihydrazino-1,2,4,5-tetrazine 3.20 (559 mg, 2.1 mmol, 1 eq) in 
DCM (10 mL) was added benzylamine (500 µL, 4.5 mmol, 2.1 eq), and the reaction 
mixture heated at 70 °C for 45 min in a microwave.  The crude material was directly 
purified by column chromatography (DCM/EtOAc, 10:1) to yield the product (472 
mg, 1.7 mmol, 80%) as a red solid. 
1H NMR (500 MHz, CDCl3): δH 7.43-7.34 (5H, m, C
j-lHAr), 6.12 (1H, s, C
cH), 2.58 
(3H, s, CaH3), 2.37 (3H, s, C
eH3), and 1.65 (2H, s, C
hH2). 
13C NMR (125 MHz, CDCl3): δC 161.3 (qC), 157.9 (qC), 152.1 (qC), 142.1 (qC), 
136.8 (qC), 129.0 (2 × CH), 128.1 (CH), 127.9 (2 × CH), 109.8 (CH), 45.7 (CH2), 
13.7 (CH3), and 13.6 (CH3). 
HPLC (method 1): tR = 6.7 min (93% purity, ELSD)  
MS (ESI) m/z: 282.1 [(M+H)+, 100%] 
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Rf (DCM/ethyl acetate, 10:1): 0.21 





exo-5-Norbornenecarboxylic acid (594 mg, 4.3 mmol, 1 eq), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (850 mg, 4.4 mmol, 1.02 
eq) and triethylamine (1.2 mL) were dissolved in DCM (10 mL).  After 10 min, 
benzylamine (800 µL, 7.3 mmol, 1.7 eq) was added to the activated carboxylic acid 
solution and the reaction mixture was microwave heated at 75 °C for 30 min.  The 
product was isolated directly by column chromatography (10% ethyl acetate in 
DCM) to yield the product as a white solid (780 mg, 3.4 mmol, 79%).  
1H NMR (500 MHz, CDCl3): δH 7.37-7.34 (2H, m, C
kHAr), 7.31-7.29 (3H, m, 
Cl,mHAr), 6.17-6.09 (2H, m, C
aH=CbH), 2.99-2.97 (1H, m, CfH), 2.95-2.92 (1H, m, 
CcH), 2.04-2.02 (1H, m, CeH2), 1.99-1.96 (1H, m, C
eH2), 1.78-1.76 (1H, m, C
dH), 
1.57 (2H, bs, NHCiH2), 1.40-1.37 (1H, m, C
gH2), and 1.36-1.33 (1H, m, C
gH2). 
13C NMR (125 MHz, CDCl3): δC 175.4 (C(O)NH), 138.6 (qC), 138.3 (2 × CH), 
136.0 (2 × CH), 128.7 (CH=CH), 127.8 (CH=CH), 127.5 (CH), 47.2 (CH), 46.4 
(CH2), 44.8 (CH), 43.8 (CH2), 41.6 (CH), and 30.6 (CH2). 
HPLC (method 1): tR = 7.2 min (95% purity, ELSD) 
MS (ESI) m/z: 228.1 [(M+H)+, 100%] 
Rf (DCM:ethyl acetate, 9:1): 0.52 
MP: 118-119 °C 
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4-Cyanobenzoic acid (7.0 g, 48 mmol, 1.0 eq) and pyrimidin-2-carbonitrile (5 g, 48 
mmol, 1.0 eq) were suspended in ethanol (20 mL), and hydrazine monohydrate (11.5 
mL, 238 mmol, 5.0 eq) was added dropwise and the mixture was refluxed overnight.  
After cooling, the precipitate was removed by filtration and washed with small 
volumes of ethanol.  To remove the bis(pyrimidin-2-yl)-1,2,4,5-dihydrotetrazine by-
product, the solid was stirred in acetone (30 mL) and filtered.  This was repeated.  
The filtered solid was suspended in acetic acid (115 mL) and oxidised by the slow 
addition of isopentyl nitrite (4.5 mL, 33 mmol, 1.5 eq).  After stirring overnight, 
diethyl ether (190 mL) was added to precipitate the product.  After filtration, the 
crude product was purified by flash chromatography (1% acetic acid in hexane:DCM 
3:7, followed by 1% acetic acid in DCM, followed by 10% methanol and 1% acetic 
acid in DCM) to yield 4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl) benzoic acid (1.8 
g, 6.4 mmol, 13%) as a purple solid.107 
1H NMR (500 MHz, DMSO): δH 9.21 (2H, d, J = 4.9 Hz, C
bHAr), 8.27-8.24 (2H, m, 
CgHAr), 8.19-8.16 (2H, m, C
hHAr), and 7.84 (1H, d, J = 4.9 Hz, C
aHAr). 
13C NMR (125 MHz, CDCl3): δC 166.6 (C(O)O), 163.1 (CNN), 162.8 (CNN), 159.0 
(qC), 158.4 (CHAr), 132.5 (qC), 130.2 (2 × CH), 129.8 (qC), 128.3 (2 × CH), and 
122.3 (CH). 
HPLC (method 2): tR = 6.7 min (99% purity, ELSD) 
MS (ESI) m/z:279.1 [(M-H)-, 100%]  
Rf (DCM/methanol/acetic acid 94:5:1): 0.11 
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4-(6-(Pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic acid 3.31 (605 mg, 2.14 mmol, 1 
eq) was suspended in DMF/pyridine (19:1, 25 mL) before the addition of N-
hydroxysuccinimide (370 mg, 3.21 mmol, 1.5 eq) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC•HCl, 500 mg, 3.22 mmol, 
1.5 eq).  The mixture was heated to 40 °C to give a homogeneous solution and after 2 
h, the solvent was removed under reduced pressure.  The crude residue was re-
dissolved in DCM (50 mL) and washed with water (50 mL).  The aqueous layer was 
extracted with DCM (20 mL).  The combined organic layers were dried with anhyd. 
MgSO4, filtered and evaporated.  The residue was dissolved in DCM (40 mL) and 
precipitated by the addition of diethyl ether (approx. 300 mL).  The precipitate was 
collected by filtration and washed with diethyl ether.  After removal of residual 
solvent in vacuo, 2,5-dioxopyrrolidin-1-yl 6-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-
yl)benzoate (527 mg, 1.39 mmol, 65%) was isolated as a red solid.107 
1H NMR (500 MHz, CDCl3): δH 9.18 (2H, d, J = 4.9 Hz, C
bHAr), 8.94-8.90 (2H, m, 
ChHAr), 8.43-8.39 (2H, m, C
gHAr), 7.63 (1H, d, J = 4.9 Hz, C
aHAr), and 2.96 (4H, br 
s, ClH2). 
13C NMR (125 MHz, CDCl3): δC 168.7 (C(O)ON), 163.5 (CNN), 163.0 (CNN), 
161.0 (2 × C(O)N), 159.1 (qC), 158.2 (CH), 136.7 (qC), 131.1 (2 × CH), 128.9 (qC), 
128.7 (2 × CH), 124.4 (CH), and 25.4 (2 × CH). 
HPLC (method 2): tR = 5.3 min (99% purity, ELSD) 
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7.3.14. Ligation of peptides 
For the test reactions Pep035 (Appendix 2) was synthesised on 2-chlorotrityl 
functionalised polystyrene resin pre-loaded with Fmoc-Lys(Dde)-OH (250 mg, 0.072 
mmol, 5.3) using a peptide synthesiser.  PNA100 (Appendix 1) which was 
synthesised on Fmoc-Rink-LL-PS resin was used for the test reactions unless 
otherwise stated.   
 
7.3.15. Test click reaction with the TBTA ligand (3.10) 
 
Peptide and PNA Synthesis: 
The peptide and PNA were prepared using standard peptide couplings (Section 7.2) 
with the peptide and PNA capped with 5-hexynoic acid and 6-azidohexanoic acid 3.3 
respectively.  The protected peptide was obtained as a white solid (16.4 mg, 65%).   
MS (MALDI) m/z: calc. 3468.92, experimental 3494.93 [M+Na]+ [48%] (error in 
mass, see internal standard test Chapter 5, Figure 5.2).   
Ligation: 
A solution of CuI (0.6 mg, 0.003 mmol, 3 eq), sodium ascorbate (1.8 mg, 0.009 
mmol, 9 eq) and tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine 1.8 (3 mg, 0.006 
mmol, 6 eq) in 20% piperidine in DMF (200 μL) was prepared and added to a 
solution of the peptide (10 mg, 0.003 mmol, 3 eq) in DMF/DMSO (1:1, 300 μL).  
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This solution was added to the azide-PNA resin and the reaction was shaken 
overnight.  The resin was washed with DMSO (5 × 0.5 mL), 20% piperidine in DMF 
(3 × 0.5 mL), DMF (3 × 0.5 mL), DCM (3 × 0.5 mL) and methanol (3 × 0.5 mL).  
The conjugate was cleaved from the resin using the method described in Section 7.2 
(TFA:TIS:DCM), analysed by HPLC and MALDI, and after purification with HPLC 
(Method 4) a white solid was obtained (2.5 mg, 0.395 μmol, 40%).  ICP-MS (Agilent 
7500ce with an octopole reaction system) analysis of the conjugate (1.25 mg sample) 
showed a copper concentration of 1.57–1.82 ppb (0.025–0.029 µM). 
HPLC (method 4): tR = 14.3 min (38% purity of crude, 254 nm) 
MS (MALDI) m/z: calc. 6330.95, experimental 6336.63 [100%] (error in mass, see 
internal standard test Chapter 5, Figure 5.2). 
 
7.3.16. Test “copper free click” ligation (3.16) 
 
Peptide and PNA Synthesis: 
The peptide and PNA (synthesised in Section 7.3.15) were capped with 
bicyclo[6.1.0]non-4-yn-9-ylmethyl succinimidyl carbonate and 6-azidohexanoic 
acid, respectively.  The protected peptide was obtained as a white solid (19.1 mg, 
74%).   
Experimental   Chapter VII  
P a g e  | 120 
MS (MALDI) m/z: calc. 3550.96, experimental 3576.91 [M+Na]+ [23%] (error in 
mass, see internal standard test Chapter 5, Figure 5.2). 
Ligation: 
The ligation was carried out by adding a solution of the peptide (10 mg, 0.003 mmol, 
3 eq) in DMF/DMSO (1:2, 450 μL) to the azide-PNA resin with shaking overnight.  
The resin was washed with DMSO (5 × 0.5 mL), DMF (3 × 0.5 mL), DCM (3 × 0.5 
mL) and methanol (3 × 0.5 mL) and the conjugate was cleaved from the resin using 
the method described in Section 7.2.5.  The conjugate was analysed by HPLC and 
MALDI and no purification was undertaken. 
HPLC (method 4): tR = 14.2 min (28% purity, 254 nm) 
MS (MALDI) m/z: calc. 6412.99, experimental 6417.34 [100%], calc. 4186.79 
(azide-PNA starting material), experimental 4191.56 [18%] (error in mass, see 
internal standard test Chapter 5, Figure 5.2). 
 
7.3.17. Test tetrazine ligation with 5-Norbornene-2-
carboxylic  
 
Activation of the chlorotrityl linker:  2-Chlorotrityl-polystyrene resin (100 mg, 0.14 
mmol) in a solid phase extraction tube was swollen in dry DCM (2 mL) for 30 min, 
filtered, and a solution of thionyl chloride (50 μL, 0.68 mmol, 4.5 eq) in dry DCM (2 
mL) was added, mixture shaken for 1 h, filtered, and washed with dry DCM (3 × 2 
mL).144 
First acid coupling onto activated chlorotrityl linker:  A solution of Fmoc-Lys(Dde)-
OH (4.5, 149 mg, 0.28 mmol, 2 eq) and DIPEA (14 μL, 0.15 mmol, 1.1 eq) in dry 
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DCM (2 mL) was added and the resin was shaken for 30 min.  After washing with 
DMF (3 × 2 mL), DCM (3 × 2 mL) and methanol (2 × 2 mL), unreacted chlorides 
were displaced by adding a solution of DCM, methanol and DIPEA (80:15:5, 2 × 2 
mL) and further shaking for 15 min.  
The peptide was synthesised following the Fmoc-deprotection and coupling 
procedures (Section 7.2), the Dde group was deprotected and a mixture of endo- and 
exo-norbornene-2-carboxylic acid (66 μL, 0.42 mmol, 3 eq) were coupled using the 
method described in Section 7.2.  Finally, the norbornene modified peptide was 
cleaved by treatment of the linker with acetic acid, trifluoroethanol and DCM (2:2:6, 
2 mL) for 2 h, and precipitation in cold ether to afford a white solid (6.2 mg, 0.007 
mmol, 10%).   
HPLC (method 2): tR = 8.3/8.4 min (75% purity, 254 nm, isomer of norbornene) 
MS (ESI) m/z: calc. 873.45, experimental 896.2 [(M+Na)+, 100%]. 
 
Fmoc-Rink-LLPS (100 mg, 0.018 mmol) was placed in a solid phase extraction tube 
and swollen for 30 min in DCM.  The PNA sequence was synthesised following 
standard Fmoc-chemistry (Section 7.2) and capped with an Fmoc-aminohexanoic 
acid.  After Fmoc-deprotection, a solution of dichloro-tetrazine (8 mg, 0.054 mmol, 3 
eq) and DIPEA (2 μL, 0.019 mmol, 1.05 eq) in DCM (2 mL) was added and the 
reaction was agitated for 2 h.  Completion of the reaction was confirmed by a 
Ninhydrin test.  A small sample was cleaved, purified and analysed. 
HPLC (method 3): tR = 6.5 min (99% purity, 254 nm) 
MS (MALDI) m/z: calc. 761.29, experimental 763.1, 765.2 [(M+H)+, 100%, 3:1] 
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The crude peptide (synthesised above, 3.5 mg, 0.004 mmol, 1.3 eq) was dissolved in 
a solution of DMF/DMSO (1:1, 0.5 mL), added to the tetrazine-PNA resin (20 mg, 
0.0036 mmol) and the reaction was shaken at 75 °C overnight.  The resin was 
washed with DMSO (3 × 0.7 mL), DMF (3 × 0.7 mL), DCM (3 × 0.7 mL) and 
methanol (3 × 0.7 mL).  The conjugate was cleaved and analysed by MALDI and 
HPLC.   
HPLC (method 2): tR = 3.6 min (29% purity, 254 nm) 
MS (MALDI) m/z: calc. 1494.61, experimental 1495.9 [11%], 764.5 [100%] 
(unreacted PNA starting material). 
 
7.3.18. Test tetrazine ligation with (E)-cyclooct-4-yl 2,5-
dioxopyrrolidin-1-yl carbonate (3.30) 
 
Deprotection and coupling procedures are described in Section 7.2.   
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To Pep035 (Appendix 2, 30 mg, theoretical loading 0.0073 mmol) was coupled 
Fmoc-aminohexanoic acid.  After the final deprotection, a solution of (E)-
cycloocten-4-yl-2,5-dioxopyrrolidin-1-yl carbonate (6.0 mg, 0.022 mmol, 3 eq) in 
DMF was added and the reaction left shaking overnight.  Completion of the reaction 
was confirmed by the ninhydrin test.  After washing the resin, the peptide was 
cleaved with a solution of acetic acid, trifluoroethanol and DCM (2:2:6, 0.5 mL) for 
3 × 1 h, and precipitated from cold ether (19.2 mg, 75%).   
MS (MALDI) m/z: calc. 3526.96, experimental 3552.97 [M+Na]+ [30%] (error in 
mass, see internal standard test Chapter 5, Figure 5.2). 
 
To PNA100 (10 mg, 0.001 mmol) was coupled Fmoc-PEG-OH (2 mg, 0.003 mmol, 
3 eq) with Oxyma as a coupling agent.  After Fmoc-deprotection, a solution of 
dichloro-tetrazine (0.5 mg, 0.003 mmol, 3 eq) and DIPEA (1 μL, 0.006 mmol, 6 eq) 
in DCM (0.5 mL) was added to the resin and the mixture shaken for 3 h.  After 
washing the resin, the reaction completion was confirmed by ninhydrin test and the 
resin was used in the next step without further analysis. 
Ligation: 
The ligation was carried out by adding a solution of the peptide synthesised above 
(10 mg, 0.003 mmol, 3 eq) in DMF/DMSO (1:2, 450 μL) to the tetrazine-PNA resin 
and the reaction shaken overnight.  The resin was washed with DMSO (5 × 0.5 mL), 
DMF (3 × 0.5 mL), DCM (3 × 0.5 mL) and methanol (3 × 0.5 mL).  The PNA-
peptide conjugate was cleaved from the resin using method described in Section 
7.2.5 and analysed by HPLC and MALDI.  
HPLC (method 4): tR = 14.3 min (33% purity, 254 nm) 
MS (MALDI) m/z: calc. 6335.89, experimental 6341.53 [36%] (error in mass, see 
internal standard test Chapter 5, Figure 5.2). 
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Norbornene-2-carboxylic acid (41 mg, 0.3 mmol, 1 eq) and HBTU (110 mg, 0.29 
mmol, 0.97 eq) where dissolved in DMF (2 mL) and DIPEA (104 µL, 0.6 mmol, 2 
eq) was added to the solution, and stirred for 10 min.  To the activated carboxylic 
acid, 5-aminofluorescein (104.2 mg, 0.3 mmol, 1 eq) was added, and the reaction 
was microwave heated at 75 °C for 45 min.  After solvent evaporation, the crude 
solid was dissolved in a solution of NaOH (72 mg, 1.8 mmol, 6 eq) in water and THF 
(1:1, 5 mL) and stirred overnight at 60 °C.  The reaction was acidified with 1N HCl 
and the precipitate was filtered of, and purified by prep-HPLC to yield the product 
(17 mg, 0.04 mmol, 13%) as a yellow solid. 
1H NMR (500 MHz, CDCl3): δH 10.44 (2H, bs, Ar-OH), 8.32 (1H, d, J = 1.6 Hz, 
CjHAr), 7.84 (1H, dd, J = 8.3, 1.6 Hz, C
lHAr), 7.18 (1H, d, J = 8.3 Hz, C
mHAr), 6.63 
(2H, bs, CbHAr), 6.60 (2H, d, J = 8.7 Hz, C
eHAr), 6.52 (2H, d, J = 8.7 Hz, C
dHAr), 
6.26-6.18 (2H, m, CsH=CtH), 3.01-2.98 (1H, m, CrH), 2.95-2.91 (1H, m, CuH), 2.35-
2.33 (1H, m, CpH), 1.95-1.92 (1H, m, CqH2), 1.69-1.67 (1H, m, C
qH2), 1.33-1.29 
(1H, m, CvH2), and 1.27-1.24 (1H, m, C
vH2). 
HPLC (method 2): tR = 12.8 min (99% purity, ELSD) 
MS (ESI) m/z: 468.2 [(M+H)+, 15%] 
MP: decomposed >250 °C 
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7.4.2. Probe-synthesis 
7.4.2.1. GAPDH-PNA-Probe (4.1) 
 
Synthesis of the two probes was performed on aminomethyl ChemMatrix resin (20 
mg, 20 µmol).  Sequential coupling and deprotection of PNA monomers are 
described in Section 7.2 After the PNA synthesis, a PEG spacer (46 mg, 0.12 mmol, 
3 eq), followed by coupling of 5(6)-carboxylfluorescein (45 mg, 0.12 mmol, 3 eq, 
GAPDH-A) or 4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic acid (3.31, 33 mg, 
0.12 mmol, 3 eq, GAPDH-B) using Oxyma/DIC for 2 × 1 h.  The probe was cleaved 
as described in Section 7.2.5.  After HPLC-purification the product was collected as 
a yellow solid (8 mg, 1.4 µmol, 7%) for GAPDH-A and a red solid (7 mg, 1.3 mmol, 
7%) for GAPDH-B. 
GAPDH-A: 
HPLC (method 4): tR = 10.1 min (99% purity, 254 nm) 
MS (MALDI) m/z: calc. 5593.17, experimental 5593.40 [100%, M-H-].  
GAPDH-B: 
HPLC (method 4): tR = 9.6 min (97% purity, 254 nm) 
MS (MALDI) m/z: calc. 5495.17, experimental 5498.10 [100%, M+H+] (error in 
mass, see internal standard test Chapter 5, Figure 5.2).  
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7.4.2.2. 28S rRNA-PNA-Probe (4.2) 
 
The synthesis and quantities were as in Section 7.4.2.1.  After HPLC-purification the 
product was collected as a yellow solid (12.5 mg, 2.8 µmol, 14%) for 28S rRNA-A 
and a red solid (5.9 mg, 1.3 mmol, 7%) for 28S rRNA-B. 
28S rRNA-A: 
HPLC (method 4): tR = 10.2 min (99% purity, 254 nm) 
MS (MALDI) m/z: calc. 4516.74, experimental 4518.58 [100%, M+H+] (error in 
mass, see internal standard test Chapter 5, Figure 5.2).  
28S rRNA-B: 
HPLC (method 4): tR = 9.6 min (99% purity, 254 nm) 
MS (MALDI) m/z: calc. 4420.76, experimental 4422.47 [100%, M+H+] (error in 
mass, see internal standard test Chapter 5, Figure 5.2).  
 
7.4.2.3. Fluorescence In-Situ Hybridisation (FISH) 
Hela cells (200,000 per well) were fixed in a 96-well PS plate using 4% aq para 
formaldehyde for 20 min, washed with PBS (2 × 10 min, pH 6.5) and incubated with 
the probes (28S rRNA and GAPDH, 4 µM) at 37 °C for 20 h.  The cells were 
washed with PBS (2 × 5 min, pH 6.5), followed by the addition of Flu-Nor (4.3, 4 
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µM) to the TZ-PNA probes.  Which were incubated for a further 2 h.  The cells were 
washed with PBS (2 × 5 min, pH 6.5), nucleus stained with DAPI (1 × 30 min), 
followed by washing with PBS (2 × 5 min, pH 6.5) and finally imaged by semi-
confocal microscopy. 
7.5. Chapter 5 
7.5.1. 4-Dimethylamino-2-hydroxy-2′,4′-dicarboxy-
benzophenone (5.6)  
 
3-Dimethylaminophenol (13.7 g, 0.10 mol) was dissolved in toluene (300 mL), 
heated to 60 °C, and trimellitic anhydride (23.0 g, 0.12 mol) added.  The mixture was 
refluxed for 24 h.  After cooling to room temperature, the solid was filtered, washed 
with toluene (3 × 50 mL), dissolved in methanol (300 mL), and refluxed for 10 min.  
Acetic acid (100 mL) was added and the mixture was evaporated to dryness.  The 
solid was recrystallized from MeOH (200 mL), collected by filtration and washed 
with methanol (50 mL) to give the product (6.29 g, 19%) as a red crystalline solid.138 
1H NMR (500 MHz, DMSO): δH 13.38 (2H, bs, C
o,pOOH), 12.36 (1H, s, CdOH), 
8.49 (1H, d, J = 1.7 Hz, CmHAr), 8.20 (1H, dd, J = 7.8, 1.7 Hz, C
kHAr), 7.52 (1H, d, J 
= 7.8 Hz, CjHAr), 6.81 (1H, d, J = 9.0 Hz, C
fHAr), 6.22 (1H, dd, J = 9.0, 2.4 Hz, 
CgHAr), 6.11 (1H, d, J = 2.4 Hz, C
cHAr), and 3.01 (6H, s, NC
aH3). 
13C NMR (125 MHz, DMSO): δC 197.6 (C(O)), 166.1 (C(O)O), 164.2 (qC), 155.8 
(qC), 143.7 (qC), 133.8 (CH), 132.7 (CH), 131.6 (C), 130.7 (CH), 130.0 (CH), 128.3 
(CH), 109.5 (qC), 104.5 (CH), 97.0 (CH), and 39.5 (CH3). 
HPLC (method 2): tR = 8.3 min (99% purity, ELSD) 
MS (ESI) m/z: 657.2 [(2M-2H)-, 72%] 
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7.5.2. 5-Carboxytetramethylrhodamine 
monohydrochloride (TAMRA•HCl, 5.5)  
 
4-Dimethylamino-2-hydroxy-2′,4′-dicarboxybenzophenone 5.6 (3.29 g, 10 mmol) 
and 3-dimethylaminophenol (1.78 g, 13 mmol) were dissolved in dry DMF (80 mL).  
Trimethylsilylpolyphosphate (10 mL) in dry DCM (5 mL) was added, and the 
mixture refluxed for 3 h.  Solvents were removed in vacuo, the residue dissolved in 
5% NaOH (70 mL), and stirred overnight.  The solution was diluted with water (150 
mL) and lyophilised.  The crude product was purified by column chromatography 
(methanol/acetic acid/DCM, 2:2:96 to 15:5:80).  Residual acetic acid was removed 
from the product by acidifying a solution of 5-TAMRA in water with 1M 
hydrochloric acid (20 mL, 2.2 eq) and lyophilisation to yield 5-TAMRA•HCl (4.2 g, 
90%) as a dark red solid.138  
1H NMR (500 MHz, CD3OD): δH 8.88 (1H, s, C
oHAr), 8.4 (1H, d, J = 7.9 Hz, 
CmHAr), 7.52 (1H, d, J = 7.9 Hz, C
lHAr), 7.10 (2H, d, J = 9.4 Hz, C
fHAr), 7.04 (2H, d, 
J = 9.4 Hz, CgHAr), 6.95 (2H, s, C
cHAr), and 3.18 (12H, bs, NC
aH3). 
13C NMR (125 MHz, CD3OD): δC 168.3 (C(O)O), 168.0 (C(O)O), 160.9 (qC), 
159.1 (qC), 158.9 (qC), 139.1 (qC), 134.5 (qC), 134.0 (CH), 133.3 (CH), 132.0 (CH), 
131.8 (CH), 115.5 (qC), 114.7 (CH), 97.4 (CH), 40.9 (CH3), and 20.7 (qC). 
HPLC (method 2): tR = 7.1 min (99% purity, ELSD) 
MS (ESI) m/z: 431.3 [(M+H)+, 50%] 
Rf (1% acetic acid / 15% methanol / DCM): 0.21  
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7.5.3. 5H-Dibenzo[7]annulene-5-one oxime (5.12) 
 
Dibenzosuberenone 5.11 (10 g, 48.5 mmol) and hydroxylamine hydrochloride (4.4 g, 
63.8 mmol) were dissolved in pyridine (30 mL), and the mixture refluxed for 18 h.  
The solution was concentrated under reduced pressure, and poured onto crushed ice 
(300 g) containing 5% hydrochloric acid (200 mL).  The product was collected by 
filtration to yield a pale yellow solid (9.46 g, 42.8 mmol, 88%).105 
1H NMR (500 MHz, CDCl3): δH 7.68-7.66 (1H, m, C
cHAr), 7.61-7.59 (1H, m, 
CnHAr), 7.46-7.40 (6H, m, C
d-f,k-mHAr), and 6.93-6.92 (2H, m, C
h,jH). 
13C NMR (125 MHz, CDCl3): δC 157.1 (C=NO), 135.4 (qC), 134.9 (qC), 134.6 
(qC), 133.6 (qC), 131.9 (CH), 131.7 (CH), 130.7 (CH), 130.2 (CH), 129.4 (CH), 
129.0 (CH), 128.8 (CH), 128.6 (CH), 127.6 (CH), and 126.8 (CH). 
HPLC (method 2): tR = 7.1 min (99% purity, ELSD) 
MS (ESI) m/z: 222.1 [(M)+, 100%] 
 
7.5.4. Dibenzo[b,f]azocin-6(5H)-one (5.10) 
 
5H-Dibenzo[7]annulene-5-one oxime 5.12 (9.46 g, 42.8 mmol) and polyphosphonic 
acid (100 mL) were heated at 140 °C for 2 h.  The reaction mixture was poured onto 
crushed ice (600 g) and stirred for 30 min.  The solid was filtered, washed with water 
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(3 × 50 mL), and dried under vacuum to yield the desired product as a grey solid 
(8.89 g, 40.1 mmol, 94%).105 
1H NMR (500 MHz, D6-DMSO): ): δH 7.33-7.30 (2H, m, C
c,nHAr), 7.26-7.20 (2H, 
m, Cd,mHAr), 7.17-7.08 (4H, m, C
e,f,k,lHAr), 7.00 (1H, d, J = 11.6 Hz, C
hH), and 6.89 
(1H, d, J = 11.6 Hz, CiH). 
13C NMR (125 MHz, D6-DMSO): 172.2 (C(O)N), 136.7 (qC), 136.6 (qC), 134.9 
(qC), 133.9 (qC), 133.1 (CH), 130.7 (CH), 139.4 (CH), 129.3 (CH), 128.5 (CH), 
128.3 (CH), 128.2 (CH), 127.9 (CH), 126.9 (CH), and 126.6 (CH). 
HPLC (method 2): tR = 7.6 min (99% purity, ELSD) 




7.5.5. 5,6-Dihydrodibenzo[b,f]azocine (5.13) 
 
Dibenzo[b,f]azocin-6(5H)-one 5.10 (8.89 g, 40.1 mmol) and LiAlH4 (3.08 g, 81.2 
mmol) were suspended in dry ether (200 mL) and the mixture refluxed for 18 h.  The 
reaction was quenched with water (10 mL), followed by filtration.  The filter cake 
was washed with ether (50 mL), and then dispersed in ether (100 mL).  This 
suspension was stirred for 30 min and re-filtered.  The combined organic layers were 
dried (anhyd. MgSO4), and evaporated to yield the product as a yellow solid (4.5 g, 
21.7 mmol, 54%).105 
1H NMR (500 MHz, CDCl3): δH 7.26-7.24 (1H, m, C
cHAr), 7.21-7.17 (3H, m, C
c-
e,lHAr), 6.99-6.96 (1H, m, C
fHAr), 6.91-6.88 (1H, m, C
kHAr), 6.63-6.60 (1H, m, 
CmHAr), 6.55 (1H, d, J = 13.2 Hz, C
hH), 6.49-6.47 (1H, m, CnHAr), 6.37 (1H, d, J = 
13.1 Hz, CiH), and 4.59 (2H, s, NCaH2). 
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13C NMR (125 MHz, CDCl3): δC 147.2 (qC), 139.2 (qC), 138.1 (qC), 134.7 (CH), 
132.7 (CH), 130.1 (CH), 128.9 (CH), 127.9 (CH), 127.6 (CH), 127.4 (CH), 127.3 
(CH), 121.8 (qC), 117.9 (CH), 117.8 (CH), and 49.6 (CH2). 
HPLC (method 2): tR = 7.6 min (68% crude purity, ELSD) 





A solution of 5,6-dihydrodibenzo[b,f]azocine 5.13 (4.5g, 21.7 mmol), glutaric acid 
monomethyl ester chloride (4.5g, 27.3 mmol) and pyridine (5 mL, 61.9 mmol) in 
DCM (50 mL) were stirred for 30 min.  Additional DCM (50 mL) was added to the 
reaction mixture and the organic layer washed with water (2 × 150 mL).  The organic 
layer was dried (anhyd. MgSO4), evaporated, and the residue purified by column 
chromatography (hexane/EtOAc 2:1) to yield the desired product (3.98 g, 11.9 mmol, 
55%) as a yellow oil.105 
1H NMR (500 MHz, CDCl3): δH 7.29-7.24 (4H, m, C
c-fHAr), 7.18-7.12 (4H, m, C
k-
nHAr), 6.78 (1H, d, J = 13.1 Hz, C
hH), 6.58 (1H, d, J = 13.1 Hz, CiH), 5.50 (1H, d, J 
= 15.0 Hz, CaH2), 4.22 (1H, d, J = 15.0 Hz, C
aH2), 3.58 (3H, s, OC
uH3), 2.20-2.06 
(3H, m, Cq-sH2) and 1.93-1.78 (3H, m, C
q-sH2). 
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13C NMR (125 MHz, CDCl3): δC 173.6 (qC(O)O), 171.8 (qC(O)N), 141.0 (qC), 
136.3 (qC), 135.7 (qC), 134.8 (qC), 132.6 (CH), 132.0 (CH), 131.1 (CH), 130.3 
(CH), 128.4 (CH), 128.1 (CH), 127.9 (CH), 127.3 (CH), 127.2 (CH), 127.2 (CH), 
127.0 (CH), 54.5 (CH2), 51.4 (CH3), 33.4 (CH2), 33.0 (CH2), and 20.4 (CH2). 
HPLC (method 2): tR = 9.3 min (99% purity, ELSD) 






Bromine (0.63 mL, 12.4 mmol) was added to a solution of methyl-5-
dibenzo[b,f]azocin-5(6H)-yl-5-oxopentanoate 5.14 (3.98 g, 11.9 mmol) in dry DCM 
(150 mL) over 10 min at 0 °C.  The reaction was stirred at 0 °C for 45 min, quenched 
with sat. Na2SO3 (3 × 80 mL), washed with brine (150 mL), and the organic layer 
dried (anhyd. MgSO4).  The product was purified by column chromatography 
(hexane/ EtOAc 3:1 to 2:1) to yield the desired product (4.23 g, 8.58 mmol, 72 %) as 
a white solid.105 
1H NMR (500 MHz, CDCl3): δH 7.73 (1H, d, J = 7.7 Hz, C
fH), 7.25-7.13 (3H, m, 
Cc-eHAr), 7.07-6.98 (3H, m, C
l-nHAr), 6.89 (1H, d, J = 7.6 Hz, C
kH), 5.92 (1H, d, J = 
9.9 Hz, ChH), 5.83 (1H, d, J = 14.8 Hz, CaH2), 5.16 (1H, d, J = 9.9 Hz, C
iH2), 4.17 
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(1H, d, J = 14.8 Hz, CaH2), 3.62 (3H, s, OC
uH3), 2.44-2.30 (3H, m, C
q,sH2), 2.23-2.17 
(1H, m, Cq,sH2) and 2.07-1.96 (2H, m, C
rH2). 
13C NMR (125 MHz, CDCl3): δC 173.7 (qC(O)O), 172.7 (qC(O)N), 138.2 (qC), 
137.2 (qC), 137.1 (qC), 132.9 (qC), 130.7 (CH), 130.5 (2 × CH), 129.6 (CH), 129.4 
(CH), 128.9 (CH), 128.9 (CH), 128.6 (CH), 60.1 (CH), 55.6 (CH), 52.5 (CH2), 51.5 
(CH3), 34.9 (CH2), 33.3 (CH2), and 20.4 (CH2). 
HPLC (method 2): tR = 9.9 min (99% purity, ELSD) 






oxopentanoate (2.05 g, 4.16 mmol) was dissolved in dry THF (140 mL) and cooled 
to ˗40 °C under nitrogen.  A solution of KOtBu (1.8 g, 16.0 mmol) in dry THF (16 
mL) was added dropwise over 30 min.  The reaction was stirred at ˗40 °C for 90 min, 
followed by the addition of additional KOtBu (0.5 g, 4.5 mmol) in dry THF (5 mL), 
and stirred for 30 min.  The reaction was poured into water (210 mL), and the crude 
product was extracted with DCM (2 × 280 mL), the combined organic layers washed 
with water (3 × 350 mL), dried (anhyd. MgSO4) and evaporated.  The product was 
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purified by column chromatography (hexane/ EtOAc 2:1) to yield the desired product 
(1.02 g, 3.06 mmol, 74%) as a yellow oil.105  
1H NMR (500 MHz, CDCl3): δH 7.72-7.69 (1H, m, C
fH), 7.43-7.25 (7H, m, Cc-e,k-
nHAr), 5.16 (1H, d, J = 13.9 Hz, C
aH2), 3.60 (1H, d, J = 13.9 Hz, C
aH2), 3.56 (3H, s, 
OCuH3), 2.46-2.41 (2H, m, C
sH2), 1.99-1.94 (2H, m, C
pH2) and 1.78-1.71 (2H, m, 
CqH2). 
13C NMR (125 MHz, CDCl3): δC 173.5 (qC(O)O), 172.7 (qC(O)N), 151.7 (qC), 
148.0 (qC), 132.9 (qC), 132.3 (CH), 128.9 (CH), 128.3 (CH), 128.3 (CH), 128.0 
(CH), 127.7 (CH), 127.0 (CH), 125.5 (CH), 123.0 (qC), 115.1 (qC), 107.7 (qC), 55.3 
(CH2), 51.4 (CH3), 33.7 (CH2), 32.8 (CH2), and 20.6 (CH2). 
HPLC (method 2): tR = 10.4 min (99% purity, ELSD) 
MS (ESI) m/z: 334.0 [(M+H)+, 100%]  
 
7.5.9. 5-(11,12-Didehydrodibenzo[b,f]azocin-5(6H)-yl)-
5-oxopentanoic acid (ADIBO, 5.9) 
 
LiOH (0.272 g, 11.3 mmol) in water (15 mL) was added drop-wise over 15 min to 
methyl-5-(11,12-didehydrodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanoate 5.15 (1.02 
g, 3.06 mmol) in THF (45 mL), and the reaction mixture stirred for 4 h.  Water (150 
mL) was added and the mixture basified using 1 M NaOH.  The aqueous layer was 
washed with DCM (3 × 300 mL), acidified with 1 M HCl, and extracted with DCM 
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(3 × 200 mL).  The combined organic layers were washed with brine (400 mL), dried 
(anhyd. MgSO4) and evaporated to yield the desired product (0.875 g, 2.74 mmol, 
90%) as a pale yellow solid.105 
1H NMR (500 MHz, CDCl3): δH 7.69-7.67 (1H, m, C
fH), 7.46-7.44 (3H, m, Cc-
eHAr), 7.26-7.23 (4H, m, C
l-nHAr), 5.29 (1H, d, J = 14.3 Hz, C
aH2), 3.67 (1H, d, J = 
14.3 Hz, CaH2), 2.37-2.26 (1H, m, C
sH2), 2.19-2.11 (2H, m, C
qH2), 2.03-1.98 (1H, m, 
CsH2), and 1.78-1.6.8 (2H, m, C
rH2). 
13C NMR (125 MHz, CDCl3): δC 178.5 (qC(O)O), 172.5 (qC(O)N), 151.5 (qC), 
148.1 (qC), 133.4 (qC), 132.3 (CH), 131.5 (CH), 131.1 (CH), 130.6 (CH), 129.4 
(CH), 128.4 (CH), 127.5 (CH), 127.3 (CH), 124.4 (qC), 115.8 (qC), 108.5 (qC), 55.2 
(CH2), 33.0 (CH2), 32.8 (CH2), and 20.2 (CH2). 
HPLC (method 2): tR = 9.6 min (99% purity, ELSD) 
MS (ESI) m/z: 319.9 [(M+H)+, 100%]  
 
7.5.10. ADIBO-Lys(Nor)-Ahx-His6-NH2 (5.16) 
 
Aminomethyl polystyrene resin (2.5 g, 1.86 mmol, loading: 1.23 mmol/g) was pre-
swollen in DCM, and Fmoc-Rink-OH linker coupled using Oxyma/DIC.  Six Fmoc-
His(Trt)-OH, Fmoc-Ahx-OH, Fmoc-Lys(Dde)-OH and 5-(11,12-
didehydrodibenzo[b,f]azocin-5(6H)-yl)-5-oxopentanoic acid (5.9) were coupled as 
described earlier (Section 7.2).  After Dde-deprotection (Section 7.2.3), exo-5-
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norbornenecarboxylic acid was coupled (Oxyma/DIC) and the peptide was cleaved 
form the linker by addition of a solution of TFA:TIS:DCM (90:5:5, 2 × 90 min) and 
the product purified by HPLC (0.92 g, 0.6 mmol, 36%). 
HPLC (method 1): tR = 4.5 min (99% purity, ELSD) 
MS (MALDI) m/z: calc. 1501.73, experimental 1503.6 [100%, M+H+].  
 
7.5.11. Synthesis of PNA-Tag (5.1) 
 
Deprotection and coupling procedures are described in Section 7.2.  Fmoc-Rink-LL-
PS resin (20 mg, 5.89 μmol, 1 eq, or 30 mg, 5.44 μmol) was placed in a well on a 96- 
filter well plate with a bottom sealing matt, followed by stepwise coupling of PNA 
monomers (0.18 mmol, 3 eq) using a liquid handler and heating in an oven to 65 °C 
for 45 min.  Aminohexanoic acid (0.18 mmol, 3 eq, DMF) and 4-(6-(pyrimidin-2-yl)-
1,2,4,5-tetrazin-3-yl)benzoic acid (0.18 mmol, 3 eq, DMSO/DCM 3:1) were coupled 
twice using Oxyma and DIC.  PNAs were cleaved with TFA:water (95:5) and 
purified using HPLC (Appendix 1 for sequences). 



























PNA001 4144.69 4150.82 8.3 
3.0 
(12) 
PNA051 4119.68 4132.11 10.1 
1.9 
(8) 
PNA002 4120.67 4125.89 8.1 
2.2 
(10) 
PNA052 4117.65 4130.21 10.3 
4.1 
(17) 
PNA003 4111.66 4118.65 9.0 
0.8 
(4) 
PNA053 4069.63 4080.95 10.2 
4.6 
(19) 
PNA004 4126.66 4132.78 9.1 
1.9 
(8) 
PNA054 4093.64 4106.19 10.1 
3.2 
(13) 
PNA005 4120.67 4126.72 9.0 
1.2 
(5) 
PNA055 4111.66 4122.98 10.1 
2.4 
(11) 
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PNA006 4126.66 4129.37 9.2 
1.0 
(4) 
PNA056 4117.65 4128.99 10.2 
3.4 
(15) 
PNA007 4111.66 4113.12 9.0 
1.8 
(8) 
PNA057 4108.64 4119.63 10.2 
4.2 
(17) 
PNA008 4093.64 4096.04 9.1 
1.1 
(5) 
PNA058 4126.66 4138.78 10.2 
8.7 
(39) 
PNA009 4102.65 4104.62 9.2 
0.8 
(4) 
PNA059 4090.62 4101.75 10.3 
3.1 
(13) 
PNA010 4120.67 4123.92 9.0 
3.2 
(14) 
PNA060 4102.65 4114.70 10.2 
7.6 
(34) 
PNA011 4102.65 4106.06 9.1 
3.2 
(13) 
PNA061 4117.65 4129.47 10.2 
5.0 
(21) 
PNA012 4072.59 4077.37 10.5 
1.7 
(8) 
PNA062 4102.65 4115.24 10.1 
3.9 
(16) 
PNA013 4093.64 4099.66 10.1 
1.6 
(7) 
PNA063 4117.65 4129.93 10.2 
3.6 
(15) 
PNA014 4099.63 4104.12 10.3 
3.7 
(17) 
PNA064 4126.66 4138.25 10.1 
4.6 
(19) 
PNA015 4102.65 4108.78 10.0 
2.1 
(9) 
PNA065 4108.64 4119.57 10.2 
8.0 
(36) 
PNA016 4111.66 4117.71 10.0 
3.5 
(16) 
PNA066 4102.65 4112.77 10.1 
6.6 
(30) 
PNA017 4108.64 4114.69 10.3 
1.9 
(8) 
PNA067 4144.69 4154.27 10.1 
9.1 
(40) 
PNA018 4144.69 4149.31 10.1 
4.4 
(20) 
PNA068 4108.64 4119.30 10.2 
3.9 
(17) 































































PNA026 4084.63 4095.28 10.2  
1.6 
(7) 
PNA076 4111.66 4114.21 10.0 
6.5 
(29) 
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PNA035 4107.64 - - - - - -  0 (0) PNA085 4144.69 4145.48 9.9 
7.3 
(30) 


















PNA038 4102.65 4112.58 10.1 
5.6 
(25) 
PNA088 4108.64 4114.61 10.3 
5.6 
(25) 
PNA039 4108.64 4120.34 10.3 
2.1 
(9) 
PNA089 4120.67 4123.51 10.0 
4.5 
(19) 









PNA041 4126.66 4137.76 10.1 
6.7 
(30) 
PNA091 4111.66 4115.81 10.0 
4.9 
(22) 
PNA042 4126.66 4137.73 10.2 
3.5 
(14) 
PNA092 4135.67 4138.40 10.2 
5.8 
(26) 
PNA043 4111.66 4123.53 10.0 
6.5 
(29) 
PNA093 4144.69 4145.36 10.1 
3.4 
(14) 
PNA044 4099.63 4110.14 10.2 
3.8 
(16) 
PNA094 4117.65 4120.14 10.3 
3.4 
(14) 
PNA045 4126.66 4137.07 10.2 
6.8 
(28) 
PNA095 4111.66 4114.40 10.1 
3.0 
(12) 
PNA046 4126.66 4137.72 10.2 
3.0 
(13) 
PNA096 4135.67 4137.01 10.1 
2.4 
(10) 
PNA047 4117.65 4129.04 10.1 
1.7 
(7) 
PNA097 4102.65 4107.71 10.2 
6.3 
(28) 
PNA048 4111.66 4123.14 10.1 
3.7 
(17) 
PNA098 4135.67 4138.82 10.1 
2.0 
(9) 
PNA049 4108.64 4119.63 10.3 
5.6 
(25) 
PNA099 4135.67 4138.43 10.1 
6.3 
(28) 
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PNA050 4117.65 4128.93 10.2 
5.8 
(26) 
PNA100 4120.67 4124.17 10.0 
6.1 
(27) 
* = The MALDI-TOF MS spectra have an error of between 0.01–0.3%, and all the masses quoted for the PNA 
are stated as seen in the spectra without correction/internal calibration (see Chapter 5, Figure 5.2 for 
explanation).  Masses are [M+H]+ unless otherwise indicated.   
** = analysed by method 4 using ELSD detector signal.  
 
7.5.12. Peptide synthesis for LigLib 1 (5.8) 
 
All peptides (Appendix 2) were synthesis on a peptide synthesiser, starting with 
Fmoc-Rink-PS (50 mg, 37 μmol).  After synthesis of the sequences, a small amount 
was cleaved and analysed by ELSD and MALDI-TOF MS, before manual coupling 
of Fmoc-Ahx-OH, Fmoc-Lys(Dde)-OH 5.3 and exo-5-norbornenecarboxylic acid 
using Oxyma/DIC as coupling agents at 60 °C for 30 min.  After selective Dde-
deprotection using hydroxylamine hydrochloride/imidazole, 5-(6) tetraethyl 
carboxyrhodamine was coupled using Oxyma/DIC for 18 h.  Each member was 
cleaved under standard conditions (Section 7.2.5), followed by purification by HPLC 
and lyophilisation to yield each member as a red-pink solid. 
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Table 7.2: Analysis and purify of synthesised peptides for LigLib 1. 









Pep001 2591.17 2594.9 9.1/9.3 2.8 (3) 
Pep002 2367.18 2370.7 9.2/9.4 1.9 (2) 
Pep003 2675.33 2679.1 8.8/9.0 3.8 (4) 
Pep004 2619.32 2623.0 9.6/9.8 5.4 (6) 
Pep005 2608.34 2612.4 9.7/10.0 5.1 (5) 
Pep006 2651.43 2655.2 8.5/8.7 1.3 (1) 
Pep007 2385.24 2388.8 8.9/9.1 4.5 (5) 
Pep008 2552.39 2556.1 8.5/8.7 3.6 (5) 
Pep009 2679.42 2683.2 8.9/9.1 2.3 (2) 
Pep010 2475.27 2479.0 10.6 1.4 (2) 
Pep011 2499.24 2502.9 9.1/9.2 7.0 (8) 
Pep012 2623.27 2627.0 9.0/9.2 5.1 (5) 
Pep013 2666.47 2670.3 9.8/9.9 11.2 (11) 
Pep014 2748.35 2752.2 9.1/9.3 1.8 (2) 
Pep015 2653.23 2657.0 9.5/9.7 4.5 (5) 
Pep016 2541.29 2544.9 8.8/9.0 2.8 (3) 
Pep017 2833.66 2838.5 8.6/8.7 2.9 (3) 
Pep018 2422.19 2425.8 9.3/9.5 16.3 (18) 
Pep019 2241.08 2244.6 9.0/9.2 5.9 (7) 
Pep020 2654.31 2658.1 9.4/9.6 2.5 (3) 
* = The MALDI-TOF MS spectra have an error of between 0.1–0.2%, and all the masses quoted for the peptide 
are stated as seen in the spectra without correction/internal calibration (see Chapter 5, Figure 5.2 for 
explanation).  Masses are [M+H]+ unless otherwise indicated.   
** = analysed by method 3 using 530 nm detection; the two peaks correspond to the different isomers of 5-(6) 
tetraethyl carboxyrhodamine which were separated during purification. 
 
7.5.13. Peptide synthesis for LigLib 2 (5.17) 
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To the synthesised peptides (Section 7.5.12), 6-azidohexanoic acid 3.3 was coupled 
using Oxyma/DIC at 60 °C for 30 min.  After Dde-deprotection using hydroxylamine 
hydrochloride/imidazole, 5-(6) tetraethyl carboxyrhodamine was coupled using 
Oxyma/DIC for 18 h.  Each member was cleaved using standard conditions (Section 
7.2.5), followed by purification by HPLC and lyophilisation to yield each member as 
a red-pink solid. 
Table 7.3: Analysis and purify of synthesised peptides for LigLib 2. 









Yield          
mg 
(%) 









Yield          
mg 
(%) 
Pep024 2678.43 2682.5 8.0/8.1 
6.59 
(7) 
Pep043 2553.35 2557.3 8.2/8.4 
7.57 
(8) 
Pep025 2605.25 2609.3 8.6 
4.76 
(5) 
Pep044 2455.16 2459.7 7.8/8.0 
6.54 
(7) 
Pep026 2648.34 2652.4 8.7 
2.28 
(2) 
Pep045 2680.19 2684.5 8.5 
4.78 
(5) 
Pep027 2618.27 2622.4 9.1 
2.19 
(2) 
Pep046 2603.39 2607.7 8.7 
3.00 
(3) 
Pep028 2733.37 2737.6 8.3/8.4 
3.53 
(3) 
Pep047 2597.34 2601.3 7.9/8.1 
4.97 
(5) 
Pep029 2635.22 2639.8 7.8/8.0 
5.20 
(5) 
Pep048 2674.25 2678.2 9.1/9.2 
3.19 
(3) 
Pep030 2664.47 2668.6 8.4/8.6 
7.52 
(8) 
Pep049 2460.27 2464.1 8.8/9.1 
17.56 
(19) 
Pep031 2567.24 2571.3 8.5/8.6 
6.87 
(7) 
Pep050 2349.18 2353.0 8.6 
7.20 
(8) 
Pep032 2457.24 2461.2 7.7/8.0 
4.39 
(5) 
Pep051 2542.22 2546.5 8.7/9.1 
7.93 
(8) 
Pep033 2642.47 2646.7 7.3/7.9 
5.67 
(6) 
Pep052 2624.34 2628.4 8.5/ 
8.35 
(9) 
Pep034 2397.22 2401.2 8.0/8.2 
5.35 
(6) 
Pep053 2534.24 2538.2 8.4 
3.47 
(4) 
Pep035 2671.43 2675.5 8.4/8.6 
4.78 
(5) 
Pep054 2692.16 2696.2 8.5 
5.96 
(6) 
Pep036 2707.40 2711.8 7.8/8.0 
6.78 
(7) 
Pep055 2718.37 - - - - - - 
0     
(0) 
Pep037 2583.33 2587.5 8.7/8.8 
6.94 
(7) 
Pep056 2639.34 2643.7 9.4 
1.05 
(1) 
Pep038 2670.37 2674.6 7.7/7.9 
10.10 
(10) 
Pep057 2629.34 2633.5 7.8/8.0 
8.10 
(8) 
Pep039 2628.44 - - - - - - 
0     
(0) 
Pep058 2736.34 2741.4 8.3 
4.30 
(4) 
Pep040 2675.23 - - - - - - 
0     
(0) 
Pep059 2638.39 2642.4 8.4/8.6 
9.59 
(10) 
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Yield          
mg 
(%) 









Yield          
mg 
(%) 
Pep041 2712.33 2716.7 8.0/8.2 
6.96 
(7) 
Pep060 2567.32 2571.5 8.9 
6.20 
(7) 
Pep042 2675.40 2679.8 8.0 
2.56 
(3) 
    
 
* = The MALDI-TOF MS spectra have an error of between 0.1–0.2%, and all the masses quoted for the peptides 
are stated as seen in the spectra without correction/internal calibration (see Chapter 5, Figure 5.2 for 
explanation).  Masses are [M+H]+ unless otherwise indicated.   
** = analysed by method 3, 530 nm detection; the two peaks correspond to the different isomers of 5-(6) 
tetraethyl carboxyrhodamine which were separated during purification. 
 
7.5.14. Synthesis of LigLib 1 
 
For the ligation, the TZ-PNA (1 eq, Section 7.5.11) was dissolved in 
water/acetonitrile (0.8 mL) containing 0.1% TFA, and the peptide (1.5 eq, Section 
7.5.12) was added.  The reaction was heated to 50 °C for 18 h.  The conjugate was 
purified by HPLC, and the fractions concentrated under reduced pressure and 
lyophilised to yield the conjugates as purple/red solids.   














Lig001 6707.85 6715.2 10.5 1.25 (26) 
PNA001 
Pep001 
Lig002 6459.85 6465.7 10.8 0.84 (36) 
PNA100 
Pep002 
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Lig003 6758.99 6768.1 10.5 1.00 (76) 
PNA003 
Pep003 
Lig004 6702.98 6710.2 11.3 1.67 (34) 
PNA095 
Pep004 
Lig005 6707.00 6715.5 11.9 1.67 (35) 
PNA078 
Pep005 
Lig006 6735.05 6743.9 10.5 3.62 (75) 
PNA087 
Pep006 
Lig007 6468.90 6475.8 10.7 2.05 (48) 
PNA079 
Pep007 
Lig008 6627.04 6634.0 10.6 2.41 (62) 
PNA071 
Pep008 
Lig009 6754.07 6762.6 10.9 0.96 (28) 
PNA083 
Pep009 
Lig010 6564.92 - - -  - - - 0 (0) 
PNA094 
Pep010 
Lig011 6582.89 6589.8 11.0 2.81 (50) 
PNA091 
Pep011 
Lig012 6697.92 6705.1 10.9 2.89 (66) 
PNA081 
Pep012 
Lig013 6759.13 6790.6 11.9 2.23 (37) 
PNA077 
Pep013 
Lig014 6856.02 6864.3 11.0 1.41 (43) 
PNA098 
Pep014 
Lig015 6745.90 6753.0 11.5 3.36 (64) 
PNA089 
Pep015 
Lig016 6648.96 6656.2 10.7 0.81 (21) 
PNA096 
Pep016 
Lig017 6941.32 6948.7 10.5 1.72 (45) 
PNA082 
Pep017 
Lig018 6502.82 6509.8 11.4 2.64 (44) 
PNA088 
Pep018 
Lig019 6321.71 6329.7 11.1 0.80 (16) 
PNA075 
Pep019 
Lig020 6770.99 6779.2 11.4 0.79 (19) 
PNA093 
Pep020 
* = The MALDI-TOF MS spectra have an error of between 0.08–0.2%, and all the masses quoted for the 
conjungates are stated as seen in the spectra without correction/internal calibration (see Chapter 5, Figure 5.2 for 
explanation).  Masses are [M+H]+ unless otherwise indicated.   
** = analysed by method 4, 530 nm detection.   
*** = yield based on PNA used. 
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7.5.15. Synthesis of LigLib 2 
 
For the ligation, the peptide (1.5 eq, Section 7.5.13) was dissolved in water/ACN 
(1:1, 0.8 mL) containing 0.1% TFA, and the His-tag (2 eq, Section 7.5.10, 5.16) was 
added.  The reaction was heated to 50 °C for 18 h, after which azide-PS scavenger 
resin pre-swollen in DCM was added (10 mg) and heated at 50 °C for 8 h, followed 
by removal of the resin by filtration and the addition of TZ-PNA (1 eq, Section 
7.5.11).  The reaction was heated to 50 °C for 18 h.  After this the conjugate was 
directly purified by HPLC, and the fractions concentrated under reduced pressure 
and lyophilised to yield the conjugates as purple/red solids.   

















6.6 0.54 (5) 
PNA092 
Pep024 
Lig022 8214.65 - - -  - - - 0 (0) 
PNA080 
Pep025 
Lig023 8230.70 - - -  - - -  0 (0) 
PNA068 
Pep026 
Lig024 8200.63 - - -  - - -  0 (0) 
PNA057 
Pep027 
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6.5 2.16 (18) 
PNA090 
Pep033 
Lig031 7973.59 - - -  - - -  0 (0) 
PNA023 
Pep034 
Lig032 8253.79 - - -  - - -  0 (0) 
PNA049 
Pep035 
Lig033 8292.79 - - -  - - -  0 (0) 
PNA043 
Pep036 
Lig034 8183.71 - - -  - - -  0 (0) 
PNA041 
Pep037 






7.1 2.03 (15) 
PNA045 
Pep041 






























6.6 1.7 (15) 
PNA050 
Pep047 






7.2 0.57 (3) 
PNA086 
Pep049 
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6.9 2.36 (18) 
PNA021 
Pep050 






7.1 2.19 (13) 
PNA084 
Pep052 
Lig048 8119.62 - - -  - - -  0 (0) 
PNA022 
Pep053 
Lig049 8301.56 - - - - - - 0 (0) 
PNA099 
Pep054 
























7.1 0.52 (4) 
PNA097 
Pep060 
* = The MALDI-TOF MS spectra have an error of between 0.001–0.04%, and all the masses quoted for the 
conjugates are stated as seen in the spectra without correction/internal calibration (see Chapter 5, Figure 5.2 for 
explanation).  Masses are [M+H]+ unless otherwise indicated.   
** = analysed by method 4 using 530 nm detection.   
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Appendix 
I. PNA Sequences 
Melting temperature (Tm) describe the temperature at which half of a probe (in this 
case the PNA) sequence will be hybridised onto the target sequence (in this case 
DNA).  To calculate these theoretical temperatures, the 4 + 2 method (Wallace-
Ikatura rule)145,146 was used.  In this method, for adenine and thymine residue counts 
2 °C, and every guanine and cytosine counts 4 °C (Equation 1).  
𝑇𝑚 = 2 ℃(𝐴 + 𝑇) +  4 ℃(𝐺 + 𝐶)                                       (1)   
 
Table A.1: Table of PNA sequences synthesised. 
PNA No C-Terminal                                                           N-Terminal 
Tm /°C 
Tm 
Calc. for 1 
4 2 2 2 2 4 2 2 2 2 4 2 2 2 34 
1 C T A A A C A T A A C T A A 34 
2 A C T A A C A T C A T A C A 36 
3 C T A A C A T T C T A A A C 36 
4 C T A A A C T T C T A A T A 34 
5 C T A A C T A A T A A C A C 36 
6 C T A A A C T A A C A T T T 34 
7 T A A C C A T T T A A C C A 36 
8 C A T T C A T T A C T T A C 36 
9 C A T T C T A C A A C T A T 36 
10 A C A T C T A A A C A T A C 36 
11 C T A A T T T C A C T A A C 36 
12 T T T C T T T C T T T C T T 34 
13 A A T C A C T T C T T C A T 36 
14 T T T C A T A T C A T T C T 34 
15 A C T T A A C T A C T T A C 36 
16 A C T A C T A A A C T T A C 36 
17 A C T A T T T C A C T A T T 34 
18 A C T A A A C T C A T A A A 34 
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PNA No C-Terminal                                                           N-Terminal 
Tm /°C 
19 C A T A A A C T C A T T C A 36 
20 C T A A C A T A A C T T C A 36 
21 A C T A A A C T C T A A T T 34 
22 A C T A A C T T A A C T C A 36 
23 T T T C A A C T C T A A A C 36 
24 C A T A A C A T A A C T T T 34 
25 A C T T C T A A A C T T C A 36 
26 A C T T T T T C A C A T C T 36 
27 T T T C A A C T C A T A A C 36 
28 A A C T A T T A C A A A C A 34 
29 T T T C T T T C C T A A A C 36 
30 C A T T T T T C T T T C C A 36 
31 C T A A T T T C A A C T A A 34 
32 C A T C T A A T C A A A C T 36 
33 T T T C C T A A T T T C A C 36 
34 T A C T T A A C C A T A C A 36 
35 A C T T T A C T T A C T T A 34 
36 T A A C T A A C A C T T A C 36 
37 T A A C T T T C T A C T T T 34 
38 T A A C A A C T T T T C A C 36 
39 T A C T A C A T T A C T T T 34 
40 A T T A C A A C A C T T A T 34 
41 T A A C T A C T C A T A T A 34 
42 C A A A T A T C A C T T T A 34 
43 A C A T T A C T C A T A A C 36 
44 C A T A T T T C T T T C T A 34 
45 A A C T C A T T A A C T T A 34 
46 A C A T A A C T T A C T T A 34 
47 T A A T A C T T C A T T C A 34 
48 T A A T A A C T C T A C A C 36 
49 C A T T C A T T T A A C T T 34 
50 C A T T T A C T A C T A T A 34 
51 T A A C A A C T A C T A A C 36 
52 T A A C A C T T C A T A T T 34 
53 A C A T C T T C T A C T C T 38 
54 T A C T T A A C T T T C A C 36 
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PNA No C-Terminal                                                           N-Terminal 
Tm /°C 
55 C A A T C A A T A A C T C T 36 
56 T T T C A C T A C A T A T A 34 
57 C A T T A C T A T T T C T A 34 
58 C A T C A T T A C A A T T A 34 
59 T T T C A C T T T T T C T A 34 
60 T A C T C T A A T A A C C T 36 
61 A C T T C T A A T A C T T A 34 
62 T A A C C T A A T A C T C T 36 
63 A C A T C A T A T T T C A T 34 
64 C A T T C A T C A T T A A A 34 
65 T T T C C A T T C T A A T A 34 
66 C A T C T A T C A T A T C A 36 
67 C T A A A C A T T A A C A A 34 
68 T T T C T T T C T A A C A A 34 
69 C T A C A C T T A C A T T A 36 
70 A C T A T A C T T A A C C T 36 
71 T A C T T A A C T A A C C T 36 
72 C T A A T A A C C T A A T T 34 
73 T A A C A A C T T A A C T A 34 
74 A C T T T A A T C A A A C A 34 
75 A C A T T T T C T A A C T T 34 
76 C A T A A A T C T A C T C A 36 
77 C A T A C A T A A C A T A C 36 
78 A C T A T A T C T A T C A A 34 
79 T A C T A C T A C A T A A C 36 
80 C A A T C A A T C T A A T A 34 
81 T A A C A A T C T T T C A C 36 
82 T A C T C A T A C A A T A A 34 
83 A C A T T A T C A C T T C A 36 
84 T A A C T A T C T A C T A A 34 
85 A C T A C A A A C T A A T A 34 
86 T A A C A A T C A C T A C A 36 
87 A C T A C A T T C A T A A C 36 
88 C T A A C A T T T A T C T T 34 
89 T A T A C A A C A A C T C A 36 
90 A A T C T A C T T A A C A C 36 
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PNA No C-Terminal                                                           N-Terminal 
Tm /°C 
91 C A T T C A A T A C T A A C 36 
92 C A T A A C T A C A A A T T 34 
93 C A A A C A T A A A T C T A 34 
94 T A A T A A C T C A T C T T 34 
95 A A T C A C A T C A T T C A 36 
96 C A A A T T T C A A T C A A 34 
97 T A T C A C A T A C A T C T 36 
98 A A C T T A C T A A T C A A 34 
99 C A A T A C T T T A A C A A 34 
100 C A A T C T A A A C A T C A 36 
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II. Peptide Sequences 
Table A.2: Kinases of interest with corresponding phosphorylation sides and substrate’s. 
Sequence No Kinase Target Sequence Substrate PO3 Side 
1 Abl LGQEEDVYHTVDDDE BCAP Y513-p 
2 Abl SVTAPSPYAQPSSTF p63 Y149-p 
3 Abl GEGYKKKYQQVDEEF PDGFRb Y970-p 
4 Ack AYQSRDYYNFPLALA AR Y363-p 
5 ALK QVPQQPTYVQALFDF Grb2 Y160-p 
6 ALK SKRKGHEYTNIKYSL SHP-2 Y546-p 
7 Arg DHGAEIVYKSPVVSG tau iso8 Y394-p 
8 AurA KGKFGNVYLAREKQS AurA Y148-p 
9 Brk RLIKEDVYLSHDHNI Brk Y342-p 
10 Brk AVVNLINYQDDAELA CTNNB1 Y142-p 
11 Btk QSHVEDLYVEGLPEG TFII-I iso2 Y357-p 
12 BVR ESSSHEDYIRQFLNA BVR Y83-p 
13 CDK7 HEVVTLWYRAPEILL CDK2 Y168-p 
14 CdkL5 NNANYTEYVATRWYR CdkL5 Y171-p 
15 CK2-A1 DWGLAEFYHPGQEYN CK2-A1 Y182-p 
16 CSFR DPEGGVDYKNIHLEK CSFR Y699-p 
17 CSFR KYKQKPKYQVRWKII CSFR Y546-p 
18 CSK FTATEPQYQPGENL- Yes Y537-p 
19 CTK YTATEGQYQQQP--- Lyn Y508-p 
20 EGFR ISLDNPDYQQDFFPK EGFR Y1172-p 
21 EGFR QLTFALRYLNFFTKA PCNA Y211-p 
22 EGFR TENDDDVYRSLEELA VAV2 Y142-p 
23 EphA2 TYVDPHTYEDPNQAV EphA2 Y594-p 
24 EphA2 QLKPLKTYVDPHTYE EphA2 Y588-p 
25 EphA4 TYVDPFTYEDPNQAV EphA4 Y602-p 
26 EphA4 LNQGVRTYVDPFTYE EphA4 Y596-p 
27 EphB3 VYIDPFTYEDPNEAV EphB3 Y614-p 
28 ERK7 EDQAVTEYVATRWYR ERK7 Y177-p 
29 Etk TKVELETYKQTRQGL RUFY1 Y389-p 
30 FAK AAFRLFKYGVQLYKN Grb7 Y338-p 
31 FAK KDNFDSFYSEVAELG Trio Y2796-p 
32 Fer RQEDGGVYSSSGLKQ Fer Y714-p 
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Sequence No Kinase Target Sequence Substrate PO3 Side 
33 Fer EAKILKQYDHPNIVK Fer Y615-p 
34 Fes REEADGVYAASGGLR Fes Y713-p 
35 Fes RPSFSTIYQELQSIR Fes Y811-p 
36 FGFR1 DIHHIDYYKKTTNGR FGFR1 Y654-p 
37 FGFR2 TLTTNEEYLDLSQPL FGFR2 Y769-p 
38 FGFR3 DVHNLDYYKKTTNGR FGFR3 Y648-p 
39 FGFR4 LLAVSEEYLDLRLTF FGFR4 Y754-p 
40 FLT3 TGSSDNEYFYVDFRE FLT3 Y589-p 
41 FLT3 KEHNFSFYPTFQSHP FLT3 Y726-p 
42 FRK NKDKANRYFSPNFKV PTEN Y336-p 
43 Fyn PPVPNPDYEPIRKGQ CD3E Y188-p 
44 Fyn EHGSQGTYSNTKENG MAP2 iso3 Y67-p 
45 Fyn EEEKEETYDDIDGFD SKAP55 Y232-p 
46 Hck VLNSHDLYQKVAQEI ELMO1 Y216-p 
47 Hck RVIEDNEYTAREGAK Hck Y411-p 
48 HER2 SPAFDNLYYWDQDPP HER2 Y1221-p 
49 HER2 PTAENPEYLGLDVPV HER2 Y1248-p 
50 HER2 GAVENPEYLTPQGGA HER2 Y1196-p 
51 IGF1R YASVNPEYFSAADVY IGF1R Y980-p 
52 IGF1R DIYETDYYRKGGKGL IGF1R Y1166-p 
53 InsR DPKEDPIYDEPEGLA Dok1 Y362-p 
54 InsR NEDADENYFINEEDE PIK3R3 Y341-p 
55 ITK IRSEENIYTIEENVY TIM3 Y265-p 
56 Jak2 WDQEAQIYELVAQTV ARHGEF1 Y738-p 
57 Jak2 TSDEKVDYVQVDKEK Gab2 Y643-p 
58 Jak3 IETDKEYYTVKDDRD JAK1 Y1035-p 
59 Jak3 LPLDKDYYVVREPGQ Jak3 Y981-p 
60 Kit INGNNYVYIDPTQLP Kit Y570-p 
61 Kit DHAEAALYKNLLHSK Kit Y703-p 
62 Lck LIIEDPYYGNDSDFE ACP1 Y133-p 
63 Lck NLQERRKYLKHRLIV STAT2 Y690-p 
64 Lck GEAPSNIYVEVEDEG TSAd Y305-p 
65 LRRK2 GFPAIRDYHFVNATE LRRK2 Y1485-p 
66 Lyn TILTEVNYEVSNKDD Casp8 Y448-p 
67 Lyn NEPKKKKYAKEAWPG NIPP-1 Y335-p 
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Sequence No Kinase Target Sequence Substrate PO3 Side 
68 Mer KIYSGDYYRQGRIAK Mer Y754-p 
69 PDGFRa RLSADSGYIIPLPDI PDGFRa Y1018-p 
70 PDGFRa RVDSDNAYIGVTYKN PDGFRa Y988-p 
71 PDGFRb ERKEVSKYSDIQRSL PDGFRa Y754-p 
72 PDGFRb LWQKKPRYEIRWKVI PDGFRb Y562-p 
73 PKR QLAAKLAYLQILSEE PKR Y162-p 
74 Ret ARTTSQLYDAVPIQS PDK1 Y9-p 
75 Ret TPSDSLIYDDGLSEE Ret Y1029-p 
76 Ret AQAFPVSYSSSGARR Ret Y687-p 
77 Ret iso2 TWIENKLYGRISHAF Ret iso2 Y586-p 
78 Src VPVDPATYGQFYGGD gelsolin Y465-p 
79 Src ELLEQQKYTVTVDYW IKK-beta Y199-p 
80 Src LPGKPKVYVQDILRQ iNOS Y1055-p 
81 Src WQNYRQAYSPRRGRS Trap150 Y118-p 
82 Syk EENADDSYEPPPVEQ BLNK Y96-p 
83 Syk EEDGEPDYVNGEVAA LAB Y233-p 
84 Syk LRADENYYKAQTHGK Syk Y526-p 
85 TGFBR2 KGRFAEVYKAKLKQN TGFBR2 Y259-p 
86 TGFBR2 AKGNLQEYLTRHVIS TGFBR2 Y336-p 
87 TIE2 TYVNTTLYEKFTYAG TIE2 Y1108-p 
88 TrkA LAQAPPVYLDVLG-- TrkA iso2 Y785-p 
89 TrkB SFDAILYYYQSGGRI Kv1.3 Y162-p 
90 TXK RYVLDDEYVSSFGAK TXK Y420-p 
91 TXK KIQVKALYDFLPREP TXK Y91-p 
92 Tyk2 NHIGHTGYLNTVTVS RACK1 Y194-p 
93 Tyk2 VPEGHEYYRVREDGD Tyk2 Y1055-p 
94 VEGFR-1 DYNSVVLYSTPPI-- VEGFR-1 Y1333-p 
95 VEGFR-1 VQQDGKDYIPINAIL VEGFR-1 Y1169-p 
96 VEGFR-2 RFRQGKDYVGAIPVD VEGFR-2 Y951-p 
97 VEGFR-2 EEAPEDLYKDFLTLE VEGFR-2 Y996-p 
98 Wee1 EKIGEGTYGVVYKAR CDK2 Y15-p 
99 ZAP70 EEEGAPDYENLQELN LAT iso2 Y226-p 
100 ZAP70 SLDGSREYVNVSQEL LAT iso2 Y191-p 
 
